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1.1 MENTAL RETARDATION
1.1.1 Definition and prevalence of mental retardation
In our society, intelligence is thought to be very important for, if not determining, a
person's success. Correct brain function permits the acquisition of skills that serve as
hallmarks of developmental progress. Significant impairments of cognitive and adaptive
performance are present in two to three percent of the human population, and are
grouped under the general term mental retardation (MR). The most recent definition of
MR, issued by the American Association on Mental Retardation1 states: Mental retardation
refers to substantial limitations in present functioning. It is characterized by significantly
subaverage intellectual functioning, existing concurrently with related limitations in two or more
of the following applicable adaptive skill areas: communication, self-care, home living, social skills,
community use, self-direction, health and safety, functional academics, leisure and work.
Furthermore, the mental manifestations must be present before the age of 18 years.
In this definition, MR is a typical human condition. For the affected individual, it
implicates a limited capacity to learn and to achieve the goals that are thought to be
essential to function independently in our society. For public health, MR is a common
abnormality, that is widely distributed throughout the population and that imposes a
costly and lifelong burden. For medicine and science, however, MR represents an
aberration in the formation and/or function of the central nervous system that demands
evaluation and explanation2.
The most widely used system for classification of MR is based on severity as
determined by performance on standardized intelligence tests. The different classes of MR
vary in Intelligence Quotient (IQ), assuming a population mean of 100 and a standard
deviation of 15. The criteria of the International Statistical Classification of Diseases and
Related Health Problems, 10th revision (ICD-10), coordinated by the World Health
Organization (WHO), are summarized in Table 1.1.
Table 1.1. Classification of mental retardation according to ICD-10 criteria
Degree of mental retardation Intelligence Quotient (IQ) Age equivalent (years; months)
Borderline 70-85
Mild 55-69 8;3-10;9
Moderate 40-54 5;7-8;2
Severe 25-39 3;2-5;6
Profound <25 <3;2
Often a simplification of this classification into two large groups is used: severe MR,
comprising IQ values below 50, and mild MR, including IQ values from 50 to 70. Using
this classification, mild MR has an estimated prevalence of 2-3%3, whereas 0.3% of the
population is severely handicapped4. When MR is consistently associated with somatic,
neurological, or behavioral manifestations, it is termed syndromic mental retardation.
Mental retardation syndromes tend to have a single, specific, and identifiable heritable or
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environmental cause. In the absence of consistent somatic, neurological, or behavioral
manifestations, MR is termed nonsyndromic or nonspecific.
1.1.2 Etiology of mental retardation
As with other disorders of human development and functioning, mental retardation
may result from genetic influences, environmental insults, or some combination of the
two5. The disorder has a substantial genetic component and there may be a genetic cause
in approximately half of the severely retarded patients6. The ranks of single-gene
(Mendelian) disorders recognized to cause MR have grown steadily over the past half
century. In august 2001, the McKusick catalogue of genes and phenotypes (Online
Mendelian Inheritance in Man (OMIM); http://www3.ncbi.nlm.nih.gov/Omim) responds
with 993 entries when queried with “mental retardation”.
An excess of males has long been noted among persons with MR7. It is present in
diverse populations worldwide, and among all degrees of mental deficiency. In the
Netherlands, the male excess seems to be largest in the least severe type of mental
impairment, i.e. specific learning disabilities, and gradually drops with increasing
severity8. In most populations, the male excess is about 20%−40%. Greater mortality
among females and hormonal contributions to the causation of MR, have been proposed
as causes for the difference in incidence of MR among sexes, but these have never been
proven. The different number of sex chromosomes between males and females is regarded
to be primarily responsible for the excess of males with MR. Whereas a mutation in a gene
on a male’s single X-chromosome may cause MR, the same mutation in a female may be
compensated for by the presence of a normal allele on her second X-chromosome. The
mutation can also be silenced by preferential inactivation of the X-chromosome carrying
the mutant allele. Accepting a male excess of 30%, it can be estimated that X-linked mental
retardation is one of the most frequent causal categories of MR, equaling that of
chromosomal aberrations. It is to be expected that most of the inherited forms of mental
retardation are X-linked recessive. Dominant forms of mental retardation (autosomal and
X-linked) might be found in sporadic cases or in families with mild mental retardation, but
individuals with severe MR do generally not reproduce. Autosomal recessive forms of MR
may be frequent, but for recognition of the inheritance pattern and disease causing gene(s)
large families are required. Such pedigrees can be found in inbred populations.
Furthermore, some frequent mutations with a high heterozygote frequency might be
found in other populations. In contrast, MR segregating in an X-linked recessive manner is
found in all populations, even if the carrier frequency is low. Males with a mutation in an
X-linked gene will be affected, whereas heterozygous females will be non-manifesting
carriers.
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1.2 X-LINKED MENTAL RETARDATION
1.2.1 Definition and prevalence of X-linked mental retardation
X-linked mental retardation (XLMR) is that proportion of mental retardation
showing the distinctive pattern of inheritance associated with the X-chromosome. The
XLMR phenotype in a family can be detected when the transmission follows the general
characteristics of X-linked recessive phenotypes2:
♦ only males are affected
♦ sons of carrier females have a 50% risk of being affected
♦ daughters of carrier females have a 50% risk of being carriers
♦ male to male transmission does not occur
♦ all daughters of affected males will be carriers
♦ unaffected males cannot transmit the phenotype
♦ carrier females may have mild expression of the disease
Using a 30% excess of males among persons with MR, and attributing all of the male
excess to XLMR, one may calculate that XLMR makes up at least 13% of all mental
retardation2,9-13:
Given that a = the percentage of females with non X-linked MR
b = the percentage of females with XLMR
c = the percentage of males with non X-linked MR
d = the percentage of males with XLMR
and a+b+c+d = 100%
c+d = 1.3 (a+b)
a = c
then a+b+1.3 (a+b) = 100%
↔ 2.3(a+b) = 100%
↔ a+b = 43.5% (all females with MR) and c+d = 56.5% (all males with MR)
Assuming that the number of females with XLMR is negligible (b = 0):
Then a = 43.5%
↔ c = 43.5%
↔ d = 13%
Turner estimated, however, that possibly 10% of mild mental retardation in females, and
20-25% of all mental retardation in males is due to defects on the X-chromosome14,15.
Indeed, these data fit in the above formula, if we use 10% of XLMR females:
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a+b = 43.5% ↔ a = 33.5% and b = 10%
c+d = 56.5% ↔ c = 33.5% and d = 23%
XLMR males + females = 33%
To summarize, mutations in X-linked genes are the cause of 13% of MR, when
disregarding the small amount of XLMR females. Since there are females with X-linked
forms of MR, the contribution of X-linked genes is higher than 13% (see formula). In any
case, X-linked genes are among the most common causes of MR. The percentage of 20-25%
by Turner14,15 is comparable with the portion of cases that can be attributed to
chromosome aberrations (~12-15%)16 and substantially exceeding the proportion that
could be attributed to subtelomeric deletions (5%)17,18 or autosomal genes (5-8%).
However, studies of various cohorts of persons with MR have found X-linked genes
responsible for 7.5% of cases or less4,5,19-24. A number of factors may contribute to the
shortfall between the estimated prevalence and the identifiable prevalence of XLMR.
Many XLMR entities may not have distinctive features which provide clues to clinical
diagnosis. Furthermore, in some pedigrees X-linkage may not be immediately
recognizable, e.g. if there is a new mutation or if there are affected females in the family2.
1.2.2 Classification of X-linked mental retardation
XLMR can be divided into two broad categories: syndromic and nonsyndromic, also
denoted nonspecific. In syndromic XLMR (or MRXS), somatic, neurological, behavioral, or
metabolic abnormalities accompany the mental retardation in a recognizable pattern. One
could expect that the genes involved in these syndromes have a general expression pattern
in the body and that their function is not restricted to development of human intellectual
learning. It is even possible that the gene is not expressed in the brain at all and that the
mental retardation is a secondary event. In contrast, there is an increasing number of X-
linked conditions in which MR is apparently the only clinical feature. These conditions are
referred to as nonspecific XLMR (or MRX), and affected males have a normal physical
appearance and no somatic, neurological, behavioral, or metabolic findings that
distinguish them from non-affected male relatives or from other males25. MRX is clinically
homogeneous but genetically heterogeneous. A recent update on XLMR genes was given
by Chiurazzi et al.26.
MRX has an estimated incidence of 1.8/1000 or 1 in 550 males10. This percentage is
often wrongly quoted in the literature as the incidence of XLMR (i.e. MRXS and MRX
combined). The prevalence of MR in the population is approximately 3%, and at least 13%
of all MR in males is due to XLMR (see 1.2.1). The prevalence of XLMR in males is
therefore approximately 0.39% or 1 in 256 males. This indicates that MRXS and MRX
contribute equally to the incidence of mental retardation.
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1.3 OUTLINE OF THE THESIS
With a population prevalence of 2-3%, mental handicaps constitute a serious medical
and social problem in our society. The cause of the mental retardation is highly variable
and involves both genetic and environmental factors. In spite of extensive medical
investigations, the etiology of mental handicap remains unexplained in most patients. It
has been estimated that at least 13% of all MR is caused by X-chromosomal gene defects
(XLMR) (see 1.2.1). With a total of 100,000 newborn males per year, this means that
approximately 400 males with XLMR are born each year in the Dutch population.
Unraveling the genetic cause of MR will have important consequences for the prognosis,
support, and possible treatment of the patients, and for genetic counseling of their
relatives.
The study described in this thesis is part of a worldwide effort to search for genes
that are important in the pathogenesis of nonspecific X-linked mental retardation (MRX).
In order to achieve this, the primary method is accurate clinical examination and genetic
linkage analysis with highly polymorphic markers in as many as possible MRX families. In
the last few years, an international nomenclature system has been set up to collect these
data and make them available to the scientific community. Since the publication of
MRX127, a significant resource of mapped MRX families has been established. To date, in
76 MRX families the genetic defect has been linked to the X-chromosome, two of which are
described in this thesis. MRX46 links to Xq25-q26 with a maximum lod score of 5.12 at θ=0
(appendix 1), and MRX65 links to the pericentromeric region with a maximum lod score of
3.64 at θ=0 (appendix 2).
Positional information about MRX genes, provided by linkage analysis, will pave the
way for the final identification of disease-causing mutations in MRX candidate genes.
However, the MRX linkage intervals are typically too large to successfully search for
candidate genes. Moreover, it is not possible to narrow down these intervals because the
individual MRX families can not be lumped together on the basis of their “common”
phenotype. Since there may be more than 50 MRX genes, other strategies have to be
followed in order to identify novel MRX genes. The high heterogeneity in MRX makes it
necessary to screen more than 100 probands per candidate gene. In order to have access to
such a large patient panel, the European XLMR consortium was established. Together
with groups in Paris, Leuven, Berlin, and Tours, we collected approximately 200 well-
characterized XLMR families.
In this thesis the identification of two (candidate) genes for MRX is described, as well
as the subsequent mutation analysis in the material from the European XLMR consortium.
In appendix 3 the identification of a novel gene, RSK4, is described. This gene is the only
known gene in the MRX critical interval in a contiguous gene syndrome in Xq21, which
also involves deafness type 3 (DFN3) and choroideremia (CHM). Since no mutations have
been found in the 200 consortium patients up to now, there is no definitive proof for the
involvement of RSK4 in MRX. The molecular analysis of a translocation breakpoint in
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Xq26, the identification of the ARHGEF6 gene and a mutation in family MRX46 is
described in appendix 4.
Another way to identify MRX genes is to screen known genes in a large cohort of
patients. Genes that cause a syndromic form of XLMR with a wide phenotypic spectrum
are excellent candidate genes for MRX. An example is the XNP gene, that is involved in
ATR-X syndrome and several other severe mental retardation syndromes. In appendix 5 we
describe a mutation in this gene in a family with mild mental retardation, in which only
retrospectively mild phenotypic characteristics of ATR-X were found.
  
Chapter 2
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2.1 NONSPECIFIC X-LINKED MENTAL RETARDATION
Before the availability of polymorphic molecular markers, no MRX entity had been
mapped. A major advance in understanding MRX came in 1988 when Suthers et al.27
employed restriction fragment length polymorphisms (RFLPs) to regionally map an MR
condition to the pericentromeric region of the X-chromosome (Xp11.3-q12). The genetic
defect was subsequently mapped in other MRX families, which revealed numerous non-
overlapping linkage intervals on the X-chromosome. Thus, it became readily apparent that
MRX is genetically heterogeneous. A convention, established in 1990, has assisted in the
systematic study of MRX families28. Those families in which linkage analysis produced lod
scores ≥ 2 were assigned MRX numbers. The subsequent development of microsatellite
markers in the early 1990s has greatly accelerated the pace of regional mapping of these
conditions2. To date, 76 MRX numbers have been assigned (Table 2.1). A number of MRX
families remain outside this system, however, having been reported prior to adoption of
the MRX convention or being of insufficient size or not informative enough to achieve a
lod score ≥ 29,29-38. Only in nine of the 76 MRX families a mutation has been found
(indicated in italics in Table 2.1). Seven genes are involved in these families: GDI139,40,
OPHN141, PAK342,43, RSK244, IL1RAPL145, ARHGEF6 (appendices 1 and 4, this thesis) and
MECP246. Besides these genes, two more MRX genes have been described: FMR247,48 which
is located next to a fragile site, and TM4SF2 which is mutated in two small families in
which no linkage analysis could be performed49.
Table 2.1. Mapping of MRX families. (Adapted from http://xlmr.interfree.it/home.htm)
Name Locus Flanking markers Gene Reference
MRX1 Xp11.3-q12 DXS426-DXS1125 27,50,51
MRX2 Xp22.2-p21.3 DXS207-DXS1065 52,53
MRX3 Xq28-qter DXS304-qter 54
MRX4 Xp11.23-q21.32 DXS255-DXYS1X 52,53
MRX5 Xp11.4-q21.31 OTC-DXS95 55
MRX6 Xq27 Not reported 56
MRX7 Xp11.23-q12 DXS1039-AR 57,58
MRX8 Xp11.3-q13.2 DXS1003-DXS1166 59,60
MRX9 Xp21.2-q12 DXS164-DXS453 61
MRX10 Xp21.3-p11.4 DXS28-DXS228 50,51
MRX11 Xp21.2-p11.4 DXS164-DXS7 50,51
MRX12 Xp21.2-p11.21 DXS1238-ALAS2 50,51
MRX13 Xp22.31-q22.3 DXS85-DXS456 50
MRX14 Xp11.3-q12 PFC-DXS135 62,51
MRX15 Xp21.2-p11.22 DXS164-DXS988 63
MRX16 Xq28 MECP2 46
MRX17 Xp11.23-q12 DXS255-DXS106 33,51
MRX18 Xp11.3-p11.23 DXS538-DXS1126 33
MRX19 Xp22.2-p22.1 RSK2 44
MRX20 Xp11.4-q21.33 DXS1068-DXS454 64
MRX21 Xp22.3-p11.4 Xpter-DXS7 65
MRX22 Xp21.1-q21.32 DXS84-DXSYS1X 66
MRX23 Xq22.3-q25 DXS1105-DXS425 67
MRX24 Xp22.32-p22.2 DXS278-DXS207 68
MRX25 Xq27.3-qter DXS297-qter 69
MRX26 Xp11.4-q21.33 MAOB-DXS454 70
MRX27 Xq23-q26.3 DXS424-DXS102 71
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Table 2.1 (continued).
Name Locus Flanking markers Gene Reference
MRX28 Xq28-qter DXS1113-qter 72
MRX29 Xp22.13-p21.3 DXS989-DXS1234 73
MRX30 Xq22 PAK3 42
MRX31 Xp11.23-q13.3 DXS1126-DXS1124 74
MRX32 Xp22.2-p21.3 DXS1053-DXS992 75
MRX33 Xp22.13-p11.4 DXS365-MAOB 72
MRX34 Xp22.1-p21.3 ILRAPL1 45
MRX35 Xq22.1-q26.1 DXS178-HPRT 76
MRX36 Xp22.13-p21.1 DXS989-DMD 37
MRX37 Xp22.32-p22.31 DXS1223-DXS1224 38
MRX38 Xp22.13-p21.1 DXS1226-DXS1238 77
MRX39 Xp11 Translocations 78
MRX40 Xq21.1-q21.2 DXS233-CHM 79
MRX41 Xq28 GDI1 40
MRX42 Xq24-q25 not reported 80
MRX43 Xp22.31-p21.1 DXS987-DMD 81
MRX44 Xp11.3-p11.21 DXS1003-ALAS2 81
MRX45 Xp11.3-p11.21 DXS1003-ALAS2 81
MRX46 Xq26 ARHGEF6 Appendices 1 and 4, this thesis
MRX47 Xq22 PAK3 43
MRX48 Xq28 GDI1 40
MRX49 Xpter-p22.31 Xpter-DXS8022 82
MRX50 Xp21.1-p11.21 DXS8012-DXS991 82
MRX51 Xp21.1-p11.23 DXS8012-DXS1003 83
MRX52 Xp11.21-q21.33 ALAS2-DXS3 81
MRX53 Xq22.3-q25 DXS1210-DXS1047 84
MRX54 Xp22.13-p21.3 DXS989-DXS1218 85
MRX55 Xp11.4-q12 DXS1068-DXS1275 86
MRX56 Xp21.1-p11.21 Not reported 80
MRX57 Xq24-q25 Not reported 80
MRX58 Xp22.13-q12 DXS989-DXS1111 87
MRX59 Xp22.31-p21.1 DXS987-DMD 88
MRX60 Xq12 OPHN1 41
MRX61 Not reported Not reported
MRX62 Xq21.33-q25 DXS458-DXS737 Ronce et al., unpublished data
MRX63 Xq21.33-q27.2 DXS990-DXS1227 Moraine et al., unpublished data
MRX64 Xq28 DXS1113-qter 89
MRX65 Xp11.23-Xq21.33 DXS573-DXS990 Appendix 2, this thesis
MRX66 Not reported Not reported
MRX67 Not reported Not reported
MRX68 Xq21.33-q23 DXS8020-DXS1220 Frints et al., unpublished data
MRX69 Xp11.21-q22.1 DXS991-DXS178 Frints et al., unpublished data
MRX70 Xq23-q25 DXS8063-DXS1047 83,90
MRX71 Xq24-Xq27.3 DXS1001-DXS8043 Frints et al., unpublished data
MRX72 Xq28 DXS1073-F8c 91
MRX73 Not reported Not reported
MRX74 Xp11.4-p11.3 DXS556-DXS1003 Ronce et al., unpublished data
MRX75 Xq25-q26.2 DXS8098-DXS1062 92
MRX76 Xp22.31-p21.3 DXS987-DXS8039 Kleefstra et al., unpublished data
Note: Localization of flanking markers according to the “Sixth International Workshop on Human X
Chromosome Mapping 1995”93 and http://www.gdb.org (for those not displayed in 93). Therefore, the
subchromosomal localization (locus) displayed in this table might slightly differ from that originally reported.
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Figure 2.1 presents the linkage data from all reported MRX families with a lod score
above two. Furthermore, the nine known MRX genes are indicated, as well as the XNP
gene that was found mutated in a family in which only retrospectively some phenotypic
characteristics were found (appendix 5, this thesis). Many of the published families have
overlapping linkage intervals. Assuming that these families have allelic mutations, the X-
chromosome comprises 8 exclusive linkage groups, indicating that at least 8 additional
genes are involved in the 76 families reported. However, each of the reported MRX genes
is involved only in one or two families, indicating that a linkage group is likely to contain
more than one MRX gene. Hence, it is plausible that more than 50 MRX genes exist.
Figure 2.1. Chromosomal distribution of MRX loci. Left: linkage intervals on the X-chromosome in MRX
families with lod score >2. Right: MRX genes and the family numbers in which a mutation is identified.
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 2.2 IDENTIFICATION OF MRX GENES
Complete analysis of individual large MRX families using a dense map of highly
informative markers will allow, at best, a localization within a 10-15 megabases (Mb)
interval. The complete X-chromosome is approximately 163 Mb and contains an estimated
maximum of 1500 genes94,95. With a gene density of 7 to 11 genes per Mb, a linkage
interval in an individual family therefore can contain more than 100 genes. In view of the
high genetic heterogeneity, an overlap in localization between two MRX families cannot be
taken as an indication that the same gene is implicated, and thus, cannot be used to obtain
a more restricted localization. Linkage data can be very useful however, as soon as a
candidate gene for MRX is identified. Probands of families with corresponding
localization can be screened for mutations in these genes. Once the conditions for analysis
of mutations have been defined for a given gene, they can be used systematically on a
relatively large number of samples in a single experiment, in which also families without
linkage data can be tested.
There are generally three ways to identify candidate genes for MRX:
1. Positional cloning
2. (Positional) candidate gene analysis
3. Mutation analysis of known MRXS genes
2.2.1 Positional cloning
Positional cloning is based on the chromosomal localization of the gene, i.e. the
position of the gene in the human genome, without using any prior knowledge about the
biological function of the gene product. Information about the position can be obtained
through linkage analysis in affected families. The linkage intervals are generally too large
to successfully clone the disease genes. The cloning and identification of MRX genes is
greatly facilitated by the presence of fragile sites or cytogenetic aberrations, like
translocations, inversions, and deletions. Especially translocations in mentally retarded
patients provide an excellent opportunity to clone the X-chromosomal gene disrupted by
the translocation. Also deletions encompassing a number of contiguous genes on the X-
chromosome have been described, and in some instances the deletions are presumed to
include genes that cause MRX. Microscopically visible male viable deletions of the X-
chromosome are clustered in two regions, Xp22.3−Xp21, and Xq21. These regions also
harbor microdeletions96-101.
Positional cloning has been successful in the identification of five of the nine known
MRX genes: FMR2, OPHN1, TM4SF2, IL1RAPL1, and ARHGEF6. In 1996, the FMR2 gene,
which was located next to the FRAXE fragile site in Xq28, was cloned by analysis of the
DNA of two unrelated boys with submicroscopic deletions near FRAXE and mental
retardation47. FMR2 is the first MRX gene described. The molecular basis of FRAXE has
been identified as the absence47,48 or truncation47 of the FMR2 protein. This is a
consequence of either transcription silencing of the FMR2 gene through methylation of the
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FRAXE CpG island in subjects with the full mutation (> 200 CGG copies)102, or deletion
within the FMR2 gene creating null alleles47,103. No FMR2 point mutations have been
identified so far.
Positional cloning of the X-chromosomal gene disrupted by an X-autosome
translocation in a mentally retarded individual, and subsequent mutation analysis in MRX
families has been successful in the identification of three MRX genes. Billuart et al.41
identified a novel gene with 25 exons, OPHN1 or oligophrenin-1, that was spanning the
breakpoint in Xq12. A single base-pair (bp) deletion, resulting in a frameshift, was
detected in family MRX60. The TM4SF2 gene at Xp11.4 is inactivated by the X-
chromosomal breakpoint of a balanced translocation t(X;2)(p11.4;p21.3) in a female patient
with MR and autistic behavior49. Subsequently, in two of 33 MRX families mutations were
found (missense and nonsense, respectively). Molecular analysis of a reciprocal X/21
translocation in a male with mental retardation showed that the ARHGEF6 gene in Xq26
was disrupted by the rearrangement. Mutation screening of 119 patients with nonspecific
mental retardation revealed a mutation in MRX46 (appendices 1 and 4, this thesis).
Mapping of four contiguous gene deletion syndromes exhibiting MR with only
adrenal hypoplasia or with adrenal hypoplasia and glycerol kinase deficiency (GKD), and
three deletions without MR but with either adrenal hypoplasia or adrenal hypoplasia and
GKD, revealed a locus for MRX in the Xp22.1-p21.3 region104. This locus was confirmed by
the detection of two inherited overlapping microdeletions in Xp22.1-p21.3 associated
exclusively with MRX100,101,105. In one of these families, MRX34, the deletion appeared to
span only 350 kb, and comprises three of the eleven exons of a novel gene. This gene
shows homology to the Interleukin (IL)-1 receptor accessory protein (IL1RAP), and is
named IL1RAPL1 (for IL1RAP-like-1)45. In a small MRX family, a nonsense mutation was
detected, leading to a barely detectable amount of IL1RAPL1 transcript.
Positional cloning strategies have not always been successful in the identification of
MRX genes. In several cases, a gene has been cloned that is involved in a chromosomal
aberration, but subsequent mutation analysis in a large panel of MRX families failed to
prove the causal involvement of the gene in MRX. Examples are DXS6673E106 and
GRIA3107, both disrupted by a translocation, and VCX-A108 and RSK4 (appendix 3, this
thesis), which are located in the MRX critical interval in contiguous gene deletion
syndromes. In several cases no gene was found to be disrupted by the translocation or
inversion109. The fact that in many cases no MRX gene could be identified, indicates that
(in case of a translocation) the autosomal breakpoint could contain a gene for MR, or that
large rearrangements per se can be causative for MR. Since translocation breakpoints can
affect the expression of a gene several hundreds of kilobases away110, a position effect can
be an important reason for the lack of gene identification by positional cloning. The
position effect can be caused by the dissociation of a regulatory element from the gene,
juxtaposition of the gene with an enhancer element from another gene, or integration of a
gene into a region with another chromatin structure110. A well known example of a
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position effect leading to disease is the chromosomal rearrangement involving POU3F4 in
X-linked deafness type 3 (DFN3). Mutations have been found within the gene111, but
micro-deletions that overlap in an 8 kb fragment located 900 kb upstream of the POU3F4
gene have also been described111-113. This hotspot for microdeletions is thought to
disconnect the POU3F4 gene from a regulatory element112,114. Finally, in all cases in which
no gene could be identified by positional cloning, it cannot be ruled out that there is no
correlation between the mental retardation and the observed chromosomal aberration.
2.2.2 (Positional) candidate gene analysis
Due to the Human Genome Project, the number of cloned genes on the X-
chromosome has increased rapidly over the last few years. Genes that are known to play a
role in brain development are functional candidate genes for mental retardation. Strictly
taken, functional candidate gene analysis is rarely performed nowadays, because
positional information on linkage intervals and precise localization of genes is almost
always available. In a positional candidate gene approach, mutation analysis of functional
candidate genes will be focused on families with linkage intervals encompassing the
candidate gene, or conversely, the most promising candidate genes in a known linkage
interval will be analyzed115. Two of the nine known MRX genes have been found by a
positional candidate gene approach: GDI1 and PAK3.
D’Adamo et al.40 searched for mutations in genes that map to Xq28 and are
predominantly expressed in the brain. One gene that met these criteria was GDI1, which
encodes GDP-dissociation inhibitor α (GDIα). GDIα forms complexes preferentially with
RAB3A, which is crucially important for synaptic neurotransmitter release116-120. Because
GDI1 was such a promising candidate gene for MRX, D’Adamo et al.40 set out for mutation
analysis of this gene, and identified a missense and a nonsense mutation in families
MRX41 and MRX48, respectively. Subsequently, a missense mutation in a family with
nonspecific X-linked semidominant MR was reported by another group39.
In the search for the gene involved in the neural migration disorder X-linked
lissencephaly (X-Lis)121,122, a gene that was highly expressed in brain (cerebral cortex and
hippocampus) was identified. This gene, denoted PAK3, was disregarded as the X-Lis
gene, but was still a strong candidate for mental defects mapping to Xq24. Following a
positional candidate disease analysis, mutations in the PAK3 gene have been found in
MRX3042 and MRX4743.
2.2.3 Mutation analysis of known MRXS genes
The difference between syndromic and nonspecific MR is obvious for clinical and
diagnostic purposes. However, in the analysis of common genetic disorders, one should
keep in mind that even the same mutation in a single gene can produce a remarkably wide
range of associated clinical phenotypes. It is therefore reasonable to expect that a
proportion of patients with mild or severe MRX will have mutations in genes already
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known to cause syndromic forms of MR. In several X-linked mental retardation
syndromes a broad phenotypic spectrum has been observed. Mutations in the Ribosomal
S6-kinase 2 gene (RSK2) have been described in Coffin-Lowry syndrome (CLS; MIM
303600), which is characterized by mental retardation with a peculiar pugilistic nose, large
ears, tapered fingers and drumstick terminal phalanges. A variable phenotypic expression
pattern was observed in CLS and a mutation has also been described in a family in which
the phenotype was unusual in that the degree of mental retardation and dysmorphic
features was milder123. The finding of a missense mutation in family MRX1944, made RSK2
the first gene involved in syndromic and nonspecific XLMR, and paved the way for the
analysis of other MRXS genes in families with MRX.
Recently mutations in the MECP2 gene, encoding methyl-CpG binding protein 2,
have been identified in males with nonspecific MR124 and in MRX1646. Until then,
mutations were only found in females with Rett syndrome (RTT; MIM 312750), a severe X-
linked dominant neurodegenerative syndrome. Mutations in males were considered to be
lethal125. Another example of extreme clinical heterogeneity is the X-linked mental
retardation syndrome with α-thalassemia (ATR-X; MIM 301040) in which mutations have
been found in X-linked nuclear protein (XNP)126. Mutations in the XNP gene have
subsequently been reported in families affected with Juberg-Marsidi syndrome (MIM
309590)127, Carpenter-Waziri syndrome128, severe mental retardation with spastic
paraplegia129, Holmes-Gang syndrome130, and Smith-Fineman-Meyers syndrome (MIM
309580)131.
Recently, an XNP null mutation was found in a family in which two patients had
moderate to profound MR and the typical facial characteristic features of ATR-X
syndrome. Two other patients from the same family and with the same XNP mutation had
mild MR and epilepsy but did not have the characteristic facial dysmorphisms132.
Subsequent mutation screening of a large number of patients with several phenotypes
including MRX, revealed a missense mutation in a family diagnosed with nonspecific
XLMR (appendix 5, this thesis). The mental retardation was borderline to moderate. Only
with hindsight and upon careful scrutiny of the available data, childhood hypotonia was
seen in some patients. Because of the molecular findings, HbH inclusion bodies were
sought for and found. These are characteristic for ATR-X syndrome.
These data suggest that the involvement of a particular gene in both MRXS and MRX
is possible, and that future studies will reveal additional examples. Other candidates
comprise the genes for XLMR with aggressive behavior (MAOA)133, Aarskog-Scott
syndrome (FGD1)134, and Norrie disease (NDP)135.
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3.1 DEVELOPMENT OF MEMORY
3.1.1 Axon outgrowth
Once a neuron has migrated to its final position, it begins to extend an axon at its
growing tip by means of a specialized structure, called the growth cone. Growth cones
appear as an enlargement of the shaft of the axon. Several finger-like extensions, called
filopodia, project from the growth cone136. Filopodia continually extend and retract. In
between the filopodia are thin membranes called lamellipodia137, which are also motile
and give the growth cone its characteristic ruffled appearance (Figure 3.1). Both the
lamellipodia and filopodia contain a high density of actin filaments138. Microtubules are
found mainly in the cell body, the shaft of the neuron and the central region of the growth
cone139. Growth cone motility is thought result from actin polymerization. Three members
of the Rho subfamily of small GTP-binding proteins (Rho, Rac, and Cdc42) as well as Ras
have been shown to regulate the actin-based cytoskeleton in fibroblasts (reviewed by
Nobes and Hall140) and may have similar roles in neuronal growth cones. Studies in both
fibroblast and neuronal cell types have identified the following pathway: activation of
Cdc42 leads to the formation of filopodia and to the stimulation of Rac. Ras can also
activate Rac, which in turn gives rise to the formation of lamellipodia and the activation of
Rho141. In fibroblasts, active Rho induces the formation of actin-dominated stress fibers
(axial bundles of F-actin underlying the cell bodies) and focal adhesions (multimolecular
complexes associated with the actin cytoskeleton that contain a number of structural
proteins and proteins involved in signal transduction). In neurons, which do not have
stress fibers and focal adhesions, Rho is thought to regulate neurite retraction (reviewed
by Vancura and Jay142) (Figure 3.2).
Figure 3.1. Whole-mount electron micrograph of a
growth cone in vitro. Two distinct cytoplasmic domains
are present. The approximate boundary between the two
domains is shown by the dotted line. The central (C)
domain contains the microtubules (mt), mitochondria (m),
and dense-core vesicles. The peripheral domain (P)
contains bundles of actin microfilaments (arrowheads)
that form the core of the majority of filopodia. (From
Bridgman and Daily143).
Axon growth requires an enormous investment on the part of the cell, as it must
construct and extend a neurite process many times longer than the cell body. This requires
transport of material through the growing axon as most of the proteins and membranes
that comprise the axon are synthesized in the neuronal cell body. Members of the Rab
subfamily of Ras-related small GTP binding proteins are key regulators of vesicular
transport (Figure 3.2).
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The outgrowth of neurons is always in a certain direction, mediated by the growth
cones itself. This so called axon guidance is influenced by the contacts the filopodia make
with other cells and with the extracellular matrix. In general, the growth cone moves in the
direction where its filopodia make the most stable contacts. In addition, diffusible
substances can bind to receptors on the growth cone surface, and so influence its direction
of migration. Some of these cues promote axon extension (attractive cues), whereas others
inhibit it by causing growth cone collapse (repulsive cues)144-146. Some cues act at long
range and others at short range, thus giving four ways in which the growth cone can be
guided.
Long-range attraction involves diffusible chemo-attractants released from the target
cell, whereas short-range guidance is mediated by contact-dependent mechanisms
involving molecules bound to other cells or to the extracellular matrix. The distinction
between long-range and short-range guidance is mitigated by the finding that distant
targets (long-range) are reached by making use of “stepping stones” or “guide posts”:
localized regions to which the growth cone moves when its filopodia make contact.
Many of the glycoproteins involved in neural adhesion, like NCAM, cadherins and
integrins, contain extracellular immunoglobulin motifs. In addition, a variety of receptor
tyrosine kinases in the axon plasma membrane can regulate axon outgrowth in response to
extracellular signals.
Figure 3.2. Proposed roles for Rho GTPases in axon growth. Activation of Cdc42 leads to the formation of
filopodia and to the stimulation of Rac. Ras can also activate Rac, which in turn gives rise to the formation of
lamellipodia and the activation of Rho. Active Rho then causes neurite retraction. Various Rab family
members (namely Rab2, 3A,5A, and 8) participate in different steps of vesicular transport or endocytosis.
Activation of Rab2 results in increased spreading, adhesion, and neurite outgrowth, by mechanisms that
remain unclear. Although Rab3A participates in synaptic vesicle fusion in mature neurons, the protein’s role
in endocytosis in immature neurons is equivocal. Rab5A is implicated as a regulator of endocytosis, whereas
Rab8 is a key regulator of anterograde vesicle traffic in differentiating neurons. (Adapted from Vancura and
Jay142)
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3.1.2 Formation and refinement of synaptic connections
When axons reach their targets, specialized connections, called synapses, are made.
These are essential for signaling between the neurons and their target cells. In the brain,
the axon of one neuron makes contact with a dendrite from another neuron. Dendrites are
formed in the same way as axons (via filopodia) and they extend from the cell body of the
neuron. Rho affects the number of dendrites and the degree of branching146, and thereby
strongly determines the ability of the neuron to form synaptic connections. Contact
between a presynaptic and a postsynaptic neuron is important for signaling, as well as for
survival of the presynaptic neuron. If an axon does not reach its target, the neuron often
dies. The survival of neurons depends on neurotrophic factors, such as nerve growth
factor (NGF) and brain-derived neurotrophic factor (BDNF), which are produced by the
target cell and for which the neurons compete. The receptors for the neurotrophins are
receptor tyrosine kinases. Different types of neurons require different neurotrophins for
their survival, and the requirement for certain neurotrophins also changes during
development.
For proper brain function, the initial contacts between the growth cone of the neuron
and its target cell must be refined and stabilized. The process of stabilization involves the
assembly of specialized structures that permit the release of synaptic transmitter from the
nerve terminal and its efficient reception by the target cell. The presynaptic terminal
regulates the number and organization of transmitter receptors and other molecules on the
postsynaptic membrane. This process is best studied in the peripheral nervous system, but
it is probably controlled in similar ways in the central nervous system. A primitive form of
synaptic transmission exists from the moment the axon reaches the (muscle) target. First,
the presynaptic axon is capable of releasing its neurotransmitter, acetylcholine (ACh),
before it makes contact with its postsynaptic target cell. Second, the postsynaptic muscle
membrane is capable of responding before it is contacted, via the presence of nicotinic
ACh receptors on its membrane. Subsequently, the distribution of the ACh receptors
changes and new receptors are formed, which ultimately leads to a cluster of ACh
receptors at the synaptic site. The synapses are further stabilized by other molecules in the
postsynaptic basal lamina, to ensure that the ACh receptors remain at the site of the
regenerating synapse. Recognition of the basal lamina by the ingrowing nerve terminal
may depend on specific glycoproteins found primarily at synaptic sites. In neuromuscular
synapses, s-laminin is such a molecule147.
Change in the strength of synapses is often referred to as “synaptic plasticity”, and
changes in the strength of thousands of synapses in a neuronal network ultimately create
human memory148. Memory storage in the mammalian brain is thought to be mediated by
long-term potentiation (LTP) in the synaptic connections in the hippocampus149. The
synapses in the hippocampus are extremely plastic, and a brief high frequency train of
action potentials produces a long lasting increase in synaptic strength (LTP). The collateral
axons in the hippocampus use glutamate as their transmitter. Glutamate produces LTP by
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acting on at least two types of receptors in the dendritic spines: N-methyl-D-aspartate-
(NMDA)- and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors150.
The AMPA receptors mediate basal synaptic transmission, because the ion channel
associated with the NMDA receptor is blocked by Mg2+ at the resting potential (voltage
dependent block). Upon depolarization and binding of sufficient glutamate, the NMDA
receptor is unblocked and activated. NMDA channels are permeable to Ca2+. The
induction of LTP depends on postsynaptic depolarization, the influx of calcium, and the
subsequent activation of second messenger kinases in the postsynaptic cell. LTP has both
short-term and long-term phases. Short-term (minutes to hours) changes create a transient
memory, that does not require protein synthesis. For long-term changes the memory must
be stabilized through gene transcription and synthesis of new synaptic proteins151,152. This
requires the conversion of ATP to the second messenger cAMP by adenylyl cyclase. cAMP
in turn activates protein kinase A (PKA). For long-term changes PKA must translocate to
the nucleus, where it phosphorylates and activates a protein called cAMP response
element-binding protein (CREB). CREB, a nuclear transcription factor, binds to specific
cAMP response element (CRE) sequences on DNA and regulates the transcription of
specific genes, including immediate early genes (i.e. needed for DNA replication and
recombination) such as c-FOS153.
3.2 FUNCTION OF MRX GENES
Specific abnormalities of dendrites have been found in some children with severe
mental retardation and without other evidence of cortical malformation154. The anomalies
include truncation of dendrites, simplification of dendritic arborization, malformed
dendritic spines, and cytoskeletal disturbances155. These abnormalities have been
described for Fragile X syndrome156,157 and other developmental disabilities associated
with MR, including Down syndrome158-160. Such abnormalities in brain microstructure
could impair the ability of the brain to adequately process and store information, resulting
in MR. It can be expected that some of the genes causative for MRX actually encode
proteins that are required for axon outgrowth and/or the establishment and stabilization
of neural connections. Indeed, the products of some of the MRX genes appear to be
directly involved in these processes.
Currently, there are seven genes identified with mutations exclusively in MRX
families, and two genes involved both in MRXS and MRX. Furthermore, the XNP gene is
involved in clinically highly variable mental retardation syndromes, ranging from severe
forms of ATR-X syndrome to apparent MRX. GDI1 is involved in vesicle trafficking
necessary for axon outgrowth. OPHN1, ARHGEF6, and PAK3 regulate the Rho GTPases
that drive axon outgrowth, and that activate a downstream MAPK pathway. TM4SF2,
RSK2, and probably FMR2 play a role in this pathway, and have a function in axon
guidance and the stabilization of synapses that ultimately leads to memory formation. The
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function of IL1RAPL1 is unknown, but it might play a role in synaptic neurotransmitter
release. MECP2 and XNP are thought to be regulators of epigenetic gene silencing. In the
following paragraph the proposed function(s) of the MRX(S)-gene products is discussed.
GDI1
Movement of proteins along the exocytic and endocytic pathways of the eukaryotic
cell occurs by small vesicular carriers that mediate selective transport161. Essential for this
process are a large group of prenylated small GTPases encoded by the Rab gene family.
Rab proteins exist in both inactive GDP-bound and active GTP-bound forms. Conversion
between the two forms is promoted by factors that either accelerate guanine-nucleotide
exchange (GEF), or stimulate guanine-nucleotide hydrolysis (GTPase activating proteins;
GAP)162.
Rab proteins bind to the peripheral membrane of synaptic vesicles and regulate the
fusion events that underlie endocytosis and exocytosis. The traffic-directing function of
Rab proteins depends upon their anchoring to vesicle membranes, and this in turn
depends upon the post-translational addition of geranylgeranyl lipids to their carboxyl
termini163. This addition is carried out by Rab geranylgeranyl transferase (GGT)164, a
multicomponent enzyme consisting of a catalytic component B, and a Rab escort protein
(REP; component A)165. The binding of REP to Rab further provides an “escort” service to
mediate membrane docking of the Rab protein. Following membrane fusion and
inactivation by GAP, a GDP-dissociation inhibitor (GDI) extracts the GDP-bound Rab
from the membrane to the cytosolic reservoir for re-use166,167. In the subsequent step of the
pathway (Figure 3.3), GDI is released to the cytosol and Rab can again be converted to the
GTP-bound form by GEF.
In mammals, three different GDI isoforms (GDIα, -β, and -γ) have been described
that interact with more than 30 different Rab proteins and participate in different fusion
processes168,169. In the mammalian brain, the most abundant form is GDIα167, which
complexes preferentially with Rab3A. Rab3A is crucially important for synaptic
neurotransmitter release119,120. In humans GDIα is encoded by the GDI1 gene in Xq28166. It
shows homology to the REP1 gene in Xq21, which is involved in choroideremia and is an
escort protein for several Rabs, including Rab1A, Rab3A, and Rab27170-172. Two missense
mutations and a nonsense mutation in GDI1 were found to be associated with MRX39,40.
These mutations suggest that the MRX is caused by either the abolished synthesis of GDIα
(nonsense mutation in MRX48) or by a reduced ability to form a complex with the GDP-
bound form of Rab (missense mutations in MRX41 and R). Indeed for the L92P mutation
in MRX41 a 6-fold decrease in the affinity between Rab3A and GDIα was demonstrated40.
All three mutations will lead to a significant decrease in the pool of Rab proteins available
for synaptic vesicle cycling. Although it was suggested first that the mental retardation in
families with a GDI1 mutation is the result of a defect in synaptic activity, there is evidence
that GDIα is also involved in vesicle transport necessary for axon outgrowth. Mouse
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studies revealed that Gdiα is expressed and upregulated early in brain development,
before any synaptic activity is detectable40. Moreover, rat hippocampal neurons40 and
PC12 cells173 treated with Gdi1 antisense oligonucleotides exhibited inhibition of axonal
growth. Therefore, it seems likely that GDIα expression is essential for outgrowth, and not
for differentiation, of axons during brain development. This role for GDIα in neural
development is supported by the results obtained in Gdiα-deficient mice. These mice are
viable and fertile, and showed no morphological abnormalities in their brains174. The
Gdiα-deficient mice showed normal steady-state levels of synaptic proteins, including
Rab3A, and a sharp increase in facilitation of excitatory hippocampal
neurotransmission174. Behavioral analysis and morphological studies on brain
microstructure in the GDIα-deficient mice may yield better insight in the pathology of
XLMR.
Figure 3.3. Synaptic vesicle (V) transport, mediated the small Rab GTPases. Rab geranylgeranyl
transferase (GGT) adds two geranylgeranyl tails to the Rab proteins, necessary for anchoring to the vesicle
membrane. One of the components of GGT, REP, provides an escort service to facilitate membrane docking.
Conversion between the GTP- and GDP-bound form is mediated by GEFs and GAPs. GDI retrieves the
GDP-bound Rab from the membrane.
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OPHN1
Billuart et al.41 characterized the X-chromosomal breakpoint of a t(X;12)175 in a female
MRX patient. A novel gene with 25 exons, OPHN1 or oligophrenin-1, was spanning the
breakpoint in Xq12. A frameshift mutation, leading to a premature stopcodon, has been
identified in family MRX6041,176. OPHN1 encodes a protein that contains a GTPase
activation domain (GAP) for Rho GTPases. Like all members of the Ras superfamily, the
activity of the Rho GTPases is determined by the ratio of their GTP/GDP-bound forms in
the cell162, which is regulated by the opposing effects of GEFs and GAPs. Despite their
name, small GTPases hardly have any intrinsic GTPase activity. GAPs increase the
intrinsic rate of hydrolysis of bound GTP. GEFs enhance the exchange of bound GDP for
GTP. In addition, the Rho-like GTPases are regulated further by GDIs, which can keep the
Rho proteins in their GDP-bound state (Figure 3.4).
The best-studied Rho GTPases are RhoA (Ras homologous member A), Rac1 (Ras-
related C3 botulinum toxin substrate 1) and Cdc42 (cell division cycle 42), often referred to
as Rho, Rac and Cdc42. In addition to their downstream effects on the actin cytoskeleton,
Rho family members affect each other’s activity, and a signal-transduction pathway from
Cdc42 to Rac to Rho has been proposed141. Several proteins that exhibit GAP activity for
Rho GTPases have been identified in mammalian cells (reviewed by Van Aelst and
D’Souza-Schorey177). These proteins all share a related 140 amino acids GAP domain, but
the specificity for members of the Rho subfamily varies with each GAP protein. In
addition to accelerating the hydrolysis of GTP, Rho GAPs may mediate other downstream
functions of the Rho proteins in mammalian systems as an effector178-181. The link between
different Rho GTPase cascades might be established by complex formation of different
GAPs182,183.
Figure 3.4. The switch between the active (GTP-bound) and inactive (GDP-bound) form of Rho is mediated
by GTP-activating proteins (GAP) and guanine nucleotide exchange factors (GEF). OPHN1 acts as a GAP
for the Rho GTPases Rho, Rac, and Cdc42, and is therefore indirectly involved in the organization of the
actin cytoskeleton and in gene transcription.
Oligophrenin-1 is highly expressed in fetal and adult brain and in several other
tissues, and shows in vitro GAP activity for the Rho GTPases Rho, Rac and Cdc42, but not
for other small GTPases tested41. OPHN1 is expressed in primary cultures of neuronal and
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glial cells (Chelly et al., pers. comm.), which corresponds with the recent finding of
overexpressed oligophrenin-1 in human glial tumors184. Both the disruption of OPHN1 by
the translocation breakpoint and the frameshift mutation in MRX60 predict a loss of
function of the oligophrenin protein, which may result in constitutively active Rho
GTPases. This may lead, either directly or indirectly, to aberrant formation of neuronal
processes as was shown in mice transgenic for an activated form or Rac144 and in cortical
cells transfected with constitutively active forms of Rho, Rac, or Cdc42146.
PAK3
PAKs (p21-activated kinases) are effectors of the Rho-like family of small (21 kDa)
GTP-binding proteins, hence their name. Mammalian tissues contain at least four PAK
isoforms: PAK1 (Pakα), which is highly expressed in brain, muscle and spleen185-187; PAK2
(Pakγ), with ubiquitous tissue distribution186,188,189; PAK3 (Pakβ), which is highly enriched
in brain, but with a cell-type distribution that differs from that of PAK1180,190; and PAK4,
most highly expressed in prostate, testis and colon191. The PAKs contain at least four
recognizable sequence elements: two-to-four proline-rich regions that may recognize Src-
homology 3 (SH3) domains; a domain referred to by different authors as p21-binding
domain (PDB), GTPase binding domain (GBD) or Cdc42/Rac1 interactive binding domain
(CRIB); an acidic region; and a C-terminal serine/threonine protein kinase domain
(reviewed by Sells and Chernoff192).
The PDB/GBD/CRIB domain of all mammalian PAKs is able to bind to the small
Rho GTPases Rac1 and/or Cdc42. Upon this binding, the PAKs autophosphorylate at
several serine and threonine residues and acquire increased kinase activity towards
exogenous substrates. PAK kinase activity is essential for the Rho-mediated disassembly
of focal adhesions and actin polymerization in fibroblasts185,193-195. The recruitment of PAK
to the focal complexes can take place via binding of its N-terminal proline-rich domain to
the SH3-domain of PAK interacting exchange factor (PIX)196. Since PIX is also a GEF for
Rac and Cdc42, a potential feedback loop is created in which PAK acts downstream of Rac
and Cdc42 as an effector, but also upstream via its binding to PIX196. The PAK/PIX
interaction allows a signal transduction from Cdc42 to Rac197. Via the activation of Rac and
Cdc42, PAK is involved in the formation of lamellipodia and filopodia198, but these
functions do not require PAK kinase activity199,200. The kinase activity of PAK is required
in the nucleus for phosphorylation of MEK1 and RAF1201-203, and the control of the Jun N-
terminal kinase MAPK pathway (Figure 3.5).
PAK3, via its N-terminal non-catalytic domain, acts upstream of Rac mediating
lamellipodia formation through interaction with βPIX197. The interaction with αPIX or
βPIX stimulates the activity of PAK3204. Mutations in the PAK3 gene have been found in
MRX3042 and MRX4743. The MRX30 mutation introduces a premature stop codon in the
kinase domain of the protein and produces a stable truncated protein lacking kinase
activity and an autophosphorylation site, although the truncated protein can still bind
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activated Rac and Cdc4242. The missense mutation in MRX47 is located in a polybasic
region upstream of the PDB/GBD/CRIB domain and predicts a reduced GTPase binding
and stimulation of PAK activity43. Thus, both mutations have an effect on the kinase-
dependent function of PAK3. Both mutations leave the SH3-binding motif (and therefore
the possibility of binding to PIX) intact. This means that the kinase-independent activities
of PAK3 are not blocked by the mutation. The mental retardation in these families might
therefore be caused by a defect in activation of MAPK signaling and thus activation of
transcription and synaptic plasticity.
Figure 3.5. PIX proteins act as guanine nucleotide exchange factors (GEFs) for the Rho GTPases Cdc42
and Rac. Furthermore, they can bind to PAK kinases, thereby linking Cdc42 to Rac. PAK has a function
upstream of Rac mediating morphological effects through interaction with PIX. At the same time this does
not rule out kinase dependent actions as a downstream effector of Rac. Cdc42 and Rac are involved in the
formation of filopodia and lamellipodia, respectively. (Adapted from Obermeier et al.197, and Van Aelst and
D'Souza-Schorey177)
ARHGEF6
Manser et al.196 identified two PAK-binding proteins containing Src-homology 3
(SH3), Dbl-homology (DH) and pleckstrin-homology (PH) domains, which they named
αPIX and βPIX (for: PAK-interacting exchange factors) (see above text for PAK3). αPIX
also contains a region homologous to the calponin-related domains (CH) of Vav and
IQGAP, necessary for actin binding205. Binding of proline-rich regions of PAK kinases
takes place via the SH3-domain of PIX196. The PH domain is a lipid-binding surface and
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probably also a protein-protein interaction surface, and seems to be essential for proper
cellular localization206. The DH domain is the hallmark of Rho GEFs and constitutes the
catalytic core of the Rho-GEF enzymatic activity for Rac and Cdc42. Several GEFs for small
GTPases have been shown to bind both the GTPases and its downstream effector. Because
there are more than 35 RhoGEFs and only a few Rho GTPases, the GEFs may be important
for the selectivity of GTPase-effector interaction196,207.
Both αPIX and βPIX show GEF activity for Rac and Cdc42, and can bind PAK
proteins. The binding to PAK makes it possible that PIX transduces signals from Cdc42 to
Rac196,197,204(Figure 3.5). Furthermore, through this interaction, PIX co-localizes with PAK
in focal adhesions and forms activated Cdc42- and Rac-driven focal complexes196,208. PIX
proteins can therefore be placed in the previous described signaling pathways involved in
regulation of the formation of lamellipodia and filopodia at neurite growth cones.
Molecular analysis of a reciprocal X/21 translocation in a male with mental
retardation showed that the ARHGEF6 gene in Xq26, encoding αPIX, is disrupted by the
rearrangement. Mutation screening of 119 patients with nonspecific mental retardation
revealed a mutation in MRX46 (appendix 1 and 4, this thesis). The intronic mutation in
MRX46 leads to enhanced skipping of exon 2, and therefore to a partial deletion of the CH
domain of the protein. The exon skipping in the affected males is not complete, meaning
that there are some wildtype transcripts remaining that contain exon 2. Furthermore,
unaffected individuals have up to 10% of exon 2 skipped product, indicating that a simple
dominant negative effect of the mutation is unlikely. Probably, the MRX phenotype in
family MRX46 is caused by a disturbance in the ratio between full-length and exon 2 (CH
domain) skipped product. The mental retardation could be caused by a defect in the GEF
activity of αPIX, and/or by a defect in the localization of the protein, because the CH
domain is necessary for actin binding.
TM4SF2
Tetraspanins form a widely distributed protein superfamily209,210, structurally
characterized by four hydrophobic transmembrane regions (TM1-4) and two extracellular
domains. The extracellular domains are known as large and small extracellular loops, with
short intracellular amino and carboxy tails. The tetraspanin superfamily is composed of
several subfamilies, and some 160 family members are known211. In humans, tetraspanins
are localized in different organs and tissues. CD9, CD63, CD81 and CD82 are nearly
ubiquitous, whereas other tetraspanins seem to be restricted to specific tissues, such as the
lymphoid cells (CD53) or mature B cells (CD37). Tetraspanins are thought to be key
players in the regulation of cell adhesion, proliferation, activation and migration210.
Tetraspanins are known as molecular facilitators, associating in large cell-surface signaling
complexes (referred to as the tetraspanin-web), which include integrins212, co-receptors
(CD4, CD8 and CD2)213,214 and other tetraspanins215,216. Complex formation with ß-1
integrins is described by various authors209,212. Tetraspanins might recruit signaling
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enzymes, such as PI 4-kinase217, into complexes with integrins. It is hypothesized that
these complexes should provide localized production of PtdIns-4-P, and subsequently
PtdIns-4,5-P. These both can then be substrates for PI 3-kinase, and both are also
established regulators of the actin cytoskeleton (Figure 3.6)212.
Figure 3.6. Tetraspanins are involved in integrin signaling and play a role in neural adhesion. Cell adhesion
may regulate the distribution of PI 4-kinase (PI4K), thus leading to a localized conversion of PI to PI(4)P,
which is then converted by PI3K and PI5K to additional products (e.g. PI(3,4)P, PI(4,5)P and PI(3,4,5)P).
PI(4,5)P then contributes to growth factor signaling and regulation of the cytoskeleton. (Adapted from
Hemler212)
The TM4SF2 gene at Xp11.4 codes for a tetraspanin protein218, and is inactivated by
the X-chromosomal breakpoint of a balanced translocation t(X;2)(p11.4;p21.3) in a female
patient with MR and autistic behavior49. Subsequently, in two MRX families from the
European MRX consortium mutations were found (missense and nonsense, respectively).
TM4SF2 is ubiquitously expressed in fetal and adult tissues. The mouse Tm4sf2 is highly
expressed in brain starting at a very early stage of differentiation (day E10.5). In adults, the
highest levels of expression were observed in brain structures that correspond to the
hippocampus and in the cortex, including the primary olfactory cortex49. The high level of
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expression in structures known to be involved in memory development152,219,220 suggests a
role in physiological processes underlying memory and learning abilities.
The mutations found in TM4SF2 gene are predicted to lead to defective integrin
signaling. The disruption of the gene by the translocation leads to a barely detectable RNA
transcript, whereas the nonsense mutation predicts a truncated protein lacking the fourth
transmembrane segment and the carboxy-terminal domain. The missense mutation affects
a non-conservative amino acid in the large extracellular loop49,211. Al three mutations
therefore could lead to an abolished or reduced binding to β-integrin, and subsequently
have an effect on neural adhesion and axon guidance49.
IL1RAPL1
IL1RAPL1 and IL1RAPL2 are recently identified members of the interleukin-1 (IL-1)
receptor protein family (IL1R), whose role in the IL-1 signaling mechanism was delineated
in inflammatory response221,222. IL1RAPL1 has first been described by Carrié et al.45 as
IL1RAPL, and by Born et al.223 as TIGIRR-2. IL1RAPL2 was known before as TIGIRR-1223
and IL1-R9224. Both IL1RAPL proteins show homology to the known human IL1RAcP
(IL1R accessory protein), which is encoded by the IL1RAP gene221. Like the other IL1R
family members, IL1RAPL1 and -2 contain three predicted extracellular immunoglobulin
(Ig) domains, a single transmembrane domain, and a highly conserved cytoplasmic
region223. The C-terminal cytoplasmic region is extended relative to other IL1R family
members, and is reminiscent of the Drosophila IL1R/Toll family members Toll and 18-
Wheeler. However, sequence homology within the cytoplasmic domain clearly shows that
these receptors are more similar to the IL1R family than to the Toll family223.
The homology of the IL1RAPL proteins with IL1RAcP suggested a similar role in
signaling events downstream of IL-1. IL1RAcP by itself has no measurable affinity for IL-
1225,226. Upon binding of IL-1 to its receptor, however, a higher affinity binding complex is
formed containing both IL1R and IL1RAcP225. IL1RAcP is also required for IL-1
signaling227,228, via the IL1R-associated kinases (IRAK). IRAK in turn interacts with tumor
necrosis-factor receptor-associated factor 6 (TRAF-6)229,230, which plays a role in the
activation of nuclear factor κB (NF-κB)231. IL-18 is structurally related to IL-1, and
signaling by IL-18 is mediated by IL18R and IL18RAcP, both members of the IL1R
family232-234. Neither IL1RAPL1 nor IL1RAPL2 could mediate NF-κB activation in response
to IL-1 or IL-18223,224. It is possible that they bind IL-1 or IL-18, but activate an NF-κB-
independent signaling pathway.
IL1RAPL1 is expressed at low level in fetal and adult brain45,223. In the mouse, in situ
hybridization studies showed that it is first detectable in brain at day E10.5 and is
upregulated at day E12.5, particularly in the hippocampus, parts of the cortex and the
olfactory bulbs45. These brain structures are involved in the hippocampal memory system,
suggesting therefore a specialized role for IL1RAPL1 in memory. IL-1 may regulate the
process of learning and memory by modulating neuronal activity in the hippocampus235.
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Additionally, circulating IL-1 is able to act on hippocampal neurons to modulate the
release of acetylcholine, a neurotransmitter involved in the regulation of memory
processes236,237. IL1RAPL1 might therefore act downstream of IL-1 in the regulation of
neuronal activity, via an up to now unknown signaling pathway.
Since the function of IL1RAPL1 is unclear, we can only speculate about the
mechanism by which mutations in the IL1RAPL1 gene cause MRX. Three of the eleven
IL1RAPL1 exons are deleted in MRX34, the entire gene is deleted in family P5 (MR-2), and
in another family a nonsense mutation was detected in the last exon45. RT-PCR revealed
that this mutation leads to a barely detectable IL1RAPL1 transcript compared with that
produced in normal controls. Both mutations therefore are predicted to be loss of function
mutations.
The IL1RAPL2 gene is also located on the X-chromosome (Xq22) and is expressed in
fetal brain223,224. Therefore, it is a likely candidate gene for MRX. However, no mutations
were found in the DNA from approximately 150 patients of the European MRX
consortium (J Chelly, pers. comm.).
FMR2
Fragile sites appear as nonstaining regions, chromatid gaps, or, less frequently, as
breaks in metaphase chromosome spreads. Fragile sites are highly conserved in evolution
and can be found in many species, including primates, mouse, and horse, suggesting a
common structure or function238-240. More than 100 fragile sites on human chromosomes
have been reported to date, which are divided into two major groups. Fragile sites
expressed in all individuals are called common fragile sites, the rest are called rare fragile
sites. Both types are classified according to their induction conditions. Over 80 common
fragile sites are known and induced by aphidicolin, 5-bromodeoxyuridine (BrdU) or 5-
azacytidine. Twenty-five rare fragile sites in the human genome are induced in culture by
the use of distamycin A, BrdU or folate depression. Five rare folate sensitive fragile sites
have been identified at the molecular level (FRAXA, FRAXE, FRAXF, FRA16A, and
FRA11B). These folate sensitive fragile sites are characterized by an expanded and
methylated trinucleotide repeat of CGG or CCG241-248. Of the three X-chromosomal sites,
FRAXA, FRAXE, and FRAXF, the former two are, in their expanded form, associated with
mental retardation.
FRAXA expansion results in Fragile-X syndrome due to down regulation of
expression of the FMR1 gene in Xq28, which carries a polymorphic CGG repeat in the 5’
untranslated portion of its first exon249,250. Normal individuals have between 2 and 50
copies of the CGG repeat. Repeat units larger than 50 CGGs become unstable and affected
individuals have an amplification leading to more than 200 copies241-243,251,252. In
individuals with Fragile-X syndrome, the CGG repeat and the adjacent CpG island are
methylated253,254, and the FMR1 gene is transcriptionally inactive249,250,255.
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FRAXE is a rare fragile site in Xq28, approximately 600 kb distal to FRAXA256,257. An
association of FRAXE expression and mild nonspecific mental retardation in males was
first reported in 1993248. FRAXE expression involves the amplification of a (CCG)n repeat
adjacent to a CpG island. Normal alleles vary from 4 to 39 copies248,258,259. In FRAXE
expressing males more than 200 copies are found. Furthermore, the FRAXE associated
CpG island in these males is fully methylated248. The incidence of FRAXE full mutations in
the population has been estimated as 1 in 23,500260. In 1996, two groups cloned the first
MRX gene, FMR2, which was located next to the fragile site. One of these groups studied
two unrelated boys with submicroscopic deletions near FRAXE and mental retardation47.
The other group used a large-scale sequencing approach48.
The molecular basis of FRAXE has been identified as the absence or truncation47,48 of
the FMR2 protein. This is a consequence of either methylation of the FRAXE CpG island in
individuals with the full mutation (> 200 CCG copies) and consequent transcriptional
silencing of the FMR2 gene102, or deletion within the FMR2 gene47,102. No FMR2 specific
point mutations have been identified so far. FMR2 is expressed in adult brain and
placenta, and in fetal brain, lung, and kidney261. Based on similarity with MLLT2/AF4262,
LAF4263 and AF5q31264, the FMR2 protein was predicted and subsequently demonstrated
to localize to the cell nucleus261. Nuclear localization is consistent with its postulated
function in transcriptional activation261. Little is known about the function of the
AF4/FMR2 family of nuclear proteins. The recent identification of the Drosophila gene
lilliputian (lilli) as a novel member of this family265,266, provides the first insight into the
function of this class of transcription factors. Lilli has a specific function in regulating the
efficiency of signal transduction downstream of Raf, which is an effector of Ras. Raf
activates the extracellular signal-regulated kinase (ERK)-mitogen activated protein kinase
(MAPK) pathway, which will be discussed later in this chapter. As a putative transcription
factor, Lilli may regulate the expression levels of one or multiple components of the
Ras/MAPK signaling pathway265. Furthermore, Lilli regulates the expression of Sry α, a
zygotic regulator of the actin cytoskeleton, and therefore is required for maintaining the
actin network during cell growth and differentiation266. Based on its homology with Lilli,
FMR2 might also be acting on the Ras/MAPK signaling pathway that is involved in
maintenance of the actin cytoskeleton (Figure 3.7).
Some males with normal intellectual abilities and full methylation of the FMR2 gene
have been reported, either identified by a cytogenetically visible FRAXE
expansion248,256,267-269 or by the absence of an FMR2 transcript on Northern blot102. It has
been speculated that the normal phenotype in these individuals is the result of the clinical
variability of the disease, or mosaic methylation in different (especially neuronal)
tissues102,270. Clinical variability may arise if the severity of the FRAXE MR phenotype is
compensated by modifying factors of the genetic background or if the effect of FRAXE full
mutation is so mild that the phenotype remains within the normal intellectual range in
some individuals. The uncertain genotype-phenotype correlation in FRAXE-associated
MR, however, might also be explained by the involvement of another gene than FMR2.
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Recently, Gécz identified the FMR3 gene, which is transcribed in the opposite orientation
to FMR2271. The RNA transcript is most abundantly expressed in adult brain (medulla and
spinal cord), but no ORF was present, indicating that there is no FMR3 protein formed. All
FRAXE repeat expansions tested cause absence of both FMR2 and FMR3 transcripts271. On
the other hand, the intragenic FMR2 deletion does not affect FMR3, which makes the
contribution of the FMR3 gene to the FRAXE MR phenotype unlikely.
Figure 3.7. Proposed function of FMR2. Dotted
lines indicate likely connections in the
intracellular pathway, based on homology with
Drosophila gene lilliputian.
RSK2
Mitogen-activated protein kinases (MAPK) are ubiquitous kinases involved in signal
transduction in eukaryotic organisms272-274. The cascade is a three-kinase module
comprising a MAPK, a MAPK kinase (MAPKK) and a MAPKK kinase (MAPKKK)274-276.
One of the best-studied MAPK cascades consists of the ERK MAPKs, the MAPK/ERK
kinase (MEK) MAPKKs, and the Raf and Mos MAPKKKs. Raf and Mos can phosphorylate
MEK on two serine residues, thereby activating them. Active MEK in turn phosphorylates
ERK, making them active towards downstream substrates. Among the substrates of ERK
are the family of p90 kDa ribosomal S6 kinases (RSK; also known as p90rsk or MAPK-
activated protein kinase)277-280. RSK is unique among serine-threonine kinases in that it
contains two functional kinase domains: an N-terminal domain that phosphorylates
downstream substrates and a C-terminal kinase involved in the auto-activation of RSK.
The RSK isoforms are activated by virtually all extracellular signaling molecules that
stimulate the Ras-ERK pathway, i.e. growth factors and cytokines as well as many peptide
hormones and neurotransmitters. ERK and RSK are present in the nucleus as well as in the
cytoplasm281.
The human RSK family of kinases includes four isoforms: RSK1, RSK2, RSK3280,282,
and RSK4 (appendix 3, this thesis). The isoforms are encoded by distinct genes and show
75-80% amino acid identity. The members of the RSK family show variable tissue
expression, suggesting that they may be involved in different functions in the organism.
RSK2 is the best studied family member. The substrates of RSK include transcription
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factors like CREB, the estrogen receptor-α (ERα), NFκB and c-Fos283-286 (Figure 3.8).
Furthermore, RSK associates with the transcriptional coactivator proteins CREB-binding
protein (CBP) and p300287. RSK binds to polyribosomes and phosphorylates several
proteins in the ribosomal complex288. Finally, RSK has been shown to phosphorylate
glycogen synthase kinase-3 (GSK3), the neural cell adhesion molecule L1CAM, the Ras
GEF Sos, and the p34cdc2-inhibitory kinase Myt1289-292. The diversity of these substrates
suggests that RSK is involved in regulation of a wide variety of cellular functions. Also
histone H3 appears to be a direct or indirect target of RSK2, suggesting that chromatin
remodeling might contribute to MAPK-regulated gene expression293.
Figure 3.8. Role of RSK in signal
transduction. RSK is activated by
ERK and mediates intracellular
signals in response to growth factors,
hormones and neurotransmitters that
are capable of activating the Ras-ERK
pathway. RSK phosphorylates
cytosolic and nuclear proteins that are
involved in diverse cellular processes,
including gene transcription, protein
synthesis and proliferation. (Adapted
from Frödin and Gammeltoft294)
Coffin-Lowry syndrome (MIM 303600) is characterized by mental retardation, facial
and digital dysmorphologies and progressive skeletal malformations. Analysis of the
RSK2 (RPS6KA3) gene in Xp22 in patients with this syndrome revealed intragenic
deletions, nonsense and splice-site mutations that resulted in absent or truncated,
nonfunctional proteins. Furthermore, several missense mutations were reported that also
inactivate RSK2 kinase activity295-297. Interestingly, a missense mutation in a family with
mild mental retardation without any dysmorphisms (MRX19) leads to 5-6 fold decrease in
kinase activity44. Apparently, 15-25% of RSK2 activity is sufficient for normal skeletal
development, but not for normal brain function. It cannot be excluded, however, that the
missense mutation in MRX19 only affects the activity of RSK2 in brain cells. The
involvement of RSK2 in brain function might be established via the phosphorylation of
CREB, which has been implicated in LTP298. It is likely that the gene product of the RSK4
(RPS6KA6) gene in Xq21 plays a similar role in brain development (appendix 3, this thesis),
because deletions of this gene are involved in a contiguous gene syndrome, consisting of
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deafness type 3 (DFN3), MRX and choroideremia (CHM). Until now there is no conclusive
evidence that the RSK4 gene is responsible for MRX, because no mutations were detected
in almost 200 patients from the European MRX consortium. Furthermore, one patient with
a partial deletion of the gene is not mentally retarded. However, the homology with RSK2
still suggests a role in brain development, and functional studies and extended mutation
screening may yet provide the definitive proof.
MECP2
The MECP2 gene in Xq28 encodes methyl-CpG binding protein 2, a small protein
that contains two recognizable domains: an 85 amino acid methyl-cytosine-binding
domain (MBD), and a 104 amino acid transcriptional repression domain (TRD). The MBD
binds to DNA that contains symmetrically methylated CpGs, whereas the TRD interacts
with the transcriptional corepressor SIN3A to recruit histone deacetylases (HDACs).
Interaction between this transcription repressor complex and chromatin-bound MECP2
causes deacetylation of core histones resulting in transcriptional repression299-302.
Deacetylation of the core histones H3 and H4 alters the chromatin structure and renders
the methylated DNA inaccessible to the transcriptional machinery. The MECP2 protein
binds via its MBD to the promoter regions of certain genes that are enriched with CpG
dinucleotides. The methylation of these CpG-islands regulates gene expression by altering
chromatin structure, thereby “turning off” the gene. Rather than to suppress specific
genes, MECP2 is thought to suppress the tissue-specific genes whose activity is not
required in that particular cell type.
Mutations in the MECP2 gene have been found in patients with Rett syndrome (RTT;
MIM 312750), a progressive neurological developmental disorder and one of the most
common causes of mental retardation in females, with an incidence of 1 in 10,000-15,000303.
Patients with classic RTT develop normally until 6 to 18 months of age, then gradually lose
speech and purposeful hand movements. They develop microcephaly, seizures, autism,
ataxia, intermittent hyperventilation, and stereotypic hand movements. After initial
regression, the condition stabilizes and patients usually survive into adulthood. Mutations
in MECP2 account for 70 to 80% of RTT cases and are involved in a broad spectrum of
phenotypes304-313. The fact that such a globally applied mechanism as gene silencing results
in the delayed onset and neuronal specificity observed in RTT suggests that specific genes
are silenced by MECP2. These are presently unknown.
As RTT occurs almost exclusively in females, it has been proposed that RTT is caused
by an X-linked dominant mutation with lethality in hemizygous males. Since the MECP2
gene is subject to X-inactivation314, random X-inactivation in the brain of heterozygous
females might explain that mutations in females are not lethal. The presence of wildtype
MECP2 in half of the cells is apparently sufficient for appropriate neuronal migration and
correct formation and organization of brain structures. However, during the post-natal
period of brain development, when synaptic connections are established and stabilized,
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altered MECP2 activity and the resulting inappropriate expression of MECP2 target genes
may have serious consequences for the development of cognitive function315 (Figure 3.9).
Recent results indicate that MECP2 mutations are not necessarily lethal in males.
Mutations were first reported in severely retarded males with progressive neurological
symptoms316-318 and later in males with non-progressive encephalopathy319, Angelman-
syndrome phenotype320, and even nonspecific XLMR124. Very recently, MECP2 mutations
in MRX16 and two other MRX families from the European MRX consortium have been
reported46,321. Preliminary screening of sporadic unexplained MR, in which fragile-X
screening was negative, indicates that MECP2 mutations are found in 2% of cases46. When
confirmed, MECP2 has a contribution to MRX, equaling that of Fragile-X syndrome.
How MECP2 mutations lead to mental retardation is unclear, since the downstream
target genes are not yet known. Chromatin remodeling provides a mechanism by which
the methylation state of a differentiated cell can be passed on through mitosis. It is
possible that in neurons with defects in epigenetic gene silencing, normally inactive genes
become active. It can be imagined that defects in gene regulation can lead to altered
electrochemical activity in the nervous system and thus disrupt the establishment of
synaptic connections322. Also, it is reasonable to expect that at least some genes regulated
by MECP2 are critical for neuronal development, since small neuronal size and reduced
dendritic arborization are commonly found in brains from RTT patients323-325.
Furthermore, methylation has been implicated as a regulator of CREB function326,
indicating that DNA methylation might play a role in long-term learning and memory327.
Figure 3.9. MECP2 is mutated in RTT syndrome and MRX. (A) During normal development, MECP2 induces
transcriptional repression of its target genes through binding of the MBD domain to 5-methyl cytosine on
DNA (CH3) and binding of the TRD domain to histone deacetylase (HDAC) and the transcriptional co-
repressor SIN3A. (B) The transcriptional silencing complex is not formed with mutant MECP2, resulting in a
mental retardation phenotype.
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X-inactivation plays an important role in the genotype-phenotype correlation of
MECP2 mutations. It is expected that favorably skewed X-inactivation in females may lead
to the absence of clinical features. Indeed, such an X-inactivation pattern has been
observed in healthy carriers of a MECP2 mutation305,316. The phenotype of carrier females
with random X-inactivation depends on the severity of the mutation. Significantly milder
disease was noted in patients carrying missense mutations as compared with those
carrying truncating mutations. And, in the case of truncating mutations, late mutations are
associated with milder disease308. If the mutation is very mild, i.e. when it is not lethal in
males, random X-inactivation in the carrier mothers might not even have a phenotypic
effect. Indeed, random X-inactivation was reported in healthy carrier females46,318,319.
Strikingly, carriers of the A140V mutation who showed random X-inactivation, were
reported to have either no phenotype46, or to have mild MR124. Since the X-inactivation
pattern is studied in peripheral blood leukocytes, it is likely that non-random X-
inactivation in neuronal cells is involved.
XNP
SNF/SWI proteins (homologues of S. cerevisiae "sucrose nonfermenter" and
"switching defective") control transcription by opening the nucleosome structure at a
promoter and by facilitating the binding of transcription factors to their cognate sites328.
SWI/SNF can bind to either nucleosomes or DNA in an ATP-independent fashion329,330,
but the nucleosome remodeling activity of SNF/SWI is ATP-dependent329,331. SWI/SNF
proteins form large, multi-subunit complexes, containing eight or more proteins. A
"minimum catalytic core" complex of three SWI/SNF components, BRG1, INI1, and
BAF155/BAF170, is necessary for nucleosome remodeling332. SWI/SNF complexes have
been shown to contain either actin or actin-related proteins333,334. Actin might be required
for SWI/SNF association with the nuclear matrix but not for its catalytic activity334. The
finding that SWI/SNF also represses transcription335,336 was unexpected, since the
disruption of nucleosome structure would facilitate the binding of transcription factors,
thereby activating transcription. However, repression of transcription by SWI/SNF could
be caused by facilitated binding of transcriptional repressors, but also a mechanism
independent of nucleosome remodeling activity could be involved, like histone
modification337. It was suggested that, in higher eukaryotes, the epigenetic regulation of
transcription by chromatin remodeling plays a critical role in the controlled expression of
developmental programs and the stability of the cellular determined state338-340.
The X-linked nuclear protein (XNP) belongs to the SNF2/SWI2 subfamily of helicase
proteins341,342. The XNP protein contains a putative DNA-binding domain composed of
three multicysteine zinc finger motifs, and a helicase domain composed of seven
conserved motifs343. The helicase domain is expected to possess the ATPase activity and
may be involved in chromatin remodeling by interacting with DNA using the energy of
ATP hydrolysis341,343. The XNP protein participates in the formation of multiple protein
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complexes and is able to associate with the human EZH2 protein344, a human homologue
of the Drosophila gene Enhancer of zeste, which is involved in the regulation of homeotic
gene expression through chromatin remodeling345. Furthermore, XNP interacts with
heterochromatin protein (HP1)346. XNP is a nuclear protein closely associated with the
nuclear matrix at interphase and found close to pericentromeric chromatin during
mitosis347,348. The XNP transcript is ubiquitously expressed and particularly abundant in
human and mouse brain. In the developing mouse brain, the gene is highly expressed in
areas where neural proliferation is occurring.
Mutations in the XNP gene in Xq13 have first been reported in ATR-X syndrome
(MIM 309580), which is characterized by severe mental retardation, α-thalassemia,
characteristic facial dysmorphisms, microcephaly and urogenital malformations126.
Subsequent mutations have been found in a variety of other severe mental retardation
conditions with facial dysmorphisms127-131. Recently, mutations have also been found in a
family in which two affected males showed moderate to profound MR and had the typical
characteristic features of ATR-X, but two others had mild MR and epilepsy and did not
have the typical facial dysmorphisms132. This led to the hypothesis that the gene could be
involved in familial cases of MRX and a mutation was found in a family previously
diagnosed with MRX (appendix 5, this thesis). Retrospectively, some mild dysmorphic
signs were seen in photographs taken in childhood, but the main conclusion that can be
drawn from this finding is that males with an apparently nonspecific MR may carry a
mutation in this gene.
The pathogenic effect of mutations in the XNP gene is unclear. Mutations in the zinc
finger of the protein cause impaired nuclear location and altered DNA binding
properties349. The exact mechanism of protein mislocalization is uncertain, and may be a
consequence of failure of protein-protein interaction or a failure of DNA binding activity.
All mutations associated with α-thalassemia are located within the helicase domain. It has
been hypothesized that XNP regulates expression of several genes, including the α-globin
gene, as well as other genes involved in development of the brain. Yet, target genes other
than the α-globin gene have not been identified.
3.3 ROLE OF MRX GENES IN MEMORY DEVELOPMENT
Over the last three years, the repertoire of genes involved in MRX has expanded
rapidly. Despite this high degree of apparent heterogeneity, two groups of MRX genes
seem to exist: The first group (containing MECP2 and XNP) plays a role in regulation of
transcription via chromatin remodeling. The other group comprises those MRX genes that
are directly involved in neuronal morphogenesis. Strikingly, most of the genes in the latter
group can be placed in one signaling pathway that involves the Rho GTPases and MAPK.
This pathway is directly involved in actin cytoskeleton organization that drives the
outgrowth of neurons. IL1RAPL1 and GDI1 cannot directly be placed in either of these two
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groups. IL1RAPL1 might be involved in the release of ACh in hippocampal neurons,
thereby playing a role in the regulation of memory processes. GDI1 is involved in vesicle
trafficking necessary for neuron outgrowth, and in the control of synaptic
neurotransmitter release through Rab3A.
The known and proposed functions of all MRX genes are integrated in one model for
memory development (Figure 3.11).
3.3.1 Repression of transcription
Selective expression of certain genes is necessary for the correct differentiation of a
specialized cell type. It is not only essential to turn on the proper genes, but also to silence
other genes. Inactive regions in the genome are characterized by condensed chromatin
(heterochromatin), that is enriched with hypoacetylated forms of histones H3 and H4. The
promoters of these genes are generally hypermethylated. Epigenetic silencing mechanisms
like hypoacetylation and hypermethylation can be stably maintained through mitosis, and
can therefore be passed on to all daughter cells.
DNA methylation in mammalian cells occurs at the 5-position of cytosine within the
CpG dinucleotide, creating 5-methyl cytosine. There are about 45,000 CpG islands in the
mammalian genome, most of which reside within or near the promoters or first exons of
genes and are unmethylated in normal cells, with the exception of CpG islands on the
inactive X-chromosome in females350. The unmethylated CpG islands have an open
chromatin structure that is deficient in the linker histone H1 and contain nucleosomes
enriched in acetylated forms of histones H3 and H4351.
DNA methylation is established by DNA methyltransferases and leads to
transcriptional silencing of the associated gene. Methyl-CpG binding proteins, including
MECP2, selectively recognize methylated DNA and associate with co-repressor complexes
that include histone deacetylases301,302. Recruitment of a histone deacetylase by MECP2
occurs indirectly through its interaction with the SIN3A adaptor protein, which causes
transcriptional silencing, in part by deacetylating the histones301,302. This directs the
formation of stable repressive chromatin structures352 (Figure 3.10).
XNP is a member of the SNF2/SWI2 family of transcription factors. SNF/SWI
proteins are able to alter the structure of nucleosomes via the formation of large, multi-
subunit complexes. Although they were first thought to disrupt the nucleosome structure,
therefore acting as transcriptional activators, it is now known that they remodel
nucleosomes between two states: the "inactive" state and the "remodeled" state, with equal
proficiency353,354. XNP is thought to regulate gene expression by altering chromatin
structure via direct binding to heterochromatin-associated proteins. XNP interacts with
heterochromatin protein (HP1)346 and with EZH2344, which is implicated in the assembly
of repressive protein complexes and is involved in gene silencing. Apparently, also here
the nucleosome remodeling leads to a facilitated binding of transcriptional repressors. It is
unclear, however, how the interaction of XNP with EZH2, forming a transcription
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repression complex, leads to the activation of α-globin expression. Interestingly, the
human α-globin cluster was found to be located in a segment of chromatin which becomes
hyperacetylated when the α-genes are fully active in erythroid cells355. Furthermore,
patients with ATR-X syndrome also have methylation defects, which include both hypo-
and hypermethylation at certain repetitive elements356. Since DNA methylation and
histone deacetylation precede the chromosome remodeling, it is likely that XNP acts on
one of these processes. It has been hypothesized that XNP might be a member of a
HDAC/MECP complex involved in establishing or maintaining the pattern of methylation
in the genome356.
Figure 3.10. The mechanism whereby DNA methylation and histone deacetylation cooperate to repress
transcription. A transcriptionally active region targeted for silencing is proposed to acquire DNA methylation
first, which then recruits the methyl-CpG binding proteins and their associated co-repressors and histone
deacetylases. As DNA methyltransferase can interact directly with histone deacetylase, it is also possible
that transcription is first silenced by deacetylation by other tethering factors, after which the methylation
machinery and the methyl-CpG binding proteins are recruited to “cement” the promoter in the silent state. In
either case, the deacetylated nucleosomes adopt a more tightly packed structure that inhibits the access of
transcription factors to their binding sites. (Adapted from Robertson and Wolffe357)
(CBP)
(MECP2)
(RSK2)
(XNP)
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Mutations in MECP2 and XNP both lead to a variety of mental retardation
phenotypes, depending on the severity of the mutation. Both genes are highly expressed
in brain. Chromatin remodeling and methylation of DNA apparently are essential for
normal brain development. DNA methyltransferase activity is high in neurons358,
indicating that gene silencing is very important for the correct function of neurons (during
brain development and in adult life), allowing only the essential genes to be expressed.
Activation of only a few genes that are normally inactivated during neuronal
morphogenesis can have dramatic consequences for the correct functioning of learning
and memory processes. The elucidation of which genes are normally silenced by MECP2
and XNP will give more insight in the pathogenesis of mental retardation.
Finally, also the RSK2 protein plays a role in chromatin remodeling, via the
phosphorylation of histone H3 upon stimulation with epidermal growth factor (EGF)293.
The growth-factor dependent interaction of RSK2 with the transcriptional coactivator
CREB-binding protein (CBP)287, a histone acetyltransferase359, raises the possibility that
histone acetylation and phosphorylation may act together to facilitate gene expression293.
3.3.2 Signaling through Rho GTPases and MAP kinases
As described in the first paragraph of this chapter, neuronal development starts with
the outgrowth of axons. The formation of filopodia and lamellipodia is regulated by the
Rho GTPase cascade. Activation of Cdc42 leads to activation of Rac and finally to
activation of Rho. MRX genes that can be placed directly in this cascade are ARHGEF6,
OPHN1, and PAK3. OPHN1 acts as a GAP on Cdc42, Rac and Rho. Mutations in this gene
therefore lead to an abolished GAP activity, meaning that the switch from the GTP-bound
to the GDP-bound form of the Rho GTPases cannot take place, leaving them constitutively
active. αPIX, the product of the ARHGEF6 gene, acts as a GEF on Cdc42 and Rac, but also
binds to PAK. PAK3 is a downstream effector of Cdc42 and Rac. Mutations in both genes
therefore have an effect on the normal Cdc42-Rac-Rho pathway that is necessary for the
formation of filopodia and lamellipodia, via modulation of actin cytoskeleton organization
in the growth cone.
Axon guidance is dependent on neural adhesion via binding to molecules like
integrins. The activation of the MAPK pathway by Rho GTPases appears to be integrin
dependent360. It is possible that TM4SF2, through its interaction with β-1 integrins, plays a
role in activation of the MAPK pathway, although the mechanism is not yet elucidated.
PAK can directly phosphorylate Raf, a MAPKKK, which in turn activates MEK (MAPKK)
and ERK (MAPK). ERK can activate the RSK2 protein, both in the cytoplasm and in the
nucleus. The subsequent phosphorylation of downstream substrates of RSK2 ultimately
leads to the maintenance of the actin cytoskeleton and formation of memory via the
activation of CREB. Although not proven, the FMR2 protein might play a similar role,
based on its homology with the Drosophila lilliputian that regulates the MAPK pathway
and is also thought to be involved in the maintenance of the actin cytoskeleton265,266.
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Combining the proposed functions of the MRX genes described above into a model
(Figure 3.11) gives insight in the pathways involved in the development of memory
processes. Loss of function mutations in the MRX genes involved in this pathway suggest
that the mental retardation could be caused by impaired ability of actin cytoskeleton
organization to drive neurite outgrowth leading therefore to aberrant neuronal
morphogenesis, dendritogenesis and connectivity between neuronal cells. Obviously,
other genes involved in this pathway are candidate genes for mental retardation.
Figure 3.11. Schematic involvement of the currently known MRX genes (depicted in gray). Dotted lines
indicate likely connections in the pathway.
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4.1 MRX GENES
As one could perhaps have predicted from the complexity of the CNS, the MRX
genes encode a range of proteins, including transmembrane proteins, transcription factors,
kinases and proteins that regulate members of the Ras superfamily of small GTP-binding
proteins. Up to now, molecular studies performed by 1) FISH analysis and physical
mapping of X-chromosome rearrangements in mentally retarded individuals (positional
cloning), and 2) by testing candidate genes that map in the X-chromosome regions defined
by linkage studies (positional candidate gene approach), have identified seven genes that
are specifically mutated in MRX families: FMR247,48, GDI139,40, OPHN141, PAK342,43,
IL1RAPL145, TM4SF249, and ARHGEF6 (appendices 1 and 4, this thesis). Furthermore, in two
MRXS genes mutations have been found in families with MRX: RSK244, and MECP246.
Now that essentially all human genes have been identified by the human genome projects,
the strategies for detecting novel MRX genes need to be reassessed. Specifically, the
candidate gene approach will be most effective in future identification of novel MRX
genes. Positional cloning approaches do not always lead to the identification of novel
genes. Furthermore, genes that are already known to be involved in mental retardation
syndromes, now are excellent candidate genes for nonspecific MR. A good example is the
XNP gene. The MRX family in which a mutation was found (appendix 5, this thesis)
showed minimal characteristics of ATR-X syndrome, but only on retrospective analysis.
These results indicate that mild syndromic features in childhood can disappear in
adulthood. MRXS genes involved in a broad clinical spectrum should be regarded as
candidate genes for MRX.
Two main processes seem to be affected by mutations in the MRX genes. The first is
the global gene silencing in neurons during development. For the developing neuron it is
essential that the correct genes are turned on. It is of equal importance that other genes are
turned off. Both MECP2 and XNP play a role in this global gene silencing process. The
other process involved in MRX is the intracellular pathway that is initiated by Rho
GTPases. These are involved in actin cytoskeleton rearrangement, that is necessary for the
correct outgrowth of filopodia and lamellipodia from the growth cone of a neuron. Direct
regulation of these Rho GTPases takes place via OPHN1, αPIX, and PAK3. Downstream of
this pathway the MAPK pathway is activated, probably via interference of TM4SF2 and
FMR2. RSK2 has a function downstream of the MAPK pathway. RSK2 can phosphorylate
CREB in the nucleus. This protein in turn is essential for LTP and memory.
All MRX genes are expressed early in development, and most of them are expressed
in the hippocampus in the adult brain. This brain structure is considered one of the
important regions for learning and memory, and alterations, both during development
and postnatally, may account for mental handicap. The study of mouse knock-outs for the
MRX genes, which are under way in different laboratories, will help to clarify some of the
underlying pathogenic mechanisms.
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4.2 THE X-CHROMOSOME AND INTELLIGENCE
4.2.1 How many MRX genes exist?
In 1996, delineation of the number of non-overlapping MRX localizations led to a
minimum estimate of eight genes51. This estimate has since been increased to 17, by
including the seven identified MRX genes and two genes for syndromic and nonspecific
XLMR. In the most recent compilation eight non-overlapping regions can still be counted
(see Figure 2.1, this thesis). As only in 9 of 76 MRX families (Table 4.1) a mutation has been
identified, only 12% of cases has been solved. On average, each MRX gene identified until
now, is mutated in approximately 1% of patients tested. The overall number of X-linked
genes implicated in mental retardation may therefore be substantially more than 17. A
better estimation can be made if also the mutations found in small (unlinked) families are
counted. The European MRX consortium has searched for mutations in seven of the MRX
genes (GDI1, OPHN1, PAK3, IL1RAPL1, TM4SF2, ARHGEF6, and MECP2) in
approximately 150 patients. In these seven genes in total 16 mutations were found (Table
4.1), which is still only 10% of tested patients. The MECP2 gene was found to be mutated
in four families, meaning that this gene alone contributes to more than 2% of MRX cases.
Analyses in a large cohort of mentally retarded males, for whom the fragile-X diagnostic
test was negative, indicates also MECP2 mutations in 2% of cases46.
Table 4.1. Genes involved in MRX
Gene Means of identification Mutation in MRX family Mutation in small family
FMR2 Positional cloning 47 - -
GDI1 Functional candidate MRX41, MRX4840 Family R (P6)39
OPHN1 Positional cloning MRX6041 -
PAK3 Functional candidate MRX3042, MRX4743 -
RSK2 MRXS gene295 MRX1944 -
IL1RAPL1 Positional cloning MRX3445 N36, P545
TM4SF2 Positional cloning - L28, T1549
ARHGEF6 Positional cloning MRX46 (appendices 1 and 4, this
thesis)
-
MECP2 MRXS gene304 MRX1646 L26318, T3646, T44321
XNP MRXS gene126 - N29 (Appendix 5, this thesis)*
*This family was implicated in the European consortium panel of 200 MRX patients, but after the XNP
mutation was identified, childhood hypotonia and HbH inclusion bodies were found in some patients of the
family.
One could argue that not in all 150 patients of the European XLMR consortium an X-
chromosomal gene is involved, and that the actual number of MRX patients tested is
lower. This cannot be excluded. The European XLMR consortium includes only families
with more than two affected males, and in which the disease is only transmitted by
females. Even in the families with the lowest criteria, i.e. two affected brothers, it has been
estimated that there is 80% chance that the mental retardation is the result of a defect in an
X-linked gene361. Thus, it is likely that X-linked genes are involved in most of the families
from the European XLMR consortium.
Some X-linked genes involved in chromosomal aberrations associated with MR have
been described, in which up to now no mutation in MRX families has been found. At least
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four of these genes exist: DXS6673E106, GRIA3107, VCX-A108, and RSK4 (appendix 3, this
thesis). The RSK4 gene is particularly interesting, because of its high homology with RSK2.
Future mutation analysis of three novel exons may yet reveal a mutation in MRX.
Although other genes might be located in the MRX critical interval in Xq21, this is
unlikely, given the paucity of ESTs and predicted genes in the region
(http://genome.cse.ucsc.edu/).
Taking all into account, it seems fair to expect 50 or more MRX genes on the X-
chromosome. Although unlikely, it is still possible that there is a small number of major
genes which are frequently mutated and account for a significant proportion of mentally
retarded patients. Some authors have reported that the distribution of the genetic loci over
the X-chromosome is not “at random”, and that there is a clustering of MRX loci around
the centromere. Indeed, looking at the overlap of linkage intervals in the 76 MRX families
reported, one would expect a hotspot for mutations in the pericentromeric region of the X-
chromosome, with  the highest mutation frequency in Xp11.23  (Figure 4.1).  However,  the
Figure 4.1. Distribution of linkage data in MRX family and genes on the X-chromosome. Black bars indicate
the distribution of MRX linkage intervals, normalized for the size of the intervals. Shortly, linkage intervals
were given a fixed value of 100, divided by the size of the linkage interval in megabases. This means that the
probability of the presence of an MRX gene in a certain chromosome band is higher if the linkage interval is
small. Per chromosome band, the calculated values of the MRX families linked to the band were added. The
gray line indicates the gene density on the X-chromosome. (Adapted from combined sequence data of the
Sanger and EMBL centers, at http://www.ensembl.org/perl/mapview?chr=X)
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high number of families linked to this region does not necessarily mean that this region
contains an unknown MRX gene that is frequently mutated. In the same figure the gene
density on the X-chromosome is depicted, and Xp11.23 appears to contain more genes
than other regions. Probably more MRX genes are located in this region. The most
prominent difference between gene density and the MRX linkage data is seen in Xq28.
However, already three MRX genes are identified in this band: FMR2, GDI1 (mutated in
MRX41 and MRX46), and MECP2 (mutated in MRX16).
MRX gene identification may be "easiest" in regions with low gene density, but
where a lot of MRX families are linked. In this view, Xp21.3 and the region from Xp21.1 to
Xp11.3 are good candidate regions.
4.2.2 Are there any autosomal MR genes?
Several authors have posited the idea that a concentration of genes on the X-
chromosome concerned with intelligence may be a major explanation of the male excess in
MR9,14,362-366. Indeed, a number of X-chromosomal genes for nonspecific MR have been
identified, whereas no autosomal genes are known. Further evidence for the importance of
X-linked genes that influence intelligence is provided by the fact that there is greater
variability of intelligence among males367. Males have fewer performers in the middle
(mean) range than females, and more in the extremes beyond 2 standard deviations. It has
been hypothesized that because of hemizygosity for genes on the X-chromosome, males
feel the full influence of these intelligence genes, whether positive or negative. In females,
a second X-chromosome serves to modify the influence, lessening the impact of positive or
negative influences of specific genes for intelligence9. One would expect that on the X-
chromosome also genes for superior intelligence exist. No variations in X-linked genes
have been identified that might account for higher IQ (>130), but such families have not
been sought or investigated.
There is a strong bias toward identifying genes on the X-chromosome. Against the
idea of the disproportionate influence of the X-chromosome in determining intelligence is
the observation that microdeletions and subtelomeric deletions almost anywhere in the
autosomal genome produce mental retardation17,368. Given the broad spectrum of genes
that are expressed in the brain during and/or following development, it is expected that
numerous autosomal genes are involved in cognitive function. Several autosomal genes
have been identified for syndromes in which mental retardation is a recurrent feature, but
no autosomal genes for nonspecific mental retardation have been described. Current
research into the identification of autosomal genes is focused on screening patients with
idiopathic MR for submicroscopic rearrangements and deletions particularly in telomeric
regions. Several such rearrangements have recently been identified17,109,368,369. Knight et
al.368 described subtle chromosomal abnormalities in 7.4% of children with unexplained
moderate to severe MR, indicating that subtle chromosomal rearrangements are the
second most common cause of moderate to severe MR after Down’s syndrome.
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Homozygosity mapping in consanguineous families with affected offspring would be
another approach370. Linkage analysis revealed only one autosomal locus for nonspecific
mental retardation (without additional phenotypic characteristics)371. Autosomal recessive
mental retardation is probably not always recognized and is likely to be highly genetically
heterogeneous. There are not many autosomal dominant pedigrees with MR expected,
because except for milder forms, these individuals do not reproduce. Identification of
autosomal genes involved in cognitive function will benefit from knowledge accumulating
in the field of XLMR, as these genes will likely encode proteins that play a role in the same
molecular pathways. If the number of MRX genes does exceed 50 (but even if there are
less) and if genes essential for normal cognitive function are randomly distributed in the
genome, the level of complexity of the underlying molecular basis for mental retardation
will be enormous370.
4.3 Future prospects
To date, causative genetic defects were identified for 17 families with nonspecific X-
linked mental retardation. Since it is expected that there might be more than 50 MRX
genes, the identification of novel genes remains a challenge. Positional cloning has so far
proven the most efficient way to identify MRX genes. In some cases, however, the
breakpoint-spanning fragments have been cloned and sequenced, but no gene could be
identified. Also, positional cloning is a time-consuming method, and the involvement of
the cloned gene in MRX can be proven only when a mutation in another family is found.
Identification of MRX genes will thus require systematic testing of many candidate genes
for mutations in probands of families with compatible localization. One could envisage to
directly screen candidate genes on such a cohort of patients. Indeed, in the TM4SF2 gene,
mutations were found in two small families without significant linkage data. The
identification of novel MRX genes therefore requires the analysis of a large number of
MRX families, both large linked families and families that are too small to obtain a
significant lod score.
The availability of probands may thus constitute a limiting factor in the identification
of novel MRX genes. In order to overcome this limitation it will be necessary to join forces
and to exchange patient material. Establishment of the European XLMR consortium was
the first initiative to construct a large patient panel, which has resulted in a collection of
approximately 200 well-characterized XLMR families. Most of these families have
nonspecific MR. Inclusion criteria are the existence of at least two affected males in the
family, and only females transmitting the disease. In some pedigrees, carrier females
might show milder mental retardation.
Given the necessity to test large numbers of patients, high-throughput mutation
analysis is required for identification of novel MRX genes. Nowadays direct sequencing on
a 96 capillary machine, with or without pre-screening protocols like SSCP, DGGE or D-
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HPLC, is the fastest way to perform such analyses. Once the conditions for analysis of
mutations are defined for a given gene, they can be used easily on a relatively large
number of samples in a single experiment. For individual molecular genetics laboratories
it is time consuming and too expensive to test all 1500 X-chromosomal genes in 200
patients. Only if direct sequencing reactions become less expensive and/or collaboration
with large genome sequencing centers provide a greater capacity for mutation analysis,
such a large project can be successful. Until then, it will be useful to select candidate genes
on positional and/or functional information. Positional information can be obtained by
traditional positional cloning approaches. In the near future the identification of
microdeletions on microarrays will also provide information on the position of MRX
genes. Genes that act on transcriptional regulation or play a role in signaling pathways
through Rho GTPases and MAP kinases are excellent functional candidate genes for MRX.
Furthermore, additional MRX candidate genes might be identified by their altered
expression in MRX patients with chromosomal aberrations372. In this way genes can be
identified that are either directly involved in the chromosomal rearrangement, or
indirectly via a position effect.
Therapy for nonspecific X-linked mental retardation will not be possible in the near
future. Future studies have first to give more insight in the mechanisms leading to MRX,
and in the microstructure of the brains of MRX patients. For neurodegenerative disorders,
a possible new therapeutic neurological and neurosurgical methodology involves cell
implantation into the living brain in order to replace neuronal systems. Embryonic stem
cells implanted in the brains of mice and rats develop into neurons and make renewed
connections373, and even adult cells from the bone marrow can enter the brain in mice and
become neuron-like cells374. Pilot studies in humans with Parkinson's disease gave
promising results, although the optimal cells for replacement cannot be reliably obtained
or generated in sufficient numbers for a standardized medically effective intervention375.
In any case, neurodegeneration (progressive neuron loss) and neurodevelopment are
different mechanisms in the brain. Therefore, such therapy protocols might not even be
applicable to treat mental retardation. Of equal importance, the use of gene- and cell based
therapies, and whether or not this research should be pursued on mentally retarded
individuals is also subject of ethical debates.
For the families in which the genetic defect is found, genetic counseling becomes
possible. For some families linkage data alone may be beneficial, as a means of carrier
identification, prenatal detection, and postnatal diagnosis. With few exceptions, the only
DNA diagnostic test is offered for the Fragile-X syndrome. FMR1 repeat expansion
explains approximately 2% of all MR in males376. If it turns out that the MECP2 mutations
are equally frequent, diagnostic screening for mutations in this gene should be
implemented. The other MRX genes contribute only 0.5-1% to the prevalence of MRX. It
will be hard to develop a cost-effective screening for these genes in a DNA-diagnostic
laboratory. With today’s DNA-diagnostic protocols it is feasible to test only these genes
that are more frequently causally involved in MR. To increase the number of positive
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DNA-based diagnoses in MRX it will be necessary to include several genes in one test. A
good test will give the most positive results with the lowest number of exons tested.
Therefore, an inventory has to be made of the contribution of each gene to MRX. Those
genes that are most frequently mutated in a panel of well-defined MRX families (e.g. those
from the European XLMR consortium) have to be tested in an even larger panel of patients
for whom the Fragile X screening was negative. The genes in which the most mutations
will be identified in the latter group are candidates to include in a diagnostic test.
The ultimate scientific goal is not just finding the genes for MRX, but understanding
how they function. Knowledge of the complete set of MRX genes will undoubtedly
suggest new areas of investigation of neuronal function. Insight in the organization and
functioning of the human brain can be obtained by cognitive neuroimaging, both in
healthy and in mentally retarded individuals. Such in vivo measurements can produce
pictures that shed new light on brain functions ranging from the processing of sensory
information to higher level thinking tasks. A major approach in cognitive neuroimaging is
to scan the brain's hemodynamic activity during the execution of a cognitive task.
Functional magnetic resonance imaging (fMRI) and positron emission tomography (PET)
may in the future focus on those brain areas in which MRX genes are known to be
specifically active. Based on knowledge of the underlying genetic pathophysiological
mechanism, future functional imaging as well as neuropsychological testing (and
combinations of these) could also be fine-tuned to specifically target biological and
physiological processes that are predicted to be affected. In this way, the current rapid
increase of the basic genetic level may soon translate into a better functional
understanding of human brain function. It will take many years before all of this is of
practical benefit to the mentally retarded patient. For now it is encouraging that at least
some progress has been made in understanding the molecular mechanisms underlying
human brain function.
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ABSTRACT
We report linkage data on a new large family with nonspecific X-linked mental
retardation (MRX), using 24 polymorphic markers covering the entire X-chromosome. We
could assign the underlying disease gene, denoted MRX46, to the Xq25-q26 region. MRX46
is tightly linked to the markers DXS8072, HPRT, and DXS294 with a maximum lod score of
5.12 at θ=0. Recombination events were observed with DXS425 in Xq25 and DXS984 at the
Xq26-Xq27 boundary, which localizes MRX46 to a 20.9 cM (12 Mb) interval. Several X-
linked mental retardation syndromes have been mapped to the same region of the X-
chromosome. In addition, the localization of two MRX genes, MRX27 and MRX35,
partially overlaps with the linkage interval obtained for MRX46. Although an extension of
the linkage analysis for MRX35 revealed only a minimal overlap with MRX46, it cannot be
excluded that the same gene is involved in several of these MRX disorders. On the other
hand, given the considerable genetic heterogeneity in MRX, one should be extremely
cautious in using interfamilial linkage data to narrow down the localization of MRX genes.
Therefore, unless the underlying gene(s) is characterized by the analysis of candidate
genes, MRX46 can be considered a new independent MRX locus.
Figure 1. Five generation family with MRX. Twenty-seven family members, including 10 affected males,
were available for DNA study. Haplotypes of the linked markers in Xq25-q26 and the recombined markers
delimiting the probable gene location are shown. Deduced haplotypes from subjects who had died are
shown between brackets. The disease chromosome is indicated by a black bar.
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INTRODUCTION
X-linked mental retardation (XLMR) is considered to be the most frequent type of
mental handicap in males. It has been estimated that mutations in X-chromosomal genes
account for 25 to 50 % of all cases of mental retardation1. A small part of XLMR can be
attributed to recognizable syndromes and to date more than 100 XLMR syndromes
(MRXS) have been described2. More often, however, the mental handicap is not associated
with consistent phenotypic characteristics. This is referred to as nonspecific XLMR or
MRX.
Linkage analyses in individual families with MRX have currently shown over 50 loci
on the X chromosome which are clustered in eight non-overlapping regions3,4. The
inclusion of the FRAXE mental retardation gene5 and the RAB-GDI gene6 suggests a
minimum of 10 X linked genes which are involved in non-specific mental retardation. In
this report, we present a large family with non-specific X linked mental retardation and
the mapping of the underlying gene to Xq25-q26, a region that has rarely been implicated
in MRX.
PATIENTS AND METHODS
Clinical report
The family (Figure 1) was ascertained when IV.7 was referred for genetic counseling.
The pedigree included 12 mentally retarded males in three generations, nine of whom
were clinically examined. In order to determine the mental status of these patients, the
following intelligence tests, standardized for school aged children, were used: (1) the
Wechsler Intelligence Scale for Children Revised (WISC-R)7,8, (2) the Coloured Progressive
Matrices (CPM)9,10, (3) the Revised Amsterdam Child Intelligence Test (RAKIT)11, and (4)
McCarthy Scales of Children's Abilities12. The RAKIT and McCarthy Scales were applied
to assess intellectual functioning below an equivalent of 6 years13. Scores of all tests were
transferred into age equivalents according to the classification of the American Association
of Mental Deficiency (AAMD)14. Cytogenetic analysis and molecular study of the FMR1
gene was performed in several patients. In III.28 the diagnostic tests included cerebral CT
scan and metabolic screening. Informed consent was obtained in all instances.
DNA analysis
DNA from 26 relatives was isolated from peripheral blood lymphocytes, according to
the procedure by Miller et al.15. In order to determine the most likely location of the gene,
linkage analysis was performed with highly polymorphic markers distributed along the X-
chromosome. Analysis of these markers involved amplification by polymerase chain
reaction (PCR) carried out in a 96 well Thermal Cycler (MJ Research Inc, Waterston, MA).
Each reaction contained 100 ng genomic DNA, 30 ng of each of the primers, in 15 µl 1 ×
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Supertaq buffer (50 mmol/l KCl, 1.5 mmol/l MgCl2, 10 mmol/l Tris-HCl, pH 9.0, 0.1%
Triton X-100, 0.01% (w/v) gelatin) in the presence of 32P-dCTP with 0.06 U Supertaq (HT
Biotechnology Ltd, England). Amplification was achieved by 35 cycles of one minute at
94°C, two minutes at 55°C, and three minutes at 72°C with the locus specific primer pairs
registered in the Genome Database (http://www.gdb.org/). The radiolabeled PCR
products were mixed with 15 µl sample buffer (95% formamide, 20 mmol/l EDTA, 0.05%
xylene cyanol, 0.05% bromophenol blue) heated to 95°C for two minutes, and 4 µl of this
mixture was separated on a 6.6% denaturing polyacrylamide gel. Subsequently, the gel
was dried and exposed overnight to Kodak X-OMAT film to visualize the separated allelic
bands.
Two point linkage analyses of the 24 polymorphic markers and the disease locus
were performed with the MLINK option of the computer program LINKAGE (version
5.03)16-18 on the basis of X linked recessive inheritance with full penetrance. The relative
order of marker loci was obtained from the Genome Database and the Report of the Sixth
International Workshop on X Chromosome Mapping19.
RESULTS
Clinical report
In all patients, pregnancy and delivery were uneventful. The mental retardation was
noticed during early childhood and appeared non-progressive. None of them had
convulsions. All patients were either institutionalized or living and working in a sheltered
Figure 2. Faces of affected males. A: II.18 at
65 years, B: III.12 at 57 years, C: III.13 at 54
years, D: III.15 at 47 years, E: III.16 at 38
years, F: III.20 at 44 years. (Photographs
reproduced with informed consent).
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environment. Physically they were all healthy. Their behavior was normal, except for the
brothers III.24, III.26, and III.28 who were described as difficult to control, chaotic, and
autistic-like, and III.16 who showed obsessive behavior. III.11 died at the age of 11 during
heart surgery. He was attending a special education unit. Obligate carriers were all
normal. Results of the clinical measurements and psychometric studies are summarized in
Tables 1 and 2, respectively.
Only minor anomalies were noted in some of the affected males. II.18 (Figure 2A)
was seen at the age of 65 years. He was short statured. Hypertelorism, a fleshy nose, full
lower lip, kypholordosis, and lower leg varices were noticed. III.12 (Figure 2B) showed no
abnormalities except for lower leg varices when seen at the age of 57 years. III.13 (Figure
2C) was examined at the age of 54 years. Except for a left sided hydrocele no abnormalities
were detected. III.15 (Figure 2D) and III.16 (Figure 2E) showed no abnormalities on
examination at the ages of 47 and 38, respectively. III.20 (Figure 2F) was examined at the
age of 44 years. Left sided hydrocele and a large hyperpigmented spot on the back were
seen. III.24 showed a highly arched palate, short and broad neck, and flat feet on
examination at the age of 34 years. He was short statured. Ophthalmologic examination of
III.26 at the age of 29 years showed hypertelorism, myopia gravis ODS, and some
lenticular opacities. In III.28 hypertelorism and myopia gravis OD, resulting in amblyopia
and divergent strabismus, were seen on ophthalmologic examination. The degree of
mental retardation in the affected family members tested varied from mild to profound. It
is concluded that pedigree structure and clinical data are fully compatible with a diagnosis
of nonspecific X-linked mental retardation.
Table 1. Summary of clinical measurements (centiles)
Height (cm) Weight (kg) OFC (cm) Ear length
(mm)
OCD (mm) ICD (mm) THL (cm) Testicular
volume (cm3)
II-18 160 (<3) 56 (<10) 56 (50) 75 (97) 95 (75-97) 38 (>97) 18 (50-75) 20 (50)
III-12 182 (50) 85 (90) 56 (50) 71 (75-97) 81 (3-25) 29 (25-50) 19,5 (97) 22 (50-90)
III-13 168 (<10) 83 (90) 56,5 (50-90) 60 (50) 83 (25) 31 (50) 19 (75-97) 23 (50-90)
III-15 182 (50) 92 (>90) 58,5 (>90) 65 (75) 95 (75-97) 35 (75-97) 18 (50-75) 25 (50-90)
III-16 182 (50) - 59 (>90) 61 (50) 84 (25-50) 31 (50) 19 (75-97) -
III-20 172 (3-10) 76 (50-90) 58 (90) 60 (50) 91 (50-75) 32 (50-75) 19 (75-97) 20 (50)
III-24 163 (<3) 75,5 (50-90) - - - - - -
III-26 170 (3-10) 60 (10) 54 (10-50) 60 (50) 105 (>97) 35 (75-97) 19 (75-97) -
III-28 181 (10-50) 91 (>90) 58 (50-90) 65 (75) 105 (>97) 38 (>97) 19,5 (97) -
OCD = outer canthal distance
ICD = inner canthal distance
THL = total hand length
− = no data
DNA analysis
For the initial analyses, 23 markers spread along the X chromosome were genotyped
on 12 potentially informative family members. The family was informative for all tested
markers. Once tentative linkage with HPRT and DXS294 was obtained, another marker in
the region, DXS8072, was typed and more affected and unaffected family members were
genotyped for the linked markers (26 relatives in total). Table 3 presents the results of the
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two point linkage analysis, with the lod scores for the MRX locus and each marker locus.
The proximal locus DXS425 at Xq25 and the more distal locus DXS984 at the Xq26-q27
boundary recombined with the disease in the family, delimiting the probable gene
location. Significant lod scores were obtained with markers DXS8072, HPRT, and DXS294,
indicating that the genetic defect responsible for the disease in this family is located in
Xq25-q26, with a maximum lod score of 5.12 at θ=0 (at HPRT). A reconstruction of the
haplotypes of the markers in the Xq25-q26 region is shown in Figure 1.
Table 2. Summary of psychometric data
Academic achievementCases Intelligence* Non-verbal
reasoning*
Visual/
motor skills*
Adaptive
functioning*
Reading† Writing† Arithmetic†
II-18
− +/− +/− +/− + + −
III-12
− − −
+ + + +
III-13
− +/− + − − − −
III-15
− +/− +/− +/− − − +/−
III-16 +/− + − + + +/− +
III-20
− +/− ‡ +/− + + ‡
III-24 −
− − − − − −
III-26
−
− − − unable unable − − − − − −
III-28
− − unable − − − − − − −
*levels of mental and adaptive functioning, transferred into age equivalents:
+ = > 10−9 years (= borderline and above; IQ-range ± 70−84 and above);
+/−= 8−3 and 10−9 years (= mild; IQ range 50/55−70);
− = 5−7 to 8−2 years (= moderate; IQ range 35/40−50/55);
− −= 3−2 to 5−6 years (= severe; IQ range 20/25−35/40);
− − − = < 3−2 years (= profound; IQ range < 20/25).
† levels of academic functioning, transferred into didactic age equivalents (dae):
+ = > 30 months (= adequate);
+/−= 1−29 months (= inadequate);
 − = 0 months (= unable).
‡ =no actual information available.
DISCUSSION
We have presented a new family with recessive non-specific X linked mental
retardation and assigned the causative genetic defect, MRX46, to Xq25-q26. This region is
estimated to comprise a genetic distance of 20.9 cM20 and a 12 Mb region on the physical
map19.
Seven XLMR syndromes have been assigned to X chromosomal segments
overlapping the linkage interval for MRX46 (Figure 3). Huang et al.21 reported on a family
with an X-linked mental retardation disorder (MRXS5), including Dandy-Walker
malformation, basal ganglia disease and seizures. Börjeson-Forssman-Lehmann syndrome
(BFLS)20,22,23 is characterized by severe mental retardation, microcephaly, hypogonadism,
obesity, short stature, and distinct facial anomalies including large ears, prominence of the
supraorbital ridge, and ptosis. Malmgren et al.24 reported a family with severe X-linked
mental retardation syndrome, linked to DXS294 at Xq26. This so-called Gustavson
syndrome includes microcephaly, severe mental retardation, optic atrophy with decreased
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vision or blindness, severe hearing defect, characteristic facial features, spasticity, seizures,
and restricted joint motility. The patients die during infancy or early childhood25.
Cowchock syndrome, an X-linked motor-sensory neuropathy type II with deafness and
mental retardation has been mapped between DXS425 and HPRT26,27. Recently, some of us
described a family presenting with varying degrees of mental retardation in conjunction
with isolated growth hormone deficiency28. The underlying genetic defect for this disorder
could be assigned to the Xq24-q27.3 region. Interestingly, in a recent report, an unrelated
family with similar symptoms is described in which the genetic defect is localized to the
same region29. In this family, X-linked recessive panhypopituitarism (XPH) is associated
with a duplication of the DXS102 locus, suggesting that this phenotype is caused by a gene
dosage effect. Lesch-Nyhan syndrome (OMIM 308000) is another well known syndrome
with MR, caused by mutations in the HPRT1 gene. It cannot be ruled out that one of the
genes involved in these MR syndromes is also causative in MRX46, but given the
pronounced distinctive features of each syndrome, it is difficult to imagine how mutations
in one such gene may cause (severe) non-specific MR.
Table 3. Lod scores between MRX46 and markers along the X chromosome (in order from Xpter to Xqter)
0.000 0.050
θ
0.100 0.200 0.300 0.400
DXS1060
− ∞ −1.93 −0.91 −0.08  0.19  0.19
GHGxG
− ∞ −2.05 −1.01 −0.16  0.13  0.17
DXS443
− ∞ −1.96 −1.14 −0.42 −0.11  0.01
DMD
− ∞ −6.04 −4.01 −2.07 −1.03 −0.39
DXS538
− ∞  0.02  0.40  0.52 −0.35  0.10
DXS7
− ∞ −0.68 −0.29 −0.15 −0.26 −0.29
DXS1003
− ∞ −6.34 −4.30 −2.34 −1.26 −0.53
ALAS2
− ∞ −2.23 −1.19 −0.35 −0.04  0.02
DXS453
− ∞ −5.46 −3.72 −2.05 −1.12 −0.49
DXS559
− ∞ −2.07 −1.34 −0.77 −0.49 −0.23
DXS986
− ∞ −2.07 −1.34 −0.77 −0.49 −0.23
DXS3
− ∞ −0.79 −0.39 −0.23 −0.30 −0.28
DXS178
− ∞ −2.07 −1.34 −0.77 −0.49 −0.23
Col4A5
− ∞ −2.07 −1.34 −0.77 −0.48 −0.23
DXS424
− ∞ −1.96 −1.14 −0.42 −0.11  0.01
DXS1001
− ∞ −0.96 −0.25  0.21  0.27  0.15
DXS425
− ∞  0.14  0.96  1.31  1.09  0.57
DXS8072  4.43  3.99  3.54  2.60  1.63  0.66
HPRT  5.12  4.70  4.26  3.32  2.28  1.12
DXS294  4.95  4.51  4.04  3.07  2.03  0.96
DXS984
− ∞  2.14  2.34  2.10  1.53  0.81
FraXAc2
− ∞  0.09  0.28  0.35  0.28  0.16
DXS1113
− ∞ −0.06  0.15  0.25  0.22  0.13
DXS1108
− ∞ −0.06  0.15  0.25  0.22  0.13
Very recently, two novel MRX loci encompassing Xq26, MRX27, and MRX35 have
been uncovered by linkage analysis in apparently unrelated families from the United
Kingdom and Belgium, respectively30-32. MRX27 has been localized to the Xq24-q26 region
with flanking recombination events in affected males at DXS424 and DXS102, which spans
all but the distal portion of the MRX46 linkage interval (Figure 3)31. MRX35 maps to Xq22-
q26 with flanking markers DXS178 and HPRT32. DNA samples from this family (kindly
provided by Professor JP Fryns and Dr P Raeymaekers) allowed us to assign DXS8072 as
the distal flanking marker in MRX35. Hence, the overlap between MRX46 and MRX35
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comprises a region of less than 2 cM at the Xq25-q26 boundary (Figure 3). If the same gene
is involved in the three MRX families that map to Xq26, the region to search for candidate
genes would be significantly reduced. However, given the genetic heterogeneity of MRX
one should be extremely cautious of using interfamilial linkage data to narrow down the
localization of MRX genes. This is especially true since MRX46 seems to differ from
MRX27 and MRX35 in that the variability and severity of the mental handicap is more
pronounced and, yet, carrier females never exhibit any mental impairment. Therefore, the
whole Xq26 band has to be considered for identification of candidate genes in the family
presented here. According to the physical map of Pilia et al.33 five genes for which the
complete coding region is known are located in this region (Figure 3). In addition, the
human transcript map34 (http://www.ncbi.nlm.nih.gov/SCIENCE96/) reports more than
50 expressed sequence tags for this region. Unfortunately, expression data for the
corresponding genes are not available and it is therefore not possible at this stage sensibly
to select likely candidate genes for MR from this gene pool.
Figure 3. Localization of XLMR conditions in the Xq25-q26 region. The top bar shows the order of relevant
markers and genes (underlined) on a Mb scale. The horizontal bars indicate the linkage intervals.
Arrowheads at the end of the bars indicate that the linkage interval extends beyond the chromosomal region
shown. BFLS: Börjeson-Forsmann-Lehman syndrome; GS: Gustavson syndrome; CS: Cowchock syndrome;
MR-IGHD: mental retardation with isolated growth hormone deficiency; XPH: X-linked recessive
panhypopituitarism.
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ABSTRACT
We report linkage analysis in a new family with nonspecific X-linked mental
retardation, using 27 polymorphic markers covering the entire X-chromosome. We could
assign the underlying disease gene, denoted MRX65, to the pericentromeric region, with
flanking markers DXS573 in Xp11.3 and DXS990 in Xq21.33. A maximum LOD score of
3.64 was found at markers ALAS2 (Xp11.22) and DXS453 (Xq12) at θ=0. Twenty-five of the
58 reported MRX families are linked to a region that is partially overlapping with the
region reported here. Extension of the pedigree showed a number of unaffected distant
relatives with haplotypes corresponding to the disease locus. Apparently, a new mutation
in a female is causative for the disease in the family reported here. Furthermore, we show
the importance of the combining clinical, cytogenetic, and molecular studies since one of
the family members, expected to be affected by the same genetic defect, has a 48,XXXY
karyotype.
INTRODUCTION
X-linked mental retardation (XLMR) is clinically variable and genetically
heterogeneous. Fifty-eight families with nonspecific XLMR (MRX) are listed in a review by
Lubs et al.1. Since only three genes for MRX have been identified, FMR22, GDI13 and
oligophrenin-14, the vast majority of genes are not known. Twenty-five of the 58 reported
families show linkage to the Xp11-q21 region1. The large number of families mapping to
this region suggests either a clustering of MRX genes or the existence of one or a few genes
that are frequently mutated. We report yet another family with nonspecific XLMR
(MRX65) that maps to the pericentromeric region. Haplotype analysis shows that a de
novo mutation in one of the females is causative for the condition in this family.
PATIENTS AND METHODS
Clinical report
The family (Figure 1) was ascertained when IV-15 was referred for genetic
counseling. Initially a branch of the family with six affected males in three generations was
tested (Figure 1A). In order to determine the mental status of the patients suspected for
mental retardation, we employed the three criteria form the DSM-IV definition of mental
retardation5: 1) intelligence: IQ of 70 or lower; 2) significant limitations in adaptive
functioning; 3) onset before the age of 18 years. In order to be able to establish a qualitative
description of intellectual functioning, intelligence tests, standardized for school-aged
children, were used: the Wechsler Intelligence Scale for Children, Revised (WISC-R)6,7 and
the Revised Amsterdam Child Intelligence Test (RAKIT)8. Initially, all patients suspected
for mental retardation were assessed with subtests of the WISC-R. If these proved to be too
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difficult and a floor effect threatened, we exchanged them for the RAKIT. The second
criterion was measured with a Dutch questionnaire9,10. The age of onset was obtained by
anamnestic information. Scores were translated into age equivalents according to the
classification of the American Association of Mental Deficiency (AAMD)11.
Once tentative linkage was established, genealogical research lead to an extended
pedigree with two additional affected males (III-5 and IV-22), one of whom had already
died (Figure 1B).
Figure 1. Five-generation family with MRX. Fifty-two family members were available for linkage analysis. A:
Original part of the family that is used for linkage analysis. Haplotypes of some of the linked markers in
Xp11.3-q21.33 and the recombined markers delineating the probable gene location are shown. Deduced
haplotypes from deceased individuals are represented between brackets. The disease chromosome is
indicated by a black bar. B: Extended part of the family, showing that a recent mutation in the small branch
has to be causative for the disease. Only the haplotypes for the linked markers from Fig. 1A are shown. The
solid (III-5) and hatched (IV-22) symbols indicate that the mental retardation in these males is not due to
mutation at the MRX65 locus. Obligate carrier females are indicated by half open circles.
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DNA analysis
DNA from 19 family members, isolated from peripheral blood lymphocytes
according to the procedure of Miller et al.12, was used for linkage analysis with 27 highly
polymorphic markers distributed along the X-chromosome. Once linkage was established,
33 additional relatives were tested for the linked markers. Analysis of the markers
involved amplification by polymerase chain reaction (PCR). Each reaction contained 100
ng genomic DNA and 30 ng of each primer, in 15 µl Supertaq buffer (50 mM KCl, 1.5 mM
MgCl2, 10 mM Tris-HCl pH 9.0, 0.1% Triton X-100, 0.01% (w/v) gelatin) in the presence of
32P-dCTP with 0.06 U Supertaq (HT Biotechnology LTD, Cambridge, England).
Amplification was achieved by 35 cycles of 1 min 94°C, 2 min 55°C and 3 min 72°C with
locus-specific primers registered in the Genome Database (http://gdbwww.gdb.org/).
The radiolabeled PCR products were mixed with 15 µl sample buffer (95% formamide, 20
mM EDTA, 0.05% bromophenol blue) heated to 95°C for 2 min and 4 µl of this mixture
was separated on a 6.6% denaturing polyacrylamide gel. Subsequently, the gel was dried
and exposed overnight to Kodak X-OMAT film to visualize the separated allelic bands.
Two-point linkage analyses of 27 polymorphic markers and the disease locus, tested
in 19 family members, were performed with the MLINK option of the computer program
LINKAGE (version 5.03)13-15 on the basis of X-linked recessive inheritance with full
penetrance. The relative order of marker loci was obtained from the Genome Database and
the report of the Sixth International Workshop on X-Chromosome Mapping16.
RESULTS
Results of clinical measurements and psychometric studies are summarized in Table
1. Pregnancy and delivery of patients IV-6, IV-10, IV-14, and V-1 were uneventful, whereas
no information is available for patients III-14 and III-15. The mental impairment was
noticed during early childhood and appeared nonprogressive. None of them had had
convulsions and all had normal vision and hearing. All appeared to have relatively poor
speech. Physically they were all healthy. Individual IV-10 was institutionalized and V-1
attended a special school for children with severe learning difficulties, while the others
were living and working in a sheltered environment. Some showed chaotic behavior and
aggressive outbursts. Only minor anomalies were noted in some of the affected males.
Macrocephaly and obesity were observed in one and four patients, respectively. Small
testes were observed in four of the patients (III-14, III-15, IV-6, and IV-10), but no exact
measurements were available. The level of mental impairment varied from moderate to
borderline. In all patients there was a tendency to score better in performance than in
verbal intelligence tests. The male with borderline impairment (IV-14) had normal scores
in performance tests, but showed mild mental retardation according to verbal tests. Since
no consistent features other than mental retardation were seen, it was concluded that
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pedigree structure and clinical data were fully compatible with a diagnosis of nonspecific
X-linked mental retardation.
Table 1. Summary of Clinical Measurements (centiles) and Psychometric studies
Individual Age
(years)
Height (cm) Weight (kg) OFCa (cm) Earlength
(mm)
OCDb (cm) ICDb (cm) Mental
Impairmentd
III-14 56 173 (10) 100 (>97) 57 (50-90) 8 (>97) 8.5 (25-50) 2.5 (3) mild
III-15 53 170 (3-10) 112 (>97) 58 (90) 8 (>97) 9 (50-75) 3 (50) moderate
IV-6 52 177 (10-50) 90 (>97) 55.5 (50) 7 (75-97) 9.5 (75-97) 3 (50) moderate
IV-10 24 162 (<3) 61 (10) 56.5 (50-90) 6.5 (75) 9 (50-75) 3 (50) moderate
IV-14 28 181 (50) 96.5 (>97) 59 (>97) 7.5 (97) 9 (50-75) 2.6 (3-25) borderline
V-1 6.5 106 (<3) 15 (<3) 47.5 (3) 4.5 (<3) 7.6 (25) 2.5 (3-25) mild
aOFC, occipitofrontal circumference17
bOCD, outer canthal distance
cICD, inner canthal distance
dMental impairment: borderline, IQ 70-85; mild, IQ 55-69; moderate, IQ 40-54
For the initial analysis, markers chosen at regular distance on the whole X-
chromosome were genotyped on 19 family members. Table 2 presents the results of the
two-point linkage analysis in the small branch of the family (Figure 1A), between the MRX
locus and each marker locus. Two regions with positive LOD scores were found. The
relatively low LOD score in combination with haplotype analysis (data not shown) makes
the localization of the genetic defect in the region between the MAO A and DXS6941 loci
unlikely. Thus, the candidate region was defined by the proximal locus DXS573 at Xp11.3
and the more distal locus DXS990 at Xq21.33. A maximum LOD score of 3.64 was
calculated for the markers ALAS2 and DXS453 at θ = 0. A reconstruction of the haplotypes
in the pericentromeric region is shown in Figure 1A.
In order to narrow down the linkage interval for MRX65, extensive genealogical
studies were performed, which revealed an extended pedigree with two additional
affected relatives (Figure 1B). Individual III-5 had already died. He was said to have
attended special education school and to have suffered from perinatal asphyxia.
Unfortunately no other data on this patient were available. Patient IV-22 was attending
special education school because of learning disabilities.
Members from the extended part of the family were tested for the markers that
showed linkage in the original branch. Haplotype analysis revealed seven unaffected
males with the same haplotype in the linked region as the affected individuals in the
original part of the family. This suggests that a new mutation occurred in II-3 and caused
the disease in her six of here male descendants. Consequently, the reported mental
impairment of III-5 and IV-22 has another etiology, in III-5 most likely the perinatal
asphyxia. Interestingly, IV-22 DNA analysis clearly showed two allelic bands for most
markers tested. Karyotype analysis in all 15 cells tested revealed that the patient has 48
chromosomes (48,XXXY). The extended part of the family was excluded from the linkage
analysis. Haplotypes of the markers tested are shown in Figure 1B.
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DISCUSSION
We have presented a new family (MRX65) with recessive nonspecific X-linked
mental retardation and assigned the gene to a 45-cM interval between Xp11.3-q21.33,
delimited by the markers DXS573 and DXS990.
Although some of the patients showed features that have also been reported in
XLMR syndromes, these characteristics were found not to be consistent throughout the
family. Macrocephaly, small testes, and obesity were reported in one, four, and four of the
six affected males, respectively. Therefore, the disease segregating in this family is a
nonspecific X-linked mental retardation condition, which makes it the twenty-sixth family
linked to the pericentromeric region. In approximately half of the reported MRX families
in which linkage studies are performed, the causative gene is located in this chromosomal
segment. This suggests either a clustering of genes involved in X-linked mental
retardation, or the existence of a few such genes that are frequently mutated. The results
described in this paper provide evidence for a recent mutation in MRX65. An argument
for a high mutation rate in a major MRX gene in this region is provided by the relatively
small size of the linked families. Moreover, extensive genealogical studies that date back to
the 18th century have failed so far to identify a common ancestor in the Nijmegen MRX
families (APT Smits et al., unpublished observations).
Table 2. Lod Scores Between MRX65 and Markers Spread along the X-Chromosome
(in order from Xpter to Xqter)
Marker
0.000 0.050
2
0.100 0.200 0.300 0.400
DXS1060 - ∞ -0.22  0.42  0.76  0.67  0.38
DMD - ∞ -2.78 -1.51 -0.49 -0.14 -0.08
DXS538 - ∞ -2.78 -1.51 -0.49 -0.14 -0.08
DXS7 -∞ -0.51  0.14  0.51  0.45  0.20
MAO A -∞  1.05  1.35  1.32  0.96  0.45
DXS1003  1.74  1.62  1.48  1.16  0.77  0.32
DXS426  1.44  1.34  1.23  0.96  0.62  0.24
DXS6941 -∞  0.40  0.58  0.61  0.49  0.28
DXS573 -∞  2.05  2.05  1.71  1.18  0.54
ALAS2  3.64  3.37  3.08  2.43  1.67  0.79
DXS339  1.82  1.68  1.53  1.21  0.85  0.45
DXS453  3.64  3.37  3.08  2.43  1.67  0.79
DXS559  1.82  1.68  1.53  1.21  0.85  0.45
DXS986  2.04  1.88  1.71  1.32  0.87  0.36
DXS3  2.34  2.14  1.93  1.47  0.95  0.39
DXS990 -∞  1.23  1.32  1.15  0.80  0.34
DXS1231 -∞  2.07  2.08  1.76  1.23  0.57
DXS178 -∞  1.79  1.83  1.56  1.09  0.49
Col4A5 -∞  1.77  1.80  1.51  1.04  0.46
DXS424 -∞  0.78  0.90  0.80  0.53  0.19
DXS425 -∞ -2.42 -1.56 -0.76 -0.36 -0.12
HPRT -∞ -5.84 -3.82 -1.93 -0.94 -0.35
DXS294 -∞ -3.69 -2.51 -1.36 -0.72 -0.30
DXS984 -∞ -2.20 -1.36 -0.60 -0.23 -0.06
FRAXAc2 -∞  0.12  0.32  0.40  0.34  0.20
DXS1113 -∞ -1.00 -0.70 -0.40 -0.22 -0.10
DXS1108 -∞ -1.78 -0.79 -0.02  0.23  0.22
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The present study underlines the importance of the combination of clinical,
cytogenetic, and molecular analysis. Due to the high prevalence of mental retardation in
the general (male) population, extension of pedigrees might result in inclusion of false
positive individuals (i.e., III-5 and IV-22) who were initially thought to be cases of
nonspecific X-linked mental retardation. Only the combination of molecular and
cytogenetic investigations revealed that their mental handicap was not due to a mutation
at the MRX65 locus.
Note (added in proof): The family described here is the same as family F91-09 described in
the article of Billuart et al. (1998). Although the oligophrenin-1 gene is located within the
linkage interval, no mutations were found in family MRX65.
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ABSTRACT
Large deletions in Xq21 often are associated with contiguous gene syndromes
consisting of X-linked deafness type 3 (DFN3), mental retardation (MRX), and
choroideremia (CHM). The identification of deletions associated with classic CHM or
DFN3 facilitated the positional cloning of the underlying genes, REP-1 and POU3F4,
respectively, and enabled the positioning of the MRX gene in between these genes. Here,
we report the cloning and characterization of a novel gene, ribosomal S6-kinase 4 (RSK4;
HGMW-approved symbol RPS6KA6), which maps in the MRX critical region. RSK4 is
completely deleted in eight patients with the contiguous gene syndrome including MRX,
partially deleted in a patient with DFN3 and present in patients with an Xq21 deletion and
normal intellectual abilities. RSK4 is most abundantly expressed in brain and kidney. The
predicted protein of 746 amino acids shows a high level of homology to three previously
isolated members of the human RSK family. RSK2 is involved in Coffin-Lowry syndrome
and nonspecific MRX. The localization of RSK4 in the interval that is commonly deleted in
mentally retarded males together with the high degree of amino acid identity with RSK2
suggests that RSK4 plays a role in normal neuronal development. Further mutation
analyses in males with X-linked mental retardation must prove that RSK4 is indeed a
novel MRX gene.
INTRODUCTION
X-linked mental retardation (XLMR) is the most frequent genetic cause of mental
handicap in males. A portion of all XLMR cases can be attributed to complex syndromes
(MRXS), more than 100 of which have been described1. More often, the mental handicap is
not associated with specific biochemical, neurological, or morphological abnormalities.
This is referred to as nonspecific XLMR or MRX2 and has an estimated incidence of 1 in
550 males3. At least 10 different genes are involved in the over 60 MRX families reported1,4.
In only a minority of MRX cases, mutations are found in the recently identified four MRX
genes: FMR25,6, GDI17,8, OPHN19, and PAK310. The identification of other genes involved
in MRX is hampered by the high genetic heterogeneity. The linkage intervals are generally
too large to identify successfully the causative gene by positional cloning. New MRX genes
can be identified either by candidate gene analysis, as has been achieved for GDI17,8 and
PAK310, or by fine-mapping of the disease locus by using chromosomal abnormalities such
as deletions or translocations. FMR2 was identified because of its location next to a fragile
site (FRAXE)5,6, and a translocation breakpoint in Xq12 was used for the cloning of
OPHN19. Here, we describe the positional cloning of an MRX candidate gene in Xq21 by
deletion mapping.
Deletions in Xq21 give rise to a complex phenotype including X-linked deafness type
3 (DFN3), MRX, and choroideremia (CHM)11-13. Sizable deletions have also been found in
patients with nonsyndromic DFN3 or CHM14-19 and in one patient with MRX and CHM20.
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Physical fine-mapping of the Xq21 deletions previously enabled us to clone the genes
underlying CHM and DFN3, denoted REP-1 and POU3F4, respectively21-23. The gene
underlying MRX in patients with this contiguous gene syndrome has been mapped to a
region between POU3F4 and REP-113,20. We have narrowed down the MRX critical region
in Xq21 by fine-mapping the deletion in patients with DFN3. Cosmids derived from a
yeast artificial chromosome (YAC) spanning the critical interval were used to isolate a
novel gene, named RSK4*. To demonstrate the involvement of this gene in MRX, we
searched for mutations in 200 families with multiplex cases of mental retardation
compatible with X-linked inheritance, employing single-stranded conformation
polymorphism (SSCP) analysis and direct sequencing.
Figure 1. Physical map of the Xq21 region containing the MRX locus and the RSK4 gene. A: Patients with
deletions (represented by dotted lines) that have been critical for narrowing the MRX critical interval are
represented. LGL290518 suffers from CHM; AP20 suffers from CHM and MR; and patients TD14, EP, and VS16
suffer from DFN3. B: The RSK4 gene spans approximately 75 kb. Marker p968 is present on cosmid E1;
marker DXS232 is mapped on cosmid G9. The intron sizes are drawn to scale. C: The total RSK4 cDNA is
represented by two RACE clones, two clones from a retina cDNA library (13B and H22), an RT-PCR product,
and two clones from the GenBank database (Accession Nos. 231438 (pineal gland) and 198833 (fetal
liver/spleen).
                                                
* The HGMW-approved symbol for the gene described in this paper is RPS6KA6.
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MATERIALS AND METHODS
Patient material
Patients with a deletion in Xq21 have been described previously (reviewed in
Philippe et al.24). DNA from CHM patient LGL290518, patient AP20 who suffers from CHM
and MR, and DFN3 patients TD14, EP, and VS16 has been examined for narrowing down
the MRX critical interval. Clinical data and blood samples of MRX(S) families tested in
SSCP analysis were obtained after informed consent. DNA from peripheral blood
lymphocytes was isolated according to the procedure of Miller et al.25. Affected males of
200 families were tested, 16 of which had a genetic defect linked to Xq21. Some of these
families have been described: MRX426, MRX1327, MRX2028, MRX5229, MRX6530, Wilson-
Turner syndrome31, MR with ataxia and deafness32, and MR with cleft palate and short
stature33.
Physical map of the MRX locus
Fine-mapping of the region surrounding the MRX locus was performed by analyzing
breakpoints of deletions in the Xq21 region. DNA from patients LGL2905, AP, TD, EP and
VS was analyzed by PCR analysis (DXS995, DXS232, and DXS121) and Southern blotting
(p968). p968 was generated as a 2.3-kb inter-Alu PCR product with the CotterIV primer34.
A partial cosmid contig from the region was obtained by subcloning YAC 970a10 from the
CEPH library using the sCOGH2 vector35.
Isolation of RSK4 cDNA clones
Human cDNA clone 231438 (GenBank Accession No. H92571 (3’) and H92239 (5’))
was mapped within the MRX critical interval by PCR analysis on a panel of patients with a
deletion in Xq2124. This cDNA was radioactively labeled by random primer extension36
and used to screen 1 x 106 plaques of a human embryonic craniofacial cDNA library in
Lambda ZAP II (obtained from Dr. J. Murray) at 100,000 plaques/150-mm dish by
standard protocols using Hybond-N+ membranes. Hybridizations were performed at 65ºC
overnight in 0.125 M PO4, 0.25 M NaCl, 1 mM EDTA, 7% (w/v) SDS, 10% (w/v) PEG 6000.
Positive clones were purified by secondary and tertiary screening using nitrocellulose
filters and NC hybridization buffer (6x SSC, 5x Denhardt’s, 0.2% (w/v) SDS, 10% (w/v)
dextrane sulfate). Positive phages were converted to plasmid by in vivo excision according
to the manufacturer’s protocol (Stratagene). Single colonies were grown overnight at 37ºC,
and DNA isolation was performed using a Qiaprep 8 purification kit (Qiagen). Sequence
PCRs were performed using the Taq Dye Terminator Cycle Sequencing Ready reaction kit
(Pharmacia). Sequences were analyzed on an ABI automated DNA sequencer.
One of the isolated cDNA clones as well as cosmid DNA was used to screen 1x106
plaques of a retina cDNA library (Clontech, HL 1132a) in λgt10 at 80,000 plaques/150-mm
dish, following the same hybridization protocols. Phage DNA of positive plaques was
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isolated using the Lambda miniprep kit (Qiagen), and inserts were purified and
sequenced. Additional sequence was also obtained from human fetal brain Marathon-
Ready cDNA (Clontech) by 3’ rapid amplification of cDNA ends (RACE) and 5’ RACE,
following the enclosed protocol.
To prove that the isolated cDNAs belong to the same gene, (RT-) PCR analysis was
performed on DNA and RNA isolated from a lymphoblastoid cell line of a healthy
individual. For amplification, a forward primer in the RSK4 cDNA (5’-
ggggaagtgagatttaaaaaacc-3’) and a reverse primer in the cDNA corresponding to the 3’
noncoding region (5’-accaaagttacgagtttcctag-3’) were used.
Expression of RSK4 cDNA
Northern blots containing poly(A)+ RNA from different fetal and adult tissues
(Clontech MTN, 7760-1) and a Northern dot-blot (human RNA master blot, Clontech,
7770-1) were hybridized with radioactively labeled probes made by random primer
extension of cDNA clones 231438 and H22B, following the Clontech protocol.
Identification of the genomic structure of RSK4
Intronic sequences of RSK4 were determined by long-range amplification using
ExTaq (TaKaRa Biomedicals) with exon-specific primers and sequencing of the subsequent
PCR products. Introns that appeared too large for long-range PCR were directly
sequenced on DNA from cosmid E1 or H22 using exon-specific primers. All primer
sequences are available upon request.
Mutation detection
PCR-SSCP analysis was performed according to the method of Orita et al.37, with
slight modifications. Oligonucleotides used for genomic PCR amplification of 21 RSK4
exons are listed in Table 2. In all PCR experiments γ-32P-end-labeled primers were used as
described by Van den Hurk et al.38. All PCRs were performed in a PTC-100 Programmable
Thermal Controler (MJ Research, Inc.), with cycling conditions of 95°C for 1 min, 55 or
58°C (listed in Table 2) for 2 min, and 72°C for 1 min, for 30 cycles. Samples of the reaction
were denatured and electrophoresed on a 5% nondenaturing polyacrylamide gel38. PCR
fragments with an altered electrophoretic mobility were sequenced.
RESULTS
Fine-Mapping of the MRX Critical Interval
The physical map of the Xq21 region by Colleaux et al.39 shows that YAC clone
979a10 of the CEPH Mega-YAC library contained the markers DXS995, DXS232, and
DXS121. Although of our YAC 979a10 isolate is smaller than the original clone (780 instead
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of 1600 kb), the same markers could be PCR-amplified (data not shown). This indicates
that YAC 979a10 spans the MRX critical interval including the gap in the Xq21 YAC contig
constructed by Van der Maarel et al.20.
To narrow down the MRX critical interval, the extent of the deletion in patients
LGL2905, AP, TD, EP, and VS was investigated by Southern blotting and PCR
amplification of several markers in Xq21. Hybridization of a Southern blot, containing
EcoRI-digested genomic DNA, with a probe derived from a 2.3-kb inter-Alu PCR product
of YAC 979a10 (p968) showed that this marker was not present in DFN3 patient VS (data
not shown). The marker therefore defines the proximal boundary of the MRX critical
interval. PCR amplification of marker DXS121 revealed that it was absent in CHM patient
LGL2905 (data not shown), indicating that the MRX gene is located proximal of this
marker. The MRX critical interval could therefore be assigned between markers p968 and
DXS121 (Figure 1).
Cloning and Sequencing of a Candidate Gene for MRX
A panel of males with deletions in Xq2124 was used for the fine-mapping of ESTs that
had been roughly assigned to this chromosomal region. For this purpose, DNA of the
patients was PCR-amplified with EST-specific primers. One of the clones (human cDNA
clone 231438) appeared to map exactly within the MRX critical region (Figure 1) (data not
shown). This cDNA clone was used to screen a human embryonic craniofacial cDNA
library (obtained from Dr. J. Murray) and a retina cDNA library. Eleven partially
overlapping clones were obtained, together spanning 2540 bp. The sequence did not
contain an open reading frame (ORF). These cDNA clones were mapped to cosmid E1,
which was derived by subcloning YAC 979a10 into cosmid vector sCOGH2. As these
cDNAs did not hybridize to additional cDNA clones, we decided to use an adjacent
cosmid, H22, to screen the retina cDNA library. Three partially overlapping cDNA clones
were obtained, which together with a 3’ RACE experiment and cDNA clone 198833,
allowed the construction of a 2640-bp sequence, containing a 2238-bp ORF of a novel gene.
No overlap was observed between this cDNA sequence and the 2540-bp 3’ noncoding
cDNA sequence. To investigate whether the cDNAs belong to the same gene, PCR analysis
was performed using primers in both cDNAs. PCR amplification of DNA and RNA (by
RT-PCR) extracted from a lymphoblastoid cell line of a control individual revealed
fragments of the same size (approximately 1.5 kb), indicating that the two cDNAs are
indeed part of the same gene.
The putative start codon was found in only one cDNA clone, which contains an
unusual T-stretch in the 5’ untranslated region. To confirm this sequence, we performed a
5’ RACE experiment on cDNA derived from human fetal brain. Six different clones were
sequenced and found to match the sequence of the cDNA clone from the retina cDNA
library. The size of the T-stretch varied between 7 and 50 nucleotides in the various clones.
The complete RSK4 cDNA and deduced amino acid sequence are shown in Figure 2.
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ACGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTATAAAATTATTAGTATAAAAGGGGAA 80
ATGCTACCATTCGCTCCTCAGGACGAGCCCTGGGACCGAGAAATGGAAGTGTTCAGCGGCGGCGGCGCGAGCAGCGGCGA 160
M  L  P  F  A  P  Q  D  E  P  W  D  R  E  M  E  V  F  S  G  G  G  A  S  S  G  E
GGTAAATGGTCTTAAAATGGTTGATGAGCCAATGGAAGAGGGAGAAGCAGATTCTTGTCATGATGAAGGAGTTGTTAAAG 240
 V  N  G  L  K  M  V  D  E  P  M  E  E  G  E  A  D  S  C  H  D  E  G  V  V  K  E
AAATCCCTATTACTCATCATGTTAAGGAAGGCTATGAGAAAGCAGATCCTGCACAGTTTGAGTTGCTCAAGGTTCTTGGT 320
  I  P  I  T  H  H  V  K  E  G  Y  E  K  A  D  P  A  Q  F  E  L  L  K  V  L  G
CAGGGGTCATTTGGAAAGGTTTTTCTTGTTAGAAAGAAGACCGGTCCTGATGCTGGGCAGCTCTATGCAATGAAGGTGTT 400
Q  G  S  F  G  K  V  F  L  V  R  K  K  T  G  P  D  A  G  Q  L  Y  A  M  K  V  L
AAAAAAAGCCTCTTTAAAAGTTCGAGACAGAGTTCGGACAAAGATGGAGAGGGATATACTGGTGGAAGTAAATCATCCAT 480
 K  K  A  S  L  K  V  R  D  R  V  R  T  K  M  E  R  D  I  L  V  E  V  N  H  P  F
TTATTGTCAAATTGCACTATGCCTTTCAGACTGAAGGGAAACTGTACTTAATACTGGATTTTCTCAGGGGAGGAGATGTT 560
  I  V  K  L  H  Y  A  F  Q  T  E  G  K  L  Y  L  I  L  D  F  L  R  G  G  D  V
TTCACAAGATTATCCAAAGAGGTTCTGTTTACAGAGGAAGATGTGAAATTCTACCTCGCAGAACTGGCCCTTGCTTTGGA 640
F  T  R  L  S  K  E  V  L  F  T  E  E  D  V  K  F  Y  L  A  E  L  A  L  A  L  D
TCATCTGCACCAATTAGGAATTGTTTATAGAGACCTGAAGCCAGAAAACATTTTGCTTGATGAAATAGGACATATCAAAT 720
 H  L  H  Q  L  G  I  V  Y  R  D  L  K  P  E  N  I  L  L  D  E  I  G  H  I  K  L
TAACAGATTTTGGACTCAGCAAGGAGTCAGTAGATCAAGAAAAGAAGGCTTACTCATTTTGTGGTACAGTAGAGTATATG 800
  T  D  F  G  L  S  K  E  S  V  D  Q  E  K  K  A  Y  S  F  C  G  T  V  E  Y  M
GCTCCTGAAGTAGTAAATAGGAGAGGCCATTCCCAGAGTGCTGATTGGTGGTCATATGGTGTTCTTATGTTTGAAATGCT 880
A  P  E  V  V  N  R  R  G  H  S  Q  S  A  D  W  W  S  Y  G  V  L  M  F  E  M  L
TACTGGTACTCTGCCATTTCAAGGTAAAGACAGAAATGAGACCATGAATATGATATTAAAAGCAAAACTTGGAATGCCTC 960
 T  G  T  L  P  F  Q  G  K  D  R  N  E  T  M  N  M  I  L  K  A  K  L  G  M  P  Q
AATTTCTTAGTGCTGAAGCACAAAGTCTTCTAAGGATGTTATTCAAAAGGAATCCAGCAAATAGATTGGGATCAGAAGGA 1040
  F  L  S  A  E  A  Q  S  L  L  R  M  L  F  K  R  N  P  A  N  R  L  G  S  E  G
GTTGAAGAAATCAAAAGACATCTGTTTTTTGCAAATATTGACTGGGATAAATTATATAAAAGAGAAGTTCAACCTCCTTT 1120
V  E  E  I  K  R  H  L  F  F  A  N  I  D  W  D  K  L  Y  K  R  E  V  Q  P  P  F
CAAACCTGCTTCTGGAAAACCAGATGATACTTTTTGTTTTGATCCTGAATTTACTGCAAAAACACCTAAAGATTCTCCCG 1200
 K  P  A  S  G  K  P  D  D  T  F  C  F  D  P  E  F  T  A  K  T  P  K  D  S  P  G
GTTTGCCAGCCAGTGCAAATGCTCATCAGCTCTTCAAAGGATTCAGCTTTGTTGCAACTTCTATTGCAGAAGAATATAAA 1280
  L  P  A  S  A  N  A  H  Q  L  F  K  G  F  S  F  V  A  T  S  I  A  E  E  Y  K
ATCACTCCTATCACAAGTGCAAATGTATTACCAATTGTTCAGATAAATGGAAATGCTGCACAATTTGGTGAAGTATATGA 1360
I  T  P  I  T  S  A  N  V  L  P  I  V  Q  I  N  G  N  A  A  Q  F  G  E  V  Y  E
ATTGAAGGAGGATATTGGTGTTGGCTCCTACTCTGTTTGCAAGCGATGCATACATGCAACTACCAACATGGAATTTGCAG 1440
 L  K  E  D  I  G  V  G  S  Y  S  V  C  K  R  C  I  H  A  T  T  N  M  E  F  A  V
TGAAGATCATTGACAAAAGTAAGCGAGACCCTTCAGAAGAGATTGAAATATTGATGCGCTATGGACAACATCCCAACATT 1520
  K  I  I  D  K  S  K  R  D  P  S  E  E  I  E  I  L  M  R  Y  G  Q  H  P  N  I
ATTACTTTGAAGGATGTCTTTGATGATGGTAGATATGTTTACCTTGTTACGGATTTAATGAAAGGAGGAGAGTTACTTGA 1600
I  T  L  K  D  V  F  D  D  G  R  Y  V  Y  L  V  T  D  L  M  K  G  G  E  L  L  D
CCGTATTCTCAAACAAAAATGTTTCTCGGAACGGGAGGCTAGTGATATACTATATGTAATAAGTAAGACAGTTGACTATC 1680
 R  I  L  K  Q  K  C  F  S  E  R  E  A  S  D  I  L  Y  V  I  S  K  T  V  D  Y  L
TTCATTGTCAAGGAGTTGTTCATCGTGATCTTAAACCTAGTAATATTTTATACATGGATGAATCAGCCAGTGCAGATTCA 1760
  H  C  Q  G  V  V  H  R  D  L  K  P  S  N  I  L  Y  M  D  E  S  A  S  A  D  S
ATCAGGATATGTGATTTTGGGTTTGCAAAACAACTTCGAGGAGAAAATGGACTTCTCTTAACTCCATGCTACACTGCAAA 1840
I  R  I  C  D  F  G  F  A  K  Q  L  R  G  E  N  G  L  L  L  T  P  C  Y  T  A  N
CTTTGTTGCACCTGAGGTTCTTATGCAACAGGGATATGATGCTGCTTGTGATATCTGGAGTTTAGGAGTCCTTTTTTACA 1920
 F  V  A  P  E  V  L  M  Q  Q  G  Y  D  A  A  C  D  I  W  S  L  G  V  L  F  Y  T
CAATGTTGGCTGGCTACACTCCATTTGCTAATGGCCCCAATGATACTCCTGAAGAGATACTGCTGCGTATAGGCAATGGA 2000
  M  L  A  G  Y  T  P  F  A  N  G  P  N  D  T  P  E  E  I  L  L  R  I  G  N  G
AAATTCTCTTTGAGTGGTGGAAACTGGGACAATATTTCAGACGGAGCAAAGGATTTGCTTTCCCATATGCTTCATATGGA 2080
K  F  S  L  S  G  G  N  W  D  N  I  S  D  G  A  K  D  L  L  S  H  M  L  H  M  D
CCCACATCAGCGGTATACTGCTGAACAAATATTAAAGCACTCATGGATAACTCACAGAGACCAGTTGCCAAATGATCAGC 2160
 P  H  Q  R  Y  T  A  E  Q  I  L  K  H  S  W  I  T  H  R  D  Q  L  P  N  D  Q  P
CAAAGAGAAATGATGTGTCACATGTTGTTAAGGGAGCAATGGTTGCAACATACTCTGCCCTGACTCACAAGACCTTTCAA 2240
  K  R  N  D  V  S  H  V  V  K  G  A  M  V  A  T  Y  S  A  L  T  H  K  T  F  Q
CCAGTCCTAGAGCCTGTAGCTGCTTCAAGCTTAGCCCAGCGACGGAGCATGAAAAAGCGAACATCAACTGGCCTGTAAGA 2320
P  V  L  E  P  V  A  A  S  S  L  A  Q  R  R  S  M  K  K  R  T  S  T  G  L  *
TTTGTGGTGTTCCTAGGCCAAACTGGATGAAGATGAAATTAAATGTGTGGCTTTTTTCCTATTCTTATCAAAGGCATCGT 2400
TGTCTGCTAAATTACTTGAATATTAAGTAATATTAAATCCCCATTTTTAGGGGAAGTGAGATTTAAAAAACCATTCACAG 2480
GTCCACAATATTCATACTATGTGTTTGCAGTAGTGTTCAAGTGTTTATTTAAGCATATAATTGGTGTCCACCAGGTCCTC 2560
ACAACTTCTCTGCACACAAGCTTCTAAAATTCCTTTCAAATAAAGTTACTTTAATATTTAAAAAAAAAAAAAAAAAAAAA 2640
Figure 2. Nucleotide sequence of the RSK4 cDNA with deduced amino acid sequence below. Arrowheads
show exon-exon junctions. An asterisk indicates a stopcodon at position 2316-2318. The cDNA and deduced
protein sequence are in GenBank (Accession No. AF184065).
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RSK1 --MPLAQLKEPW------PLMELVPLDPENGQTSG-----------EEAGLQPSKDEGVLKEISITHHVKA
RSK2  --MPLAQLADPW----QKMAVESPSDSAENGQQIMDEPMG-------EEEINPQTEEVSIKEIAITHHVKE
RSK3  --MDLSMKKFAVR-----R-FFSVYLRRKSRSKSS--------------SLSRLEEEGVVKEIDISHHVKE
RSK4  -MLPFAPQDEPWDREMEVFSGGGASSGEVNGLKMVDEPME-------EGEADSCHDEGVVKEIPITHHVKE
        .  .                                                  .*  . *** *.****
RSK1  GSEKADPSHFELLKVLGQGSFGKVFLVRKVTRPDSGHLYAMKVLKKATLKVRDRVRTKMERDILADVNHPF
RSK2  GHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPF
RSK3  GFEKADPSQFELLKVLGQGSYGKVFLVRKVKGSDAGQLYAMKVLKKATLKVRDRVRSKMERDILAEVNHPF
RSK4  GYEKADPAQFELLKVLGQGSFGKVFLVRKKTGPDAGQLYAMKVLKKASLKVRDRVRTKMERDILVEVNHPF
      * *****..***********.******.*    *. .**********.********.******* .*****
RSK1  VVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALGLDHLHSLGIIYRDLKPENIL
RSK2  IVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENIL
RSK3  IVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENIL
RSK4  IVKLHYAFQTEGKLYLILDFLRGGDVFTRLSKEVLFTEEDVKFYLAELALALDHLHQLGIVYRDLKPENIL
      .************************.********.*************** ***** ***.**********
RSK1  LDEEGHIKLTDFGLSKEAIDHEKKAYSFCGTVEYMAPEVVNRQGHSHSADWWSYGVLMFEMLTGSLPFQGK
RSK2  LDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLPFQGK
RSK3  LDEEGHIKITDFGLSKEAIDHDKRAYSFCGTIEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGSLPFQGK
RSK4  LDEIGHIKLTDFGLSKESVDQEKKAYSFCGTVEYMAPEVVNRRGHSQSADWWSYGVLMFEMLTGTLPFQGK
      *** ****.********..*..*.*******.**********.**..******.**********.******
RSK1  DRKETMTLILKAKLGMPQFLSTEAQSLLRALFKRNPANRLGSGPDGAEEIKRHVFYSTIDWNKLYRREITP
RSK2  DRKETMTMILKAKLGMPQFLSPEAQSLLRMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHP
RSK3  DRKETMALILKAKLGMPQFLSGEAQSLLRALFKRNPCNRLGAGIDGVEEIKRHPFFVTIDWNTLYRKEIKP
RSK4  DRNETMNMILKAKLGMPQFLSAEAQSLLRMLFKRNPANRLGS--EGVEEIKRHLFFANIDWDKLYKREVQP
      ** *** .************* ******* ******.****.  .* ****** *. .***  **..*. *
RSK1  PFKPAVAQPDDTFYFDTEFTSRTPKDSPGIPPSAGAHQLFRGFSFVATGLMEDDGKPRAPQAPLHSVVQQL
RSK2  PFKPATGRPEDTFYFDPEFTAKTPKDSPGIPPSANAHQLFRGFSFVAITSDDES--QAMQTVGVHSIVQQL
RSK3  PFKPALGRPEDTFHFDPEFTARTPTDSPGVPPSANAHHLFRGFSFVASSLIQEPSQQDLHKVPVHPIVQQL
RSK4  PFKPASGKPDDTFCFDPEFTAKTPKDSPGLPASANAHQLFKGFSFVATSIAEEYKITPITSANVLPIV-QI
      *****  .*.*** ** ***..** ****.* **.**.**.******     .          .  .* *.
RSK1  HGKNLVFSDGYVVKETIGVGSYSECKRCVHKATNMEYAVKVIDKSKRDPSEEIEILLRYGQHPNIITLKDV
RSK2  HRNSIQFTDGYEVKEDIGVGSYSVCKRCIHKATNMEFAVKIIDKSKRDPTEEIEILLRYGQHPNIITLKDV
RSK3  HGNNIHFTDGYEIKEDIGVGSYSVCKRCVHKATDTEYAVKIIDKSKRDPSEEIEILLRYGQHPNIITLKDV
RSK4  NGNAAQFGEVYELKEDIGVGSYSVCKRCIHATTNMEFAVKIIDKSKRDPSEEIEILMRYGQHPNIITLKDV
      .     * . * .** ******* ****.* .*  *.***.********.******.**************
RSK1  YDDGKHVYLVTELMRGGELLDKILRQKFFSEREASFVLHTIGKTVEYLHSQGVVHRDLKPSNILYVDESGN
RSK2  YDDGKYVYVVTELMKGGELLDKILRQKFFSEREASAVLFTITKTVEYLHAQGVVHRDLKPSNILYVDESGN
RSK3  YDDGKFVYLVMELMRGGELLDRILRQRYFSEREASDVLCTITKTMDYLHSQGVVHRDLKPSNILYRDESGS
RSK4  FDDGRYVYLVTDLMKGGELLDRILKQKCFSEREASDILYVISKTVDYLHCQGVVHRDLKPSNILYMDESAS
.***. **.* .**.******.**.*. *************  *  * **..***.*************** ***
RSK1  PECLRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDEGCDIWSLGILLYTMLAGYTPFANGPSD
RSK2  PESIRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGVLLYTMLTGYTPFANGPDD
RSK3  PESIRVCDFGFAKQLRAGNGLLMTPCYTANFVAPEVLKRQGYDAACDIWSLGILLYTMLAGFTPFANGPDD
RSK4  ADSIRICDFGFAKQLRGENGLLLTPCYTANFVAPEVLMQQGYDAACDIWSLGVLFYTMLAGYTPFANGPND
       ...*.**********  ****.************** .****  *******.* ****.*.******* *
RSK1  TPEEILTRIGSGKFTLSGGNWNTVSETAKDLVSKMLHVDPHQRLTAKQVLQHPWVTQKDKLPQSQLSHQDL
RSK2  TPEEILARIGSGKFSLSGGYWNSVSDTAKDLVSKMLHVDPHQRLTAALVLRHPWIVHWDQLPQYQLNRQDA
RSK3  TPEEILARIGSGKYALSGGNWDSISDAAKDVVSKMLHVDPHQRLTAMQVLKHPWVVNREYLSPNQLSRQDV
RSK4  TPEEILLRIGNGKFSLSGGNWDNISDGAKDLLSHMLHMDPHQRYTAEQILKHSWITHRDQLPNDQPKRNDV
      ****** *** **..**** *  .*. ***..*.***.***** **  .*.* *.   . *   *  ..*
RSK1  -QLVKGAMAATYSALNSSKPTPQLKPIESSILAQRR-VRKLPSTTL
RSK2  PHLVKGAMAATYSALNRN-QSPVLEPVGRSTLAQRRGIKKITSTAL
RSK3  -HLVKGAMAATYFALNRTPQAPRLEPVLSSNLAQRRGMKRLTSTRL
RSK4  SHVVKGAMVATYSALTHKTFQPVLEPVAASSLAQRRSMKKRTSTGL
       ..***** *** **.     * * *.  * ***** ...  ** *
Figure 3. Alignment of human RSK proteins. The conserved kinase domains (GQGSFGX19K and
GVGSYSX16K) are shown in boxes, and the APE motifs are highlighted in boldface type. Asterisk; amino
acid identity; dot; amino acid similarity. Alignment was carried out using the Clustal W program (version 1.5).
Amino acid sequences are translations from the deposited cDNA sequences in GenBank (human RSK1,
Accession No. L07597; human RSK2, Accession No. L07598; human RSK3, Accession No. L07599; and
human RSK4, Accession No. AF184965).
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Homology of the Novel Gene to Human RSKs
A FASTA search40 revealed a strong homology between the novel gene and genes of
the ribosomal S6 kinase (RSK) family of different species. Comparison of the coding
nucleotides and the deduced amino acid sequence of the novel gene with the three known
human RSK genes clearly showed that we have identified a novel member of this family,
which we have designated RSK4 (Figure 3).
Expression of the RSK4 Gene
Northern blots containing poly(A)+ RNA from a number of fetal and adult tissues
were hybridized with the insert of a retina cDNA clone containing the first 17 exons of
RSK4 (H22B, Figure 1). Three transcripts of approximately 5, 6.5, and 9 kb were detected,
with the 6.5-kb band being the most prominent. The expression is most abundant in fetal
(data not shown) and adult kidney and brain and lower in all other tissues tested (Figure
4A). To prove that these signals were not due to cross-hybridization with the other RSK
genes, the Northern blots were also hybridized with cDNA clone 231438 from the 3’
noncoding region. The same three transcripts were found, which added further evidence
to the earlier finding that the RSK4 cDNAs and the 3’ NCR are derived from the same
gene. The total cDNA clone has a length of approximately 6.5 kb, which corresponds to
the most prominent band on the Northern blot. The other (minor) transcripts are probably
caused by alternative splicing or alternative polyadenylation. Hybridization of a multiple
tissue Northern dot-blot showed highest expression in fetal kidney, pituitary, and thyroid
gland (Figure 4B).
Figure 4. Northern blot analysis of RSK4 expression. cDNA clone H22B (Fig 1.) was used as a probe. A:
Adult multiple tissue Northern blot containing poly(A)+ RNA. Transcripts of approximately 5, 6.5, and 9 kb
were detected with highest expression in kidney and brain tissue. B: Multiple tissue Northern dot-blot
showing highest expression in pituitary gland (D4). RSK4 is also expressed in thyroid gland (D6) and fetal
kidney (G3). The dot in section A4 is a hybridization artifact just beside the spotted RNA, which was not seen
in duplicate hybridizations.
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Table 1. Splice sites of the RSK4 gene
Exon Splice acceptor site Con-
sensus
Splice donor site Con-
sensus
Position Exon
size (bp)
Intron
size (kb)
1 - - - - -
2 - - - 162 - -
3 acaatgtttttcagGTAAATGGTC 85% TTCTTGTCATgtaagt 87% 221 59 ±8
4 atttctttttacagGATGAAGGAG 93% ATTTGGAAAGgtaatg 81% 338 117 ±7
5 caattttctattagGTTTTTCTTG 90% TCTTTAAAAGgtagaa 69% 420 82 ±0.8
6 tatgtaatttttagTTCGAGACAG 73% TTGCACTATGgtatgt 81% 501 81 ±1
7 taatttttaattagCCTTTCAGAC 72% ATCCAAAGAGgtaagt 10% 581 80 ±15
8 ttattttgttctagGTTCTGTTTA 90% AGCCAGAAAAgtaaag 69% 688 107 0.238
9 attttgatttacagCATTTTGCTT 89% AAATTAACAGgtatgc 83% 726 38 ±10
10 tactgttattatagATTTTGGACT 79% TGTTCTTATGgtaagt 92% 869 143 ±2
11 tttgtttgttttagTTTGAAATGC 84% TGATATTAAAgtaagt 88% 940 71 0.235
12 atcctctgtttcagAGCAAAACTT 89% AATAGATTGGgtattg 62% 1029 89 ±1.5
13 tcttttttttatagGATCAGAAGG 91% TGACTGGGATgtaagt 87% 1088 59 ±7
14 gttgtcccttctagAAATTATATA 85% ACACCTAAAGgtaatg 81% 1191 103 ±1
15 tatttggacattagATTCTCCCGG 70% AATTGTTCAGgtaaat 86% 1322 131 0.423
16 ttaaaaataaacagATAAATGGAA 65% TGCAGTGAAGgtattg 70% 1445 123 ±1
17 ttcgtatttcttagATCATTGACA 83% TTTGAAGGATgtaggt 77% 1535 90 ±1.5
18 gcgttcttttgtagGTCTTTGATG 87% TTGTCAAGGAgtaagt 80% 1694 159 ±2
19 cctttatattcaagGTTGTTCATC 84% TGCACCTGAGgtatcc 69% 1856 162 ±3
20 tatttctttcttagGTTCTTATGC 90% TGTTGGCTGGgtaaga 87% 1933 77 ±1.8
21 tattttattaatagCTACACTCCA 80% CGGAGCAAAGgtataa 69% 2051 118 -
22 tttttttaatttagGATTTGCTTT 91% TGTTGTTAAGgtaaaa 80% 2192 141 ±0.400
23 tctcattactttagGGAGCAATGG 82% - - - - -
Note. Lowercase letters indicate intron sequences; uppercase letters indicate exon sequences. The
percentage similarity to splice consensus sequences was calculated according to Shapiro and Senapathy41.
The position of the splice sites on RSK4 cDNA is as reflected in Figure 2.
Genomic Structure of RSK4
Cosmid sequencing and long-range PCR amplification of genomic DNA allowed us
to identify 21 introns interrupting the RSK4 coding region. Despite repeated trials with
different primers in the 5’ part of the gene, no specific PCR product could be generated on
genomic DNA, indicating that probably one or more large introns are present. Hence, the
gene consists of at least 22 exons that span approximately 75 kb of genomic DNA and are
located on cosmids E1, H22, and G9 in a telomeric to centromeric orientation (Figure 1).
All splice donor and splice acceptor sites fit the consensus as reported by Shapiro and
Senapathy41. The sequences of the intron-exon boundaries, as well as exon and intron
sizes, are given in Table 1. PCR analysis of different exons revealed that patient AP, who
suffers from CHM and MRX, had a deletion of the entire RSK4 gene. Patients TD and EP
(patients with DFN3) and LGL2905 (patient with CHM) contained the entire RSK4 gene.
Patient VS, however, appeared to have a deletion of the last 14 exons, although he is
diagnosed as a nonsyndromic DFN3 patient (Figure 5). Recently performed tests revealed
that this patient is of normal intelligence (Dr. H. Heilbronner and Dr. H.-J. Pander, pers.
comm.). These results indicate that 9 of the 23 RSK4 exons are located within the MRX
critical interval (Figure 1).
Figure 5. PCR amplification of RSK4 exons 4,9, 10, and 23 with primer sets
described in Table 2. +; DNA from a healthy individual (positive control), -; no
DNA template (negative control).
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Table 2. Oligonucleotides used for PCR amplification of RSK4 exons
Exon Oligonucleotide (5’ → 3’) Orientation Code Size (bp) MgCl2 concentration(mM) Ta(°C)
1 - - - -
2 - - - -
3 CACTCTTGTTTTAATACTTTTGAAC
GGAGCTTTTCTCCTTTCCCTG
Sense
Antisense
2365
2353
189 3 58
4 CAGAAGATGTTGAAAATGGATTC
CAGATTTCTACGTATGTGTTCAC
Sense
Antisense
2354
2355
245 3 58
5 GAGCAAGAATGAGTAGAAATGTG
GCTACATCTATTCACCTTATGC
Sense
Antisense
2327
2129
235 3 58
6 GGCATTTAGGAAGTTACGTTTTG
GTGTGAAAGGAAATCATAATTCTC
Sense
Antisense
2285
2130
281 1.5 55
7 GTTATCCATTAATGAACCATGTG
GTAATTAGCAGAAGAACAAAAGTG
Sense
Antisense
2131
2132
281 3 55
8 GTCTGTCTACTCATTTTGAAAG
GTTTGACAAAAAGCAGTTCCAG
Sense
Antisense
2133
2386
255 4.5 58
9 GTTTTATGTAAAATATTTTATTCCATC
CAAGTGGCTAAGGGTATAATAAG
Sense
Antisense
2409
2449
128 4.5 55
10 CGTTTTCTATTTTCTGAAGTTTTTC
GTAATATCAATCACAGGTTGGC
Sense
Antisense
2398
2390
249 3 55
11 CTATCATGTAGATCTTACAATTTG
CAGTGAGAAAAAGGTACTCTTG
Sense
Antisense
2385
2134
297 4.5 55
12 GAGATTTTTCAAATCAAAAATGTGG
CATGCAGTTACTTCTATAAAAGC
Sense
Antisense
2135
2328
194 3 55
13 GGAATGTATGAAATATGTGTATTC
CCACTGATTTGTTATTTAGATTAAAAG
Sense
Antisense
2646
2647
262 3 55
14 CTTAATACGTTTTGTGTTATCTGG
CTATCTACTAAATAAAATCTCTG
Sense
Antisense
2371
2287
187 4.5 55
15 CCTTTATAGTTAAAGAAATTCTGAC
GCAATAACAGAGAAATAATTATCC
Sense
Antisense
2286
2300
272 3 55
16 GGCTTAAGATGAATGTATATTTAG
GAAATGGTTGTCAGTTGACTC
Sense
Antisense
2136
2368
289 3 58
17 GACAAAATAATTTGTTTGCCTC
CAATAAGAAAAATAAAGTTCCAATTC
Sense
Antisense
2391
2394
212 4.5 55
18 GTAGAAAGGTAAATATAATTAAAATC
GAAGATATAGGTCCCAGAATAG
Sense
Antisense
2372
2303
297 4.5 55
19 GTAATTTGGAAAGTTTCTTTTTCTC
GGCATCATATAGATTCAACTAAAG
Sense
Antisense
2289
2373
343 3 55
20 GGAGAAAATTGAGTTTATATTGAG
CTCTTTCTAGATGAAGATATACAG
Sense
Antisense
2392
2399
204 4.5 55
21 GTTTGGGTATGTTACCCTCTAG
CACTTTACATGACACCATTAG
Sense
Antisense
2393
2450
276 4.5 55
22 GCTGTCACATTTTCAGCAAATG
GGGTTTATTAGGTATCTGATATC
Sense
Antisense
2412
2410
274 3 55
23 CTCCAGAATTTGTACTTAGTTTG
GATAAGAATAGGAAAAAAGCCAC
Sense
Antisense
2401
2414
242 3 55
Note. The fragment size of the PCR products, as well as the MgCl2 concentration and the annealing
temperature (Ta) by which the primer pairs are used in PCR-SSCP analysis is indicated.
Mutation Analysis of RSK4 as a Candidate Gene for MRX
We analyzed DNA from 200 unrelated male MRX patients for mutations in RSK4.
Primer sets in the intronic sequences were used in PCR-SSCP analysis (listed in Table 2). In
this analysis, DNA of 13 MRX and 3 MRXS families in which the molecular defect was
genetically linked to the Xq21 region was included. PCR-amplified fragments with altered
electrophoretic mobility were further analyzed by direct DNA sequencing. We identified a
G-to-A transition at position 2154 in 8 of the 200 patients, changing an aspartic acid (GAT)
to an asparagine (AAT) (D692N). Hybridization with an allele-specific oligonucleotide
revealed this amino acid substitution in 7 of 88 healthy individuals, indicating that it is a
polymorphism rather than a mutation. We also identified three different intronic
alterations. Although none of these sequence changes has an effect on the calculated splice
efficiency as shown in Table 1, a panel of control persons has been tested. Since all intronic
changes have been found in at least one control individual, these variations can be
considered as polymorphisms. All sequence changes found are listed in Table 3.
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Table 3. Polymorphisms in the RSK4 Gene
Sequence change Incidence in MRX males Incidence in controls
IVS6-28C>T 1/200 1/157
IVS13+15A>C 2/200 3/80
IVS17-63-59del5 1/200 2/145
2154G>A 8/200 7/88
Note. The nomenclature is according to Antonarakis et al.42. The IVS17-63-59del5 change was also found in
two unaffected males in the same family (apart from the two control persons mentioned in this table). The
position of the 2154G>A polymorphism (D692N) is as reflected in Figure 2.
DISCUSSION
Under the assumption that contiguous gene syndromes associated with Xq21
deletions consist of three separate disease entities, i.e., DFN3, MRX, and CHM, we have
employed a positional cloning approach to identify the elusive Xq21 MRX gene. We
identified a novel gene, RSK4, which is deleted in patients with DFN3, MRX, and CHM as
well as in one patient with MRX and CHM. With one exception, all other deletions
investigated do not involve the RSK4 gene, and, accordingly, these males are not mentally
retarded. Only DFN3 patient VS (Figure 1) lacks exons 10-23 of the RSK4 gene, but is not
mentally retarded.
RSK4 is a novel member of a family of growth-factor-related serine-threonine
kinases, known as p90rsk or RSK (for ribosomal S6 kinase)43. In humans, three closely
related members of the RSK family have previously been isolated: RSK1, RSK2 and
RSK344,45. A highly conserved feature of the RSK protein family is the presence of two
nonidentical, kinase catalytic domains that are each shared by other distinct protein
kinases46. The p90rsk protein kinases are activated by multisite serine-threonine
phosphorylation in response to a variety of growth factors and hormones47-52. Several lines
of evidence suggest that mitogen-activated protein (MAP) kinases, such as extracellular
signal-regulated kinases (ERK-1 and -2) and c-Jun amino-terminal kinase, act upstream of
the p90rsk kinases52-55.
Little is known about the function of RSK1 and RSK3. The RSK1 gene is localized on
chromosome 3, and its expression is restricted to hematopoietic and HeLa cells. RSK3 has
been mapped to chromosome 6 and contains a unique N-terminal sequence44,45. RSK2,
which has been localized to Xp22, is mutated in Coffin-Lowry syndrome (CLS; MIM
303600)56,57, a disorder characterized by mental retardation, characteristic facies, and
tapering fingers58-60. Recently, a mutation in RSK2 was found in a family with MRX61. In
keeping with its involvement in mental retardation is the demonstration that two known
substrates of RSK2 have been implicated in brain function: L1CAM, which is mutated in
several syndromic forms of MRX62, and c-AMP response element binding protein, which is
important for long-term memory formation63-65. These observations suggest that RSK4 is
an attractive candidate gene for MRX.
The products of two of the known MRX genes interact with the Rho-subfamily of
small GTPases: OPHN19 and PAK310. Rho proteins are involved in the organization of the
actin cytoskeleton and in the generation of cell extensions in several cell types, including
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neuronal cells66-68. OPHN1 encodes a RHO-GTPase-activating protein, which shows GAP
activity for Rho, Rac, and Cdc42 in vitro9. PAK3 is a member of the p21-activating kinase
genes, which link RHO-GTPases to the MAP kinase signaling pathway69. RSKs can be
activated by this signaling cascade70, suggesting that RSK2 and probably RSK4 play a role
in neuronal development and synaptic function71 (Figure 6).
Figure 6. Model for the role of RHO-GTPases
in neuronal processes. RHO-GTPases
function as molecular switches that cycle
between their active (GTP-bound) and
inactive (GDP-bound) states. Guanine-
nucleotide dissociation inhibitors (GDIs)
stabilize the inactive state. The ratio of the two
forms is regulated by guanine-nucleotide
exchange factors (GEFs) and GTPase-
activating proteins (GAPs). OPHN1 is such a
RHOGAP protein, and PAK3 is an effector of
RHO GTPases. Downstream cascades of
these effectors include the MAP kinase
signaling pathway in which RSK proteins play
an important role. Mutations in OPHN1,
PAK3, and RSK2 are involved in MRX9,10,60.
(Adapted from Antonarakis and Van Aelst71)
Despite the fact that RSK4 is a positional and functional candidate gene for MRX, we
failed to detect causative mutations in 200 unrelated male MRX patients. The fact that no
mutations have been found, together with the partial deletion of the gene in patient VS,
may suggest that RSK4 is not the gene underlying MRX in Xq21. On the other hand, the
absence of other expressed sequences in this region (Yntema et al., unpublished
observations) and the general paucity of genes in Xq2124 argue in favor of RSK4 being the
Xq21 MRX gene. The normal mental status of patient VS can be explained if VS is
considered to be an example of nonpenetrance. This is not unprecedented for Xq21
deletions, as two patients, NP and RVD, with deletions encompassing POU3F4 and REP-1,
who did not show the characteristics of DFN3 or CHM, respectively, have been
described12. An explanation for the lack of phenotypic features in these patients is that the
absence of protein can be compensated for by the expression of homologous genes with a
similar function. In the case of patient VS, it can be envisaged that the role of RSK4 can be
taken over by one of the other RSK proteins. Functional studies in the near future must
attempt to gain more insight into this hypothesis.
In all MRX genes described at present, mutations have been found in less than 1% of
the patients tested. If RSK4 is indeed causative in MRX, its contribution to mental
retardation might even be lower than that of the other reported MRX genes, given the fact
that no mutations were found in 200 patients tested. Therefore, more patients will be
tested in the near future. These studies will concentrate on families in whom the mental
retardation defect is linked to Xq21, such as MRX2672 and FG syndrome73. Additionally, a
group of sporadic patients with Coffin-Lowry syndrome, in whom no mutation in the
RSK2 gene was found55, will be included in these studies.
RHO
Cytoskeleton organization
Gene transcription
MAPK signaling (RSK2) (RSK4?)
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ABSTRACT
X-linked forms of mental retardation (XLMR) include a variety of different disorders
and may account for up to 25% of all inherited cases of mental retardation1. So far, seven
X-chromosomal genes mutated in nonspecific mental retardation (MRX) have been
identified: FMR2, GDI1, RPS6KA3, IL1RAPL, TM4SF2, OPHN1 and PAK32-9. The products
of the latter two have been implicated in regulation of neural plasticity by controlling the
activity of small GTPases of the Rho family. Here we report the identification of a new
MRX gene, ARHGEF6 (also known as αPIX or Cool-2), encoding a protein with homology
to guanine nucleotide exchange factors for Rho GTPases (Rho GEF). Molecular analysis of
a reciprocal X/21 translocation in a male with mental retardation showed that this gene in
Xq26 was disrupted by the rearrangement. Mutation screening of 119 patients with
nonspecific mental retardation revealed a mutation in the first intron of ARHGEF6 (IVS1-
11T→C) in all affected males in a large Dutch family10. The mutation resulted in
preferential skipping of exon 2, predicting a protein lacking 28 amino acids. ARHGEF6 is
the eighth MRX gene identified so far and the third such gene to encode a protein that
interacts with Rho GTPases.
RESULTS AND DISCUSSION
The patient (FCA) we studied shows severe mental retardation, mild dysmorphic
features and sensorineural hearing loss. He carries an apparently balanced X;21
translocation with breakpoints in Xq26 and 21p11. His mother (VCA) is unaffected and
carries the same translocation11. To clone the breakpoint region, we performed
fluorescence in situ hybridization (FISH) with YAC, PAC and cosmid clones from Xq26
and screened for clones spanning the breakpoint. No single clone was found that
contained genetic material located on both sides of the breakpoint. Therefore, we
subcloned PAC H211017 and cosmid B1220 mapped nearest but still proximal and distal
to the breakpoint, respectively. Clones were end-sequenced and assembled into a contig.
DNA sequences of both ends of a 5.1-kb DNA fragment showed partial homology to
cDNA KIAA000612, suggesting the presence of two exons. The KIAA0006 cDNA sequence
deposited in the database contains only part of the coding sequence, as no ATG is present
at the beginning of the ORF. Therefore, we performed 5'-RACE experiments and identified
an additional 1,213 bp at the 5' end. The complete cDNA sequence (6,017 bp) encodes a
protein of 776 amino acids with a predicted molecular weight of 87 kD. The putative
initiation codon at nt 1,207 conforms to a translation-initiation consensus13, and is
preceded by several stop codons in all reading frames (data not shown). Database searches
revealed that the predicted product of KIAA0006 is a Rho GEF protein14 (ARHGEF6;
Figure 1). Rho GEFs belong to a family of cytoplasmic proteins that activate the Ras-like
family of Rho proteins by exchanging bound GDP for GTP15,16. The ARHGEF6
polypeptide contains several evolutionarily conserved regions frequently found in other
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Rho GEF family members (Figure 1): for example, an SH3 domain, a Dbl homology (DH)
domain17 and a pleckstrin homology (PH) domain18,19. The amino-terminal calponin
homology (CH) domain20 is unique to ARHGEF6. We determined the genomic structure of
ARHGEF6 and identified 22 exons (Figure 1). Previous studies have shown that ARHGEF6
is expressed ubiquitously12,14. Using a commercially available RNA array from multiple
adult human tissues, we found no significant differences in the expression pattern of
different parts of the brain (data not shown).
Figure 1. Predicted genomic structure of ARHGEF6 and domain structure of the corresponding protein.
Numbered boxes indicate exons. The ATG start codon and TAA stop codon are shown. Schematic
organization of the identified domains in the ARHGEF6 protein is shown below: CH, calponin homology
domain; SH3, Src homology 3 domain; DH, Dbl homology domain; PH, pleckstrin homology domain.
To further characterize the translocation breakpoint, we performed serial RT–PCR on
RNA isolated from skin fibroblasts of the patient, his mother and a control individual. We
obtained products corresponding to exons 8 to 10 in all cases (Figure 2A), but
amplification of exons 8–11 and exons 8–12 was unsuccessful in the patient, suggesting
that the translocation breakpoint was located between exons 10 and 11 (Figure 2A). We
detected wild-type ARHGEF6 mRNA in the patient's mother, who carries the same
chromosomal rearrangement as her son. This is unusual, because in most females with a
balanced X/autosome translocation the normal X chromosome is preferentially
inactivated. This finding, however, is consistent with the mother's normal phenotype. To
investigate whether ARHGEF6 escapes X inactivation, we performed RT–PCR using RNA
from hamster somatic cell hybrids that contained either an active (Xa) or an inactive (Xi)
human X chromosome. We obtained PCR products only from the hybrids with Xa (data
not shown), indicating that ARHGEF6 does not escape X inactivation.
The chromosomal breakpoint of patient FCA was further characterized by genomic
walking. Two different junction-containing DNA fragments comprising the der(X) and
der(21) breakpoints were amplified and sequenced (Figure 2B–D). The der(21) breakpoint
is at nt 650 in intron 10, whereas the breakpoint on der(X) is before nt 660 in the same
ARHGEF6 intron. DNA sequences of both junction fragments adjacent to ARHGEF6 show
homology to β-satellite DNA (Figure 2C), suggesting that the translocation is reciprocal
but molecularly unbalanced, with a 10-bp deletion on the X chromosome and a 9-bp
deletion in the β-satellite DNA on chromosome 21 (data not shown). We found two short
motifs of sequence identity (TGCAATGA and TGATA (Figure 2C)) on both the X
chromosome and chromosome 21.
ATG
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
17
18 19
21
2220
TAA
CH SH3 DH PH
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Figure 2. Mapping the translocation breakpoint by the analysis of cDNA and genomic DNA fragments from
patient FCA. A: RT–PCR amplification of different ARHGEF6 exons from the RNA of the patient (FCA), his
mother (VCA) and a control person (c). Boxes indicate exons of ARHGEF6. B: Schematic representation of
the rearranged chromosome 21 and the derivative X chromosome. The translocated part of the X
chromosome (Xq26–qter) harbors ARHGEF6 exons 1–10. Exons 11–22 are on the derivative X
chromosome oriented from telomere to centromere. C: DNA sequence of the fragments and the
corresponding wild-type DNA segment of intron 10 of ARHGEF6. Top, the DNA sequence of the breakpoint
on the rearranged chromosome 21 compared with that of wild-type intron 10 (middle line). Bottom, the
sequence of the breakpoint on the derivative X chromosome. Vertical lines indicate identical nucleotides of
the junction fragments and intron 10. -satellite DNA of chromosome 21 is in bold. Homologous DNA
sequences of -satellite DNA and ARHGEF6 intron 10 are boxed. The 10 bp of intron 10 deleted by the
rearrangement are underlined. D: Amplification of translocation junction fragments by chromosome X- and
21-specific PCR primers. A novel 1.5-kb amplicon (marked by an arrow) was generated for the der(21)
chromosome (left) and a 510-bp amplicon for the der(X) chromosome (right) in patient FCA and his mother
VCA. These products were not obtained in controls. A control fragment of 580 bp containing the breakpoint
region in intron 10 of ARHGEF6 on the wild-type allele was co-amplified in the same PCR reactions.
Subsequently, we screened 119 unrelated male patients with nonspecific mental
retardation for mutations in ARHGEF6. We identified a sequence variant in intron 1, IVS1-
11TC (Figure 3A,B), in a patient (III-20 in Fig. 4A) from a large family in which the disease
locus (MRX46) was previously assigned to Xq25–q2610. This base change has a marginal
effect on the predicted splicing efficiency (79% versus 77% in the mutant21), but was not
detected on 170 control chromosomes. We showed that IVS1-11TC segregated with the
disease phenotype in the family (data not shown). To determine the effect of this sequence
variant on splicing, we performed RT–PCR amplifying exons 1–4 of ARHGEF6 cDNA
from 4 affected males (Figure 4A) and obtained products of 2 different sizes (Figure 4B).
We cloned and sequenced these products, and found that the larger amplicon
corresponded to the wild-type fragment, whereas in the smaller amplicon exon 1 was
spliced to exon 3. Thus, all mentally retarded males in MRX46 exhibited enhanced
skipping of exon 2. In this nonquantitative analysis, we did not see skipping of exon 2 in 2
carrier females or in an unaffected male (Figure 4B). Similarly, no skipping of exon 2 was
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found by qualitative RT–PCR analysis of 100 unaffected controls (data not shown). We
estimated the relative amount of the wild-type and truncated RNA from lymphoblastoid
cell lines by a semi-quantitative RT–PCR, and found it to be approximately 1:3 in patients
III-16, III-20 and IV-1 (with moderate mental retardation), and approximately 1:5 for
patient III-26 (with profound mental retardation; Figure 4C). In this assay, we also
detected small amounts of the product without exon 2 in obligate carriers and the
unaffected male (Figure 4C), suggesting that skipping of exon 2 is a rare, but normal, event
in lymphoblastoid cell lines. In 52 control individuals, the amount of the minor cDNA
fragment was found to be 3–10% of the total product (data not shown).
Figure 3. Mutation analysis of ARHGEF6 in MRX46. A: PCR products of amplicon 2 were sequenced and
the intronic mutation IVS1-11TC was detected in patients of family MRX46. Control female has a T at
position -11 in the splice acceptor site of intron 1 (arrow), whereas an affected male of family MRX46 has a C
at this position. B: Wild-type DNA sequence of the splice acceptor site of intron 1 and exon 2 is shown at the
top, whereas the sequence below presents the intronic mutation of MRX46.
SSCP analysis revealed that five women from MRX46 were heterozygous for the
IVS1-11TC mutation (Fig. 4A). In two carriers (III-3 and IV-3), we found only a small
amount of mRNA lacking exon 2 by quantitative RT–PCR (Fig. 4C) that might originate
from the wild-type allele. Indeed, all carrier females presented a skewed pattern of X
inactivation22, whereas three non-carriers (III-10, III-19 and IV-7) showed a random pattern
(Fig. 4D, and data not shown). Genotyping of DNA polymorphisms showed that in all
carrier females the X chromosome with the intron 1 mutation in ARHGEF6 was inactivated
(data not shown).
ARHGEF6 is the third MRX gene, in addition to OPHN1 and PAK3, whose protein is
involved in the Rho GTPase cycle, which mediates organization of the cytoskeleton, cell
shape and motility23,24. As it has already been shown that Rho GTPases are involved in
axonal outgrowth, as well as in control of shape and size of dendrites25, mutations of
ARHGEF6 may disturb signal transduction pathways involved in cell migration and
axonal outgrowth. The phenotypes of the patients carrying mutations in ARHGEF6 were
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different, underscoring a complex genetic heterogeneity in MRX5,26. The molecular
consequences of the gene disruption in patient FCA and preferential skipping of exon 2 in
family MRX46 are unknown at the level of cell physiology. We speculate that mental
retardation in family MRX46 might be due to the switch in the ratio between the two
ARHGEF6 isotypes, which has already been described in early onset familial adenomatous
polyposis27.
Figure 4. Analysis of the splice mutation and X-inactivation study in family MRX46. A: Simplified pedigree of
family MRX46 (original in 10). Pedigree numbers are the same as given in the original. Carrier women are
indicated by a dot and, if determined by DNA analysis, by a dash. The index case is indicated by an arrow.
B: Nonquantitative amplification of ARHGEF6 exons 1–4 by RT–PCR and analysis of products on a 1.5%
agarose gel. Lane 1, 100-bp ladder; lane 2, male control; lane 3, female control; lane 4, non-affected male
(III-27); lane 5, carrier female (III-3); lane 6, carrier female (IV-3); lane 7, affected male (IV-1); lane 8,
affected male (III-16, III-20, III-26). All affected males show an additional, smaller amplicon. C: Semi-
quantitative RT–PCR of ARHGEF6 exons 1–4 analyzed by denaturing polyacrylamide gel. The top band
contains wild-type ARHGEF6 exons 1–4, the bottom band lacks exon 2. The patients studied here are the
same as in B. The percentage of ARHGEF6 transcript lacking exon 2 is indicated below. D: X-chromosome
inactivation determined by amplification of a sequence polymorphism of the gene encoding the androgen
receptor with or without digestion of the DNA with HpaII (indicated with + and -, respectively). Carrier females
II-12 and IV-3 show nonrandom X inactivation, as only one band is obtained after HpaII digestion. In
contrast, non-carriers III-19 and IV-7 show a random X inactivation. The pattern of a nonrandom X-
inactivated control is shown in lanes 9 and 10.
METHODS
YAC, PAC and cosmid clones
We obtained YAC clones from American Type Culture Collection. PACs from
libraries RPCI-3 and -5 (P. de Jong and P. Ioannou) and cosmid clones from library 110 (P.
de Jong) were provided by the Resource Center of the German Human Genome Project at
the Max-Planck-Institute for Molecular Genetics.
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Labeling of probes and FISH
Metaphase spreads were made by standard procedures. YAC, PAC and cosmid DNA
were labeled with digoxigenin-11-dUTP (Roche Molecular biochemicals) by nick
translation (Roche Molecular Biochemicals). We used fluorescein isothiocyanate (FITC)
labeled streptavidin (1:200) for detection. Chromosomes were counterstained with
propidium iodide. Slides were observed under a Zeiss Axiophot fluorescence microscope.
Mapping of the t(X;21) breakpoint
EcoRI fragments of cosmid LLNLc110B1220Q03 and PAC RPCIP704H211017Q3 were
subcloned in pBluescript II SK and pACYC184 and sequenced from both ends using the
ABI Prism Dye Terminator kit and ABI Prism 310 Genetic Analyzer (PE Applied
Biosystems). For assembly of the EcoRI fragments, we designed a reverse primer of each
end-sequence for PCR and combined each primer with all other primers on undigested
PAC DNA as template (primer sequences are available on request).
Genomic walking, PCR of junction fragments and nucleic acid hybridization
To establish the exon-intron structure of ARHGEF6, we used cosmid
(LLNLc110B1220Q03) and PAC (RPCIP704H211017Q3 and RPCIP704I24917Q3) clones for
constructing genomic walking libraries (Universal Genome Walker kit, Clontech). The
exon-intron boundaries were determined through sequence comparisons between cDNA
and genomic sequence. For the isolation of genomic junction fragments from patient FCA,
we constructed genomic walking libraries with genomic DNA. PCR amplification of
junction fragments was carried out with specific primers for the der(21) and der(X)
chromosomes. A control fragment of 580 bp containing the breakpoint region in intron 10
of ARHGEF6 on the wild-type allele was co-amplified in the same PCR reactions (primer
sequences available on request).
For Southern-blot analysis, we digested DNA samples (PACs, cosmids and cloned
EcoRI fragments) with restriction endonucleases, electrophoresed them on 0.8% agarose
gels and transferred them to positively charged nylon membranes (Roche Molecular
Biochemicals) according to standard procedures. Labeling, hybridization and detection
were carried out using the DIG-system (Roche Molecular Biochemicals). We hybridized
the Multiple Tissue Expression Array (Clontech) with the 32P-labeled KIAA0006 cDNA
probe by standard methods.
RNA isolation, RACE– and RT–PCR, and semi-quantitative RT–PCR
We isolated total RNA using the High Pure RNA Isolation kit (Roche Molecular
Biochemicals) and performed reverse transcription of total RNA (5 µg) by random
hexanucleotide priming and Superscript II (Life Technologies) according to the
manufacturer's protocol. We carried out 5'-RACE experiments using Marathon-Ready
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cDNA from human fetal brain (Clontech). For this, we combined nested reverse primers
from exon 1 of KIAA0006 cDNA and the 5' UTR in PCR with adaptor primers (sequences
available on request). We sequenced RACE–PCR products directly or after cloning in
pBluescript II SK. We studied the effect of X-inactivation on expression of ARHGEF6 by
RT–PCR on somatic cell hybrids containing an active (cell line 578) or inactive copy (cell
line 789) of the human X-chromosome on a hamster background (fibroblast cell line
Wshg). For RT–PCR amplification the following primers were used: GEF5UTR1 (5'–
AAACCAGCGTTATCCAGGATTG–3') and KIA44 (5'–GGAGGGTTGCACATCCTTTC
AGG–3'). The identity of the resulting products was verified by direct sequencing.
We used the RNAzol B procedure (CAMPRO Scientific) for RNA isolation of EBV-
transformed lymphoblasts from members of the MRX46 family, and from control
individuals. cDNA synthesis was performed in a 10 µl reaction containing total RNA (150
ng), random hexamer primers (50 ng; Pharmacia), dNTPs (1 mM), RNAguard (4 U;
Amersham) and MMLV-RT (0.5 U; Life Technologies). Incubation was for 10 min at RT, 60
min at 37 °C, and 6 min at 99 °C. We amplified cDNA products with primers c-KIA1 (5'–
GACATGGCTTATATCTTTGGGAG–3') and KIA47 (5'–CTGTCTTTGACTGCCTTTGCAG
CCCTGAAAC–3'). We labeled part of the PCR product by adding 15 mCi [γ-32P] ATP and
T4 polynucleotide kinase (5 U; Biolabs) for 30 min at 37 °C, electrophoresed on 5%
denaturing polyacrylamide gels and exposed on a phosphor imager.
Mutation analysis and X-inactivation assay
In collaboration with the European XLMR Consortium, we investigated 35 MRX
patients from Nijmegen, 26 patients from Tours, 1 patient from Berlin and 6 patients from
Leuven. X-chromosomal inheritance was established by pedigree analysis. Fifty-one
mentally retarded patients, for whom X-chromosomal inheritance was not ensured, were
ascertained by the Institute of Human Genetics in Hamburg. We amplified the coding
exons of ARHGEF6 from genomic DNA using specific primers (primer sequences are
available on request). We visualized PCR products on agarose gels before
SSCP/heteroduplex analysis28.
The androgen receptor (AR) X-inactivation assay has been described22. Primers for
PCR amplification were as described29. PCR products were analyzed as described28.
GenBank accession number
KIAA0006 cDNA 5'-end sequence, AF207831.
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ABSTRACT
Mutations in the XNP gene have been reported in ATR-X syndrome and other severe
X-linked mental retardation conditions with facial dysmorphisms. Here, we describe a
missense mutation in exon 18 in a family with borderline to moderate mental retardation.
Like other disorders associated with an XNP mutation, skewed X-inactivation was found
in all carrier females in this family. Only retrospective examination revealed childhood
facial hypotonia and HbH inclusions in some of the affected males. These results expand
the spectrum of clinical phenotypes known to be due to mutations in the XNP gene, and
indicate that XNP mutation analysis should not be restricted to patients with severe
mental retardation and characteristic facial features.
INTRODUCTION
Mutations in the XNP gene in Xq13.3 have first been reported in alpha
thalassemia/mental retardation syndrome (ATR-X; MIM 301040), which is characterized
by severe mental retardation, α-thalassemia, characteristic facial dysmorphisms,
microcephaly and urogenital malformations1. Subsequent mutations have been reported in
families affected with Juberg-Marsidi syndrome (MIM 309590)2, Carpenter-Waziri
syndrome3, severe mental retardation with spastic paraplegia4, Holmes-Gang syndrome5
and Smith-Fineman-Myers syndrome (MIM 309580)6. All these syndromes have severe
mental retardation and facial dysmorphisms. Only recently, an XNP null mutation has
been reported in a family in which two patients showed moderate to profound MR and
had the typical characteristic features of ATR-X syndrome, whereas two others had mild
MR and epilepsy but did not have the characteristic facial dysmorphisms7.
Lossi et al.4 described that the bias in X inactivation, together with the severe MR, are
the only consistent findings in all patients, and that a first selection can be based on these
characteristics. About half of the mutations found in ATR-X syndrome patients are located
within exons 7, 8 and 9, and sequencing of this hotspot has proven to be extremely
efficient in the identification of novel XNP mutations in patients with the selected
phenotype8. We hypothesized that mutations in other regions of the gene could lead to
other, possibly less severe, mental retardation phenotypes. We therefore initiated a
mutation screening of the entire XNP gene by Single Stranded Conformation
Polymorphism (SSCP) analysis in patients with nonspecific X-linked mental retardation
(MRX). Here, we describe a missense mutation in exon 18 in a family initially diagnosed
with mild nonspecific mental retardation. Although on retrospective examination some
mild clinical characteristics of ATR-X syndrome could be identified, our results indicate
that XNP mutation analysis should not be restricted to patients with severe mental
retardation and characteristic facial features.
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Figure 1. Five generation family with mild mental retardation with or without childhood hypotonia.
PATIENTS AND METHODS
Family F96-26
A large family (Figure 1) of Dutch origin with an apparently nonspecific X-linked
mental retardation was ascertained when IV-2 was referred for genetic counseling. The
pedigree included 7 mentally retarded males in three generations. III-4 had Down
Syndrome and was excluded from further investigation. Patients II-13 and III-14 are
deceased. In order to determine the mental status of the other 4 patients, the Wechsler
Intelligence Scales were used9,10. Scores of all tests were transferred into age equivalents
according to the classification of the American Association of Mental Deficiency
(AAMD)11. In the propositus, IV-3, diagnostic tests including cytogenetic analysis, FMR1
mutation analysis, EEG, cerebral CT-scan and ophthalmologic evaluation were all normal.
Informed consent was obtained in all instances.
Mutation detection
DNA was extracted from peripheral blood lymphocytes according to the procedure
of Miller et al.12. SSCP analysis was performed on PCR-amplicons of exons 2-4, 6-8, 9 (5’
end), 10-22, and 24-27, according to the method of Orita et al.13, with slight modifications.
PCR experiments were performed with γ-32P-end-labeled primers as described by Van den
Hurk et al.14, in a PTC-100 Programmable Thermal Controler (MJ Research, Inc.). Primer
sequences and cycling conditions are available on request. PCR products were denatured
and electrophoresed on a 5% nondenaturing polyacrylamide gel14. PCR products with an
altered electrophoretic mobility were sequenced.
Hematological analysis
Peripheral red blood cells (RBCs) were screened for hemoglobin (Hb) H inclusion
bodies. Fresh EDTA-stabilized blood was mixed on a 1:1 ratio with 1% brilliant cresyl blue
in 0.9% NaCl. Cells were smeared after incubations at RT for 1 hr and at 37°C for 15 min, 1
hr and 2 hrs. The presence of HbH inclusions in erythrocytes was detected by light
microscopy.
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RESULTS
Mutation detection
We identified a missense mutation in a patient from family F96-26 (IV-3; Figure 1):
5069C>T in exon 18 giving rise to an amino acid substitution (T1621M) (numbering
according to GenBank accession number U75653). The T1621M mutation was not found in
300 control chromosomes, and segregates with the disease in the family over 5 generations
with a LOD score of 3.90 at θ=0. This family was clinically diagnosed with nonspecific X-
linked mental retardation. No abnormal facial characteristics were detected on first
examination. After the discovery of a mutation in the XNP gene, the four living mentally
retarded males were re-examined.
Clinical data family F96-26
No information is available about patient II-13. Pregnancy and delivery were
uneventful in IV-3 and V-3. IV-9 and IV-10 were born prematurely, whereas no
information is available for patient III-14. Nonprogressive mental retardation was noted in
childhood with delayed speech development as a major feature. The degree of mental
retardation varied from moderate to borderline. All showed behavioral problems with
chaotic behavior and aggressive outbursts. Results of clinical measurements and
psychometric studies are summarized in Table 1. The propositus, IV-3, was examined at
the age of 38 years. Except for a double left earlobe and full lower lip, facial hypotonia was
visible on the pictures taken in childhood (Figure 2B). III-14 (76 years old) suffers from
prostate cancer. Examination showed a full lower lip and relatively large ears (Figure 2A).
At the time of examination IV-9 was 45 years old. During childhood he was on
anticonvulsive therapy, and since 1992 he is known with micturation problems.
Cystoscopy showed mild urethral stenosis. Up-slanting palpebral fissures and a full lower
lip were noted (Figure 2C). Ophthalmologic evaluation showed strabismus and
hypermetropia in IV-9 and his brother IV-10. IV-10 died because of esophageal cancer at
age 34 before he could be examined. Pictures show double earlobe of the left ear, slightly
prominent ears, a full lower lip, and childhood facial hypotonia (Figure 2D). Reportedly,
he was moderately retarded, showed chaotic behavior, normal OFC and a kyphosis. In
patient V-3 (29 years old) unilateral hearing loss was detected in childhood. This patient
was not available for clinical re-examination, but pictures show a full lower lip and
childhood facial hypotonia (Figure 2E).
After the mutation was found, all four living affected males were tested for
Hemoglobin H (HbH) inclusions characteristic for ATR-X and XNP gene mutations. In
three of the 4 affected males (III-14, IV-9, V-3; Figures 2A, 2C, and 2E) HbH inclusion
bodies were found. X-inactivation studies showed extremely skewed X-inactivation in all
carrier females (>95% inactivation of the abnormal X-chromosome; data not shown).
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Figure 2. Faces of affected males. A: Patient III-14 in childhood and at age 76 years; B: Patient IV-3 in
childhood and at age 38 years; C: Patient IV-9 at age 3 months and 45 years; D: Patient IV-10 in childhood
and at age 34 approximately; E: Patient V-3 at age 2 and 27 years. (Photographs reproduced with informed
consent).
Table 1. Summary of Clinical measurements (centiles) and psychometric studies
Patient
No.
Age
(years)
Height
(cm)
Weight
(kg)
OFCa
(cm)
Ear length
(cm)
OCDb
(cm)
ICDc
(cm)
THLd
(cm)
Mental impairmente
 (verbal/performal/total)
Adaptive functioning
IV-3 38 178
(10-50)
75
(75-90)
54.3
(3)
6
(50)
9
(50-75)
3.4
(75-97)
19.5
(97)
Mild/mild/mild mild
III-14∗ 76 173
(3-10)
60
(25-50)
55
(3-10)
7.2
(97)
9
(50-75)
3.2
(50-75)
19.5
(97)
Mild/moderate/moderate Moderate-severe
IV-9 45 187
(50-75)
71
(50)
56
(10-25)
6.9
(75-97)
8.3
(10-25)
2.7
(3-25)
19.2
(75-97)
Mild/borderline/mild Borderline-mild
V-3 29 ND ND ND ND ND ND ND Mild/borderline/mild-
borderline
borderline
ND, not determined
aOFC, occipitofrontal circumference
bOCD, outer canthal distance
cICD, inner canthal distance
dTHL, total hand length
eMental impairment: borderline, IQ range 70-84; mild, IQ range 55-69; moderate, IQ range 40-54; severe, IQ
range<39
∗ Due to his current age (76 years) and physical condition, the patient was not capable of performing the
tests for adaptive functioning. The intelligence values shown in this table date from age 52 years.
DISCUSSION
We identified a T1621M missense mutation in the XNP gene in a patient from a
family with generally mild mental retardation and no obvious facial dysmorphisms. Co-
segregation of the mutation and the MRX phenotype was observed, with a maximum LOD
score of 3.90 at θ=0. Subsequent analysis of red blood cells revealed the presence of HbH
inclusion bodies, indicative for disruption of XNP gene function. Furthermore, X-
inactivation studies revealed extreme skewing of X-inactivation in carrier females, a
phenomenon that is typically observed in females carrying an XNP mutation.
After the discovery of the mutation, the mentally retarded persons were re-examined
to confirm the nonspecific phenotype. Only minor facial abnormalities were found.
Although a full lower lip was present in the five affected males described, there is little
A
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resemblance with the facial appearance of ATR-X patients. The facial characteristics are
very mild and were not mentioned at the first examination. In three of the patients facial
hypotonia was seen on pictures taken in childhood as is usual also for ATR-X, but this was
not seen in adulthood. In contrast to other patients with an XNP mutation, the degree of
mental retardation in this family is borderline to moderate.
The T1621M mutation is located just in front of helicase domain Ia, at a residue
conserved with the orthologous mouse gene, but not with that from C. elegans (GenBank
accession numbers NM_009530 and AF134186, respectively). Amino acid substitutions in
ATR-X patients have been described 7 and 12 residues upstream of the T1621M mutation1.
In order to get more insight in the function of the XNP protein and to identify possible
genotype-phenotype correlations, it is important to search for mutations in additional
patients who have mental retardation with and without typical facial characteristics. It
was described by Lossi et al.4 that the bias in X inactivation, together with the severe MR,
are the only consistent findings in all patients, and that a first selection can be based on
these characteristics. The findings in this study, however, strongly suggest that screening
of the XNP gene must be considered not just in males with severe X-linked mental
retardation, but of all degrees of severity.
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SUMMARY
With a population incidence of 2-3%, mental handicaps constitute a serious medical
and social problem in our society. The causes of mental retardation (MR) are highly
variable and involve both genetic and environmental factors. In spite of extensive medical
investigations, the etiology of the mental handicap remains unexplained in most patients.
It has been estimated that at least 13% of all MR is caused by X-chromosomal gene defects
(X-linked mental retardation; XLMR). This means that approximately 400 males with
XLMR are born each year in the Netherlands. XLMR can be categorized in syndromic
XLMR (MRXS) and nonsyndromic or nonspecific XLMR (MRX). In the latter only the
intelligence of the patients is affected. Therefore, identification of the genes involved in
MRX will give more insight in the normal development of the brain and particularly of
memory formation.
In order to identify genes for MRX, accurate clinical examination and genetic linkage
analysis with highly polymorphic markers in MRX families needs to be performed first. To
date, in 76 MRX families the genetic defect has been linked to the X-chromosome, two of
which are described in this thesis. MRX46 links to Xq25-q26 with a maximum lod score of
5.12 at θ=0 (appendix 1), and MRX65 links to the pericentromeric region with a maximum
lod score of 3.64 at θ=0 (appendix 2).
The MRX linkage intervals are typically too large to directly identify the underlying
genes. Moreover, refinement to gene localization is impossible because the individual
MRX families cannot be lumped together on the basis of a “common” phenotype.
Therefore, other strategies are necessary to identify MRX genes. In general, three methods
have been used: positional cloning, (positional) candidate gene analysis, and screening of
known MRXS genes.
Positional cloning, using positional information from chromosomal aberrations, has
long been the method of choice to identify novel MRX genes. This method has proven its
success in the identification of five MRX genes: FMR2, OPHN1, TM4SF2, IL1RAPL1, and
ARHGEF6. ARHGEF6 is disrupted by a translocation in a mentally retarded boy (appendix
4), and a missense mutation was identified in MRX46 (appendix 1). However, in some
cases no X-chromosomal breakpoint-spanning gene could be identified. In other cases a
gene involved in the chromosomal aberration was identified, but no gene-specific
mutation in another family could be found to prove its involvement in MRX. An example
of this is the RSK4 gene, that is commonly deleted in mentally retarded patients with a
deletion in Xq21 (appendix 3). However, no mutations were found in approximately 200
MRX families tested, which means that there is no definite proof of the involvement of
RSK4 in MRX.
Positional candidate gene analysis allowed the identification of two MRX genes:
GDI1 and PAK3. Candidate gene analysis may well prove to be effective for the future
identification of more MRX genes. For example, it is becoming clear that genes that cause
syndromic XLMR with a wide phenotypic spectrum are candidate genes for MRX as well.
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Mutations in the genes for Coffin-Lowry syndrome (RSK2) and Rett syndrome (MECP2)
have now also been found in MRX patients. The XNP gene, that is involved in ATR-X
syndrome and several other severe mental retardation syndromes, is also an excellent
candidate gene for MRX. Indeed a mutation has been identified in a family diagnosed with
MRX, in which only retrospectively some mild phenotypic characteristics of ATR-X
syndrome were found (appendix 5).
While the genes involved in MRX encode a variety of proteins, their putative
working mechanisms show considerable overlap. Learning and memory are generally
affected in MRX. This process involves four stages in the brain: 1) outgrowth of neurons;
2) axonal guidance; 3) formation of synaptic connections, and 4) synapse plasticity leading
to long term potentiation. The MRX gene products are part of this mechanism. The
outgrowth of neurons starts with the formation of filopodia and lamellipodia, which is
mediated by the Rho GTPases Rho, Rac, and Cdc42, which in turn are regulated by the
products of the MRX genes OPHN1, ARHGEF6, and PAK3. For the outgrowth of the
neurons, vesicle transport mediated by the product of the GDI1 gene is also essential. The
outgrowth of neurons always takes place in a specific direction. This process, called axon
guidance, involves repulsive cues (leading to axon collapse) and attractive cues (leading to
axon extension). The genes in the mitogen-activated protein kinase (MAPK) pathway
downstream of the Rho GTPases, regulated by TM4SF2 and probably FMR2, play a role in
axon guidance. After the outgrowth of the correct axons, connections with dendrites of
other neurons are formed, which are called synapses. These synapses have to be stabilized
and strengthened (synaptic plasticity), which involves neurotransmitter release in the
synapses. The product of the IL1RAPL1 gene is likely to be involved in this release. Finally,
a typical human memory is formed, mediated by proteins acting in the nucleus of the
neuron, downstream of the MAPKs. RSK2 acts as transcription factor and activates
proteins like CREB, which is necessary for long-term memory formation. Besides the
above mentioned pathway, epigenetic gene regulation is involved in the formation of
memory. MECP2, XNP, and possibly RSK2, play a role in this phenomenon.
The unraveling of MRX genes and the pathways in which they are working paves the
way for the identification of novel MRX genes. This will lead to a better understanding of
human brain function, and to possibilities for genetic counseling and pre- and postnatal
diagnosis.
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SAMENVATTING
Met een incidentie van 2-3%, vormen geestelijke handicaps een belangrijk medisch
en sociaal probleem in onze maatschappij. De oorzaken van mentale retardatie (MR)
omvatten zowel genetische factoren als omgevingsinvloeden. Ondanks uitgebreid
medisch onderzoek, blijft de MR in de meeste patiënten onverklaard. Naar schatting
wordt tenminste 13% van alle MR veroorzaakt door een gendefect op het X-chromosoom
(X-gebonden mentale retardatie; XLMR). Dit betekent dat er in Nederland per jaar
ongeveer 400 mannen met XLMR worden geboren. XLMR kan onderverdeeld worden in
twee groepen: syndromale XLMR (MRXS) en niet-syndromale of niet-specifieke XLMR
(MRX). Omdat een verlaagde intelligentie het enige fenotypische kenmerk is van MRX, zal
de identificatie van de betrokken genen meer inzicht geven in de normale
hersenontwikkeling, met name in de vorming van het geheugen.
Voor de uiteindelijke identificatie van MRX genen is, naast grondig klinisch
onderzoek, koppelingsonderzoek met hoog polymorfe markers in MRX families een eerste
vereiste. Tot nu toe zijn er 76 MRX families beschreven, waarin het genetische defect
gekoppeld is aan het X-chromosoom. Twee van deze families zijn in dit proefschrift
onderzocht. MRX46 is gekoppeld op Xq25-q26 met een maximum lod score van 5,12 bij
θ=0 (appendix 1), en MRX65 is gekoppeld op de pericentromere regio met een maximum
lod score van 3,64 bij θ=0 (appendix 2).
De koppelingsgebieden bij MRX zijn in het algemeen te groot om direct met goed
gevolg de oorzakelijke genen te identificeren. Bovendien maakt het niet-specifieke
karakter van de aandoening het onmogelijk om koppelingsdata te combineren tot een
meer nauwkeurige genlocalisatie. Voor de identificatie van de oorzakelijke MRX genen is
het gebruik van additionele strategieën dus noodzakelijk. Over het algemeen worden er
drie methoden gebruikt: positionele klonering, (positionele) kandidaatgenanalyse, en
screening van bekende MRXS genen.
Positionele klonering, waarbij o.a. gebruik gemaakt wordt de positionele informatie
van chromosomale afwijkingen, was lang de beste methode om nieuwe MRX genen te
identificeren. De methode is succesvol gebleken bij de identificatie van vijf MRX genen:
FMR2, OPHN1, TM4SF2, IL1RAPL1, en ARHGEF6. ARHGEF6 wordt onderbroken door
een translocatie in een mentaal geretardeerde jongen (appendix 4), en een missense
mutatie werd gevonden in MRX46 (appendix 1). Echter, bij sommige translocaties bleek er
geen gen te zijn dat onderbroken werd door het X-chromosomale breekpunt. In andere
gevallen waar wel een gen betrokken was bij de chromosomale afwijking, kon geen gen-
specifieke mutatie in een andere familie gevonden worden die de betrokkenheid bij MRX
kon bevestigen. Een voorbeeld hiervan is het RSK4 gen, dat afwezig is in mentaal
geretardeerde patiënten met een deletie in Xq21 (appendix 3). Er werden geen mutaties
gevonden in ongeveer 200 geteste MRX families, wat betekent dat er geen definitief bewijs
is van de betrokkenheid van RSK4 bij MRX.
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Positionele kandidaatgenanalyse heeft geleid tot de identificatie van twee MRX
genen: GDI1 en PAK3. Kandidaatgenanalyse zal waarschijnlijk in de toekomst het meest
effectief zijn voor de identificatie van MRX genen. Het wordt bijvoorbeeld steeds
duidelijker dat genen die betrokken zijn bij syndromale vormen van XLMR met een breed
fenotypisch spectrum, goede kandidaatgenen voor MRX zijn. In de genen voor Coffin-
Lowry syndroom (RSK2) en Rett syndroom (MECP2) zijn nu mutaties gevonden bij MRX
patiënten. Het XNP gen, dat betrokken is bij ATR-X syndroom en verschillende andere
syndromen met ernstige MR, is ook een goed kandidaatgen voor MRX. Inderdaad werd
een mutatie gevonden in een familie waarbij in eerste instantie de diagnose MRX was
gesteld, maar waarbij retrospectief een paar milde fenotypische kenmerken van ATR-X
syndroom gevonden werden (appendix 5).
Hoewel de MRX genen coderen voor een verscheidenheid aan eiwitten, blijkt het
proces van "leren en geheugen" algemeen aangedaan te zijn in MRX. Dit proces in de
hersenen kan in vier stadia worden onderverdeeld: 1) uitgroei van neuronen; 2) axon
guidance; 3) vorming van synaptische connecties, en 4) synaptische plasticiteit die
uiteindelijk leidt tot "long term potentiation". De produkten van de MRX genen maken
deel uit van dit proces. De uitgroei van neuronen begint met de vorming van filopodia en
lamellipodia, welke gereguleerd worden door de Rho GTPases Rho, Rac, en Cdc42, die op
hun beurt gereguleerd worden door de produkten van de MRX genen OPHN1, ARHGEF6,
en PAK3. Voor de uitgroei van neuronen is het transport van "vesicles" via het produkt
van het GDI1 gen eveneens essentieel. De uitgroei van neuronen vindt altijd in een
bepaalde richting plaats. Dit proces wordt "axon guidance" genoemd en betreft afstotende
signalen (leidend tot terugtrekking van het axon) en aantrekkende signalen (leidend tot
verlenging van het axon). De genen in de "mitogen-activated protein kinase (MAPK)
pathway" downstream van de Rho GTPases worden gereguleerd door TM4SF2 en
waarschijnlijk FMR2, en spelen een rol bij "axon guidance". Na de uitgroei van de juiste
axonen, worden connecties met de dendrieten van andere neuronen gevormd: synapsen.
Deze synapsen moeten gestabiliseerd en versterkt worden (synaptische plasticiteit), wat
gebeurt via het vrijkomen van neurotransmitters in de synapsen. Het produkt van het
IL1RAPL1 gen is waarschijnlijk bij dit vrijkomen betrokken. Uiteindelijk wordt een
typische menselijk geheugen gevormd, dat gereguleerd wordt door eiwitten die
werkzaam zijn in de celkern van het neuron, downstream van de MAPKs. RSK2 werkt als
transcriptie factor en activeert eiwitten zoals CREB, dat noodzakelijk is voor de vorming
van het lange-termijn geheugen. Behalve de hierboven genoemde route, speelt
epigenetische genregulatie een rol bij de vorming van geheugen. MECP2, XNP, en
mogelijk RSK2 spelen een rol bij dit fenomeen.
De ontrafeling van MRX genen en de pathways waarin zij werken maken de weg vrij
voor de identificatie van nieuwe MRX genen. Dit leidt tot een beter begrip van de werking
van het menselijke brein en tot mogelijkheden voor genetische counseling en pre- en
postnatale diagnostiek.
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Mentale retardatie, ofwel geestelijke handicap, komt bij 2 tot 3 % van de bevolking
voor, en vormt daarom een belangrijk maatschappelijk probleem. Er zijn verschillende
oorzaken voor mentale retardatie (afgekort MR), en er zijn zowel erfelijke als niet erfelijke
vormen. In sommige gevallen is er een duidelijke oorzaak voor de geestelijke handicap,
bijvoorbeeld als er zuurstofgebrek in de hersenen is opgetreden bij de geboorte of als de
patiënt het syndroom van Down heeft. Bij de meeste patiënten wordt echter nooit een
aanwijsbare reden voor de mentale retardatie gevonden, ondanks uitgebreid medisch
onderzoek. Er zijn ongeveer 30% meer mannen dan vrouwen met een geestelijke
handicap. Waarschijnlijk wordt dit veroorzaakt door erfelijke vormen van MR, waarbij er
een afwijking op het X-chromosoom aanwezig is. Omdat vrouwen twee X-chromosomen
hebben en mannen maar één, kan een foutje op dit chromosoom bij mannen tot een ziekte
leiden, terwijl vrouwen alleen draagster zijn omdat ze nog een gezond X-chromosoom
hebben. Waarschijnlijk wordt meer dan 13% van alle MR veroorzaakt door een afwijking
op het X-chromosoom. Deze aandoening wordt geslachtsgebonden mentale retardatie
genoemd, afgekort XLMR. Per jaar worden er in Nederland ongeveer 400 mannen met
XLMR geboren. XLMR kan onderverdeeld worden in syndromale XLMR (MRXS) en niet-
syndromale of niet-specifieke XLMR (MRX). Als er sprake is van een syndroom, hebben
de patiënten behalve een geestelijke handicap nog andere afwijkingen waaraan de
patiënten herkend kunnen worden (zoals bij Down syndroom). Patiënten met MRX (dus
niet-syndromaal) hebben behalve mentale retardatie geen herkenbare afwijkingen. Omdat
deze patiënten alleen een verminderde intelligentie hebben, zal opheldering van het foutje
op hun X-chromosoom dus inzicht geven in de normale ontwikkeling van de hersenen, en
met name in de vorming van het geheugen.
In eerste instantie zal bewezen moeten worden dat de afwijking bij de patiënt
daadwerkelijk op het X-chromosoom ligt. De belangrijkste methode hiervoor is
koppelingsonderzoek. In eerste instantie wordt een familie, waarin vermoedelijk MRX
voorkomt, grondig klinisch onderzocht, en blijven alleen die families over waarin er
meerdere aangedane mannen zijn die op basis van IQ-testen een geestelijke handicap
blijken te hebben, en waarin er geen andere kenmerken zijn die wijzen op een syndroom.
Bovendien moet het duidelijk zijn dat de ziekte in de familie doorgegeven wordt via
draagsters, d.w.z. moeders die wel het foutieve X-chromosoom hebben maar zelf niet zijn
aangedaan omdat ze nog een gezond X-chromosoom hebben. Daarna wordt in het
laboratorium het DNA van zoveel mogelijk familieleden onderzocht. Er wordt een soort
kaart gemaakt van de X-chromosomen van alle personen. Wanneer een bepaald gedeelte
van deze kaart overeenkomt in alle patiënten, terwijl alle gezonde familieleden dat
gedeelte niet hebben, wordt het waarschijnlijk dat het foutje bij de patiënten in dit gedeelte
van het X-chromosoom ligt. Men zegt dan dat de afwijking "gekoppeld" is aan dit gedeelte
van het X-chromosoom. In dit proefschrift is in twee Nederlandse families zo'n
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koppelingsgebied op het X-chromosoom gevonden (appendices 1 en 2). Wereldwijd zijn er
nu 76 MRX families beschreven met zo'n koppelingsgebied op het X-chromosoom.
In families waarin een koppelingsgebied is gevonden kan geprobeerd worden in dit
gebied een afwijking in het DNA te vinden dat de mentale retardatie veroorzaakt. Deze
afwijking moet zich dan bevinden in een gen: een klein gedeelte van het DNA dat de
erfelijke code bevat. De koppelingsgebieden die gevonden worden in MRX families zijn
echter over het algemeen erg groot. Bovendien blijkt het dat iedere familie zijn eigen
koppelingsgebied heeft, dat niet altijd overlapt met het gebied van een andere familie. Dit
betekent dat de geestelijke handicap in de ene familie een hele andere oorzaak heeft dan in
de andere familie, en dat er dus meerdere genen op het X-chromosoom betrokken zijn bij
mentale retardatie. Men verwacht dat er meer dan 50 genen op het X-chromosoom zijn die
een rol spelen bij ontwikkeling van het geheugen bij mensen. Gelukkig zijn er andere
manieren dan koppelingsonderzoek, om in een kleiner gebied, te zoeken naar genen voor
MRX: positionele klonering, (positionele) kandidaatgenanalyse, en screening van bekende
MRXS genen.
Positionele klonering is een methode waarbij in een heel klein gebied op een
chromosoom naar een gen gezocht wordt. Zo'n nauwkeurige localisatie is alleen mogelijk
als er een structurele fout op het chromosoom is, bijvoorbeeld als een stukje van het X-
chromosoom uitgewisseld is met een ander chromosoom (translocatie), als er een stukje
van het X-chromosoom afwezig is (deletie), of als er een stukje van het X-chromosoom is
omgedraaid (inversie). In appendix 3 van dit proefschrift is gezocht naar een gen in een
stuk DNA dat bij een aantal mentaal geretardeerde mannen afwezig was. Bij gezonde
personen ligt op dit stuk DNA een gen, het RSK4 gen, dat waarschijnlijk noodzakelijk is
voor de ontwikkeling van een normale intelligentie. We konden echter niet definitief
bewijzen dat dit gen echt betrokken is bij mentale retardatie, omdat er nog een ander gen
in dit stuk DNA kan liggen. Als we een foutje in dit gen alleen hadden gevonden in een
andere familie (dus zonder deletie), konden we definitief bewijzen dat dit gen een MRX
gen was. We hebben meer dan 200 families getest, maar geen afwijkingen gevonden. Voor
vijf andere genen die met de positionele kloneringsmethode zijn gevonden kon dit
definitieve bewijs wel gevonden worden. Eén van deze genen is beschreven in appendix 4.
Dit gen, ARHGEF6, wordt onderbroken door een translocatie in een mentaal geretardeerde
jongen. In de Nederlandse familie van appendix 1 werd een hele andere fout in hetzelfde
gen gevonden, waarmee het bewijs dat dit gen betrokken is bij geestelijke handicaps rond
was.
Twee MRX genen zijn geïdentificeerd door middel van positionele kandidaatgen
analyse. Bij deze methode wordt gezocht naar genen die op basis van hun functie een rol
zouden kunnen spelen bij mentale retardatie. Daarna wordt gekeken in welk gebied op
het X-chromosoom zo'n kandidaatgen ligt en worden de families gezocht waarbij
koppeling in dit gebied is gevonden. Nu door het Humane Genoomproject het hele DNA
van de mens in kaart gebracht wordt en bijna alle genen op het X-chromosoom bekend
zijn, zal deze kandidaatgen analyse steeds belangrijker worden. Bovendien is gebleken dat
EENVOUDIGER GEZEGD
139
er bij MRX ook foutjes gevonden kunnen worden in genen die een syndroom kunnen
veroorzaken. In de genen voor Coffin-Lowry syndroom (RSK2) en Rett syndroom
(MECP2) zijn nu mutaties gevonden bij MRX. Het blijkt dat ernstige fouten in deze genen,
waarbij het gen helemaal niet meer functioneert, tot een syndroom kunnen leiden, terwijl
minder ernstige fouten, waarbij het gen slechts minder functioneert, tot MRX kunnen
leiden. Het XNP gen, dat betrokken is bij ATR-X syndroom, en verschillende andere
syndromen met ernstige MR, is ook een goed kandidaatgen voor MRX. Inderdaad werd
een mutatie gevonden in een familie waarbij in eerste instantie de diagnose MRX was
gesteld (appendix 5). Achteraf gezien blijkt dat de patiënten in deze familie toch wat
kenmerken van het ATR-X syndroom bezitten, en dat we dus eigenlijk niet van niet-
specifieke mentale retardatie mogen spreken.
Het is niet alleen belangrijk om de genen te vinden die betrokken zijn bij MRX, maar
ook om te weten waarom een foutje in zo'n gen leidt tot geestelijke handicap. Wanneer
men kijkt naar de functie van de genen die inmiddels gevonden zijn bij mentale retardatie,
valt op dat de meeste van deze genen een rol spelen bij de ontwikkeling van de
zenuwcellen in onze hersenen. Nu er negen genen voor MRX zijn geïdentificeerd en er een
idee is over het mechanisme waarop geheugen bij de mens wordt gevormd, wordt het
waarschijnlijk makkelijker om nog meer genen voor MRX te vinden. Dit leidt tot een beter
begrip van de werking van het humane brein. Bovendien worden de mogelijkheden voor
erfelijkheidsadvies en pre- en postnatale diagnostiek vergroot als er meer genen voor MRX
ontdekt worden.
140
141
DANKWOORD
Nu mijn proefschrift klaar is, en ik nog eens terugkijk naar alle resultaten die ik de
afgelopen jaren heb geboekt, blijkt duidelijk dat ik veel mensen dank ben verschuldigd.
Eigenlijk hebben alle collega's van de afdeling Antropogenetica in Nijmegen door de
gezellige ongedwongen werksfeer bijgedragen aan het slagen van dit proefschrift.
Uiteraard zijn er mensen die meer dan een algemeen bedankje verdienen:
Hans, nu ben je voor het eerst co-promotor! Bedankt voor alles wat je me hebt
geleerd en voor het vertrouwen in een goede afloop (dat ik zelf lang niet altijd had). Door
het geroffel van je toetsenbord (af en toe onderbroken door wat gezang), wist ik dat je
altijd op de achtergrond aanwezig was om mijn talloze vragen te beantwoorden. Hilger,
bedankt dat je me de mogelijkheid hebt gegeven om bij Antropogenetica te promoveren.
Ik ben blij dat je we via het Europese consortium nog steeds over het XLMR onderzoek
kunnen praten. Han, het leek soms of je mijn gedachten kon lezen! Je positieve benadering
en je heldere kijk op mijn onderzoek zorgen ervoor dat er niet meer ellenlang
gediscussieerd hoeft te worden over wie wat wanneer en vooral hoe op gaat schrijven!
Frans, bedankt voor je bijdrage aan met name het Xq21 werk. Jammer dat het bewijs voor
een MRX gen in "jouw" gebied nog niet helemaal rond is.
Het mentale retardatie onderzoek op onze afdeling zou niets zijn zonder de
aanwezigheid van Ben. Samen met Francis, met de orthopedagogen (eerst met Tanja en nu
met Anja), met DNA-diagnostiek (Erik en Willy), en met Tjitske en Bert als meest recente
versterking zullen ook in de toekomst nog veel leuke resultaten verkregen worden.
Bellinda, jouw enthousiasme in het lab werkt aanstekelijk! Misschien wel een beetje té......
(maar de champagne was wel erg lekker!). Astrid, gelukkig was jij er om de boel
draaiende te houden toen ik in Frankrijk was, en toen ik aan mijn proefschrift aan het
werk was. Zonder jou zouden er helemaal geen resultaten meer verkregen worden op dit
moment! Johan, bedankt voor je pogingen om mij de fijne kneepjes van het moleculaire
werk bij te brengen, en vooral voor de gezelligheid en de humor die je op het lab bracht.
Gerard, ik hoop dat het niet aan mij lag dat je zo snel vertrokken was toen je eenmaal aan
MR moest werken! Ik ben blij dat je inmiddels weer terug bent op het lab.
Ook wil ik de studenten bedanken die direct of indirect aan mij werden
toevertrouwd: Freek, Mieke en Esther, bedankt voor jullie bijdrage en voor de
gezelligheid! Verder heeft de rest van de vakgroep Moleculaire Genetica natuurlijk
bijgedragen aan een leuke werksfeer: Ellen, Jacopo, Pascal en Betsie, het is rustig maar wel
erg gezellig aan onze kant van de muur! Dorien, Anneke, José, Stef, Saskia, Marc, Martijn,
Wendy, Hannie, Peter, Yvette, Alessandra, Janneke, Sioe Lie, Carolien, Marga en Sylvia,
allemaal bedankt voor de gezellige koffie- en theepauzes en voor de kletspraatjes tussen
het pipetteren door!
I want to thank the collegues of the Mandel group at the IGBMC in Strasbourg for
the nice time I had in your lab. Especially André and the RSK2 group, Maria, Sylvie,
Karine and Solange: it was really nice working with you! Maria, you are a great friend,
142
without you my stay in France would have been less fun! Furthermore, I am indebted to
our collegues of the European XLMR consortium. The exchange of knowledge and patient
material was, and still is, very important for the mental retardation research in Nijmegen.
Buiten het werk zijn mijn familie en vrienden onmisbaar gebleken. Ik wil mijn
ouders en Reinier en Marceline bedanken voor jullie onvoorwaardelijke steun en interesse
in mijn onderzoek. Monique en Rianne, mijn wekelijkse etentje met jullie was (en is) altijd
een welkome afleiding. Marinke, je hebt jarenlang als mijn thuisfront gefungeerd: ik denk
echt dat ik het zonder jou niet had gered!
Ronald, dankzij jou heb ik mijn promotie zonder al te veel stress af kunnen ronden.
Gelukkig heb je meer verstand van computers dan ik! Ik ben blij dat je met me meedacht
als het nodig was, maar vooral dat je ervoor hebt gezorgd dat ik niet meer overal over hoef
na te denken (al kan ik dat soms toch niet laten). Nu ook mijn boekje klaar is, kunnen we
echt eens gaan doen waar we zin in hebben!
143
CURRICULUM VITAE
Helger IJntema werd op 10 mei 1971 geboren in Eindhoven. Na het behalen van het
eindexamen Atheneum aan het Anton van Duinkerkencollege in Veldhoven, begon zij in
1989 aan de studie Biologie op de Katholieke Universiteit Nijmegen. Gedurende deze
studie deed zij een hoofdvak Experimentele Dierkunde bij Dr. Wim Scheenen, waarbij de
receptor voor Neuropeptide Y in de pars intermedia van Xenopus laevis werd
gekarakteriseerd. Vervolgens werd een bijvakstage Neurobiologie gedaan aan de
Universiteit van Torino, Italië (onder leiding van Prof. Dr. Aldo Fasolo), waar
immunohistochemisch onderzoek werd gedaan aan de bulbus olfactorius van de muis.
Tenslotte werd een tweede hoofdvakstage gevolgd op de afdeling Moleculaire
Hematologie, begeleid door Dr. Jules Meijerink, waarbij de identificatie van Bcl2-
gelijkende genen centraal stond. Na het behalen van het doctoraalexamen Medische
Biologie in 1995 heeft zij een jaar als wetenschappelijk onderzoekster in het Klinisch
Chemisch Laboratorium van het Medisch Spectrum Twente in Enschede onderzoek
gedaan naar het groeigedrag van niet-kleincellige longtumoren. Sinds 1 maart 1996 is zij
als wetenschappelijk onderzoekster werkzaam op de afdeling Antropogenetica van het
Universitair Medisch Centrum St. Radboud in Nijmegen, waar het in dit proefschrift
beschreven onderzoek is uitgevoerd. Tijdens haar promotie-onderzoek verbleef zij vijf
maanden in het lab van Dr. André Hanauer op het Institut de Génétique et de Biologie
Moléculaire et Cellulaire (IGBMC) in Illkirch (Strasbourg), Frankrijk.
144
PUBLICATIONS
Yntema HG, Oudakker AR, Kleefstra T, Hamel BCJ, van Bokhoven H, Chelly J, Kalscheuer
VM, Fryns J-P, Raynaud M, Moizard M-P, and Moraine C. In frame deletion in MECP2
causes mild nonspecific mental retardation. Am J Med Genet, in press.
Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, Verloes A, Andres
C, Le Fevre AC, Souville I, Steffann J, des Portes V, Ropers HH, Yntema HG, Fryns JP,
Briault S, Chelly J, and Cherif B (2001) MECP2 is highly mutated in X-linked mental
retardation. Hum Mol Genet 10: 941-946.
Kutsche K, Yntema H, Brandt A, Jantke I, Nothwang HG, Orth U, Boavida MG, David D,
Chelly J, Fryns J-P, Moraine C, Ropers H-H, Hamel BCJ, van Bokhoven H, and Gal A
(2000) Mutations in ARHGEF6, encoding a guanine nucleotide exchange factor for Rho
GTPases, in patients with X-linked mental retardation. Nat Genet 26: 247-250.
Yntema HG, van den Helm B, Kissing J, van Duijnhoven G, Poppelaars F, Chelly J,
Moraine C, Fryns J-P, Hamel BCJ, Heilbronner H, Pander H-J, Brunner HG, Ropers H-H,
Cremers FPM, and van Bokhoven H (1999) A novel ribosomal S6-kinase (RSK4; RPS6KA6)
is commonly deleted in patients with complex X-linked mental retardation. Genomics 62:
332-343.
Yntema HG, van den Helm B, Knoers NVAM, Smits APT, van Roosmalen T, Smeets
DFCM, Mariman ECM, van der Burgt I, van Bokhoven H, Ropers H-H, Kremer H, and
Hamel BCJ (1999) X-linked mental retardation: evidence for a recent mutation in a five-
generation family (MRX65) linked to the pericentromeric region. Am J Med Genet 85: 305-
308.
Yntema HG, Hamel BCJ, Smits APT, van Roosmalen T, van den Helm B, Kremer H,
Ropers H-H, Smeets DFCM, and van Bokhoven H (1998) Localisation of a gene for non-
specific X linked mental retardation (MRX46) to Xq25-q26. J Med Genet 35: 801-805.
Scheenen WJJM, Yntema HG, Willems PHGM, Roubos EW, Lieste JR, and Jenks BG (1995)
Neuropeptide Y inhibits Ca2+ oscillations, cyclic AMP, and secretion in melanotrope cells
of Xenopus laevis via a Y1 receptor. Peptides 16: 889-895.
